

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 January 2001 (11.01.2001)

PCT

(10) International Publication Number
WO 01/02583 A2

(51) International Patent Classification⁷: C12N 15/54,
15/31, 9/00, 9/12, 15/77, C12P 1/04

(DE). HABERHAUER, Gregor; Moselstrasse 42,
D-67117 Limburgerhof (DE).

(21) International Application Number: PCT/IB00/00973

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 27 June 2000 (27.06.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/142,691 1 July 1999 (01.07.1999) US
60/150,310 23 August 1999 (23.08.1999) US
199 42 095.5 3 September 1999 (03.09.1999) DE
199 42 097.1 3 September 1999 (03.09.1999) DE

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant: BASF AKTIENGESELLSCHAFT
[DE/DE]; D-67056 Ludwigshafen (DE).

Published:

— Without international search report and to be republished
upon receipt of that report.

(72) Inventors: POMPEJUS, Markus; Wenjenstrasse 21,
D-67251 Freinsheim (DE). KRÖGER, Burkhard; Im
Waldfhof 1, D-67117 Limburgerhof (DE). SCHRÖDER,
Hartwig; Goethestrasse 5, D-69226 Nussloch (DE).
ZELDER, Oskar; Rossmarktstrasse 27, D-67346 Speyer

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

A2

WO 01/02583

(54) Title: *ORYNEBACTERIUM GLUTAMICUM GENES ENCODING PHOSPHOENOLPYRUVATE: SUGAR PHOSPHO-TRANSFERASE SYSTEM PROTEINS*

(57) Abstract: Isolated nucleic acid molecules, designated PTS nucleic acid molecules, which encode novel PTS proteins from *Corynebacterium glutamicum* are described. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PTS nucleic acid molecules, and host cells into which the expression vectors have been introduced. The invention still further provides isolated PTS proteins, mutated PTS proteins, fusion proteins, antigenic peptides and methods for the improvement of production of a desired compound from *C. glutamicum* based on genetic engineering of PTS genes in this organism.

- 1 -

***CORYNEBACTERIUM GLUTAMICUM GENES ENCODING
PHOSPHOENOLPYRUVATE: SUGAR PHOSPHOTRANSFERASE SYSTEM
PROTEINS***

5 Related Applications

This application claims priority to U.S. Provisional Patent Application No.: 60/142,691, filed on July 1, 1999, and also to U.S. Provisional Patent Application No.: 60/150,310, filed on August 23, 1999, incorporated herein in their entirety by this reference. This application also claims priority to German Patent Application No.: 19942095.5, filed on September 3, 1999, and also to German Patent Application No.: 19942097.1, filed on September 3, 1999, incorporated herein in their entirety by this reference.

Background of the Invention

15 Certain products and by-products of naturally-occurring metabolic processes in cells have utility in a wide array of industries, including the food, feed, cosmetics, and pharmaceutical industries. These molecules, collectively termed 'fine chemicals', include organic acids, both proteinogenic and non-proteinogenic amino acids, nucleotides and nucleosides, lipids and fatty acids, diols, carbohydrates, aromatic 20 compounds, vitamins and cofactors, and enzymes. Their production is most conveniently performed through large-scale culture of bacteria developed to produce and secrete large quantities of a particular desired molecule. One particularly useful organism for this purpose is *Corynebacterium glutamicum*, a gram positive, nonpathogenic bacterium. Through strain selection, a number of mutant strains have 25 been developed which produce an array of desirable compounds. However, selection of strains improved for the production of a particular molecule is a time-consuming and difficult process.

Summary of the Invention

30 The invention provides novel bacterial nucleic acid molecules which have a variety of uses. These uses include the identification of microorganisms which can be used to produce fine chemicals, the modulation of fine chemical production in *C.*

- 2 -

glutamicum or related bacteria, the typing or identification of *C. glutamicum* or related bacteria, as reference points for mapping the *C. glutamicum* genome, and as markers for transformation. These novel nucleic acid molecules encode proteins, referred to herein as phosphoenolpyruvate:sugar phosphotransferase system (PTS) proteins.

5 *C. glutamicum* is a gram positive, aerobic bacterium which is commonly used in industry for the large-scale production of a variety of fine chemicals, and also for the degradation of hydrocarbons (such as in petroleum spills) and for the oxidation of terpenoids. The PTS nucleic acid molecules of the invention, therefore, can be used to identify microorganisms which can be used to produce fine chemicals, e.g., by

10 fermentation processes. Modulation of the expression of the PTS nucleic acids of the invention, or modification of the sequence of the PTS nucleic acid molecules of the invention, can be used to modulate the production of one or more fine chemicals from a microorganism (e.g., to improve the yield or production of one or more fine chemicals from a *Corynebacterium* or *Brevibacterium* species).

15 The PTS nucleic acids of the invention may also be used to identify an organism as being *Corynebacterium glutamicum* or a close relative thereof, or to identify the presence of *C. glutamicum* or a relative thereof in a mixed population of microorganisms. The invention provides the nucleic acid sequences of a number of *C. glutamicum* genes; by probing the extracted genomic DNA of a culture of a unique or

20 mixed population of microorganisms under stringent conditions with a probe spanning a region of a *C. glutamicum* gene which is unique to this organism, one can ascertain whether this organism is present. Although *Corynebacterium glutamicum* itself is nonpathogenic, it is related to species pathogenic in humans, such as *Corynebacterium diphtheriae* (the causative agent of diphtheria); the detection of such organisms is of

25 significant clinical relevance.

The PTS nucleic acid molecules of the invention may also serve as reference points for mapping of the *C. glutamicum* genome, or of genomes of related organisms. Similarly, these molecules, or variants or portions thereof, may serve as markers for genetically engineered *Corynebacterium* or *Brevibacterium* species.

30 The PTS proteins encoded by the novel nucleic acid molecules of the invention are capable of, for example, transporting high-energy carbon-containing molecules such as glucose into *C. glutamicum*, or of participating in intracellular signal transduction in

- 3 -

this microorganism. Given the availability of cloning vectors for use in *Corynebacterium glutamicum*, such as those disclosed in Sinskey *et al.*, U.S. Patent No. 4,649,119, and techniques for genetic manipulation of *C. glutamicum* and the related *Brevibacterium* species (e.g., *lactofermentum*) (Yoshihama *et al.*, *J. Bacteriol.* 162: 591-597 (1985); Katsumata *et al.*, *J. Bacteriol.* 159: 306-311 (1984); and Santamaria *et al.*, *J. Gen. Microbiol.* 130: 2237-2246 (1984)), the nucleic acid molecules of the invention may be utilized in the genetic engineering of this organism to make it a better or more efficient producer of one or more fine chemicals.

The PTS molecules of the invention may be modified such that the yield, 10 production, and/or efficiency of production of one or more fine chemicals is improved. For example, by modifying a PTS protein involved in the uptake of glucose such that it is optimized in activity, the quantity of glucose uptake or the rate at which glucose is translocated into the cell may be increased. The breakdown of glucose and other sugars within the cell provides energy that may be used to drive energetically unfavorable 15 biochemical reactions, such as those involved in the biosynthesis of fine chemicals. This breakdown also provides intermediate and precursor molecules necessary for the biosynthesis of certain fine chemicals, such as amino acids, vitamins and cofactors. By increasing the amount of intracellular high-energy carbon molecules through 20 modification of the PTS molecules of the invention, one may therefore increase both the energy available to perform metabolic pathways necessary for the production of one or more fine chemicals, and also the intracellular pools of metabolites necessary for such production.

Further, the PTS molecules of the invention may be involved in one or more 25 intracellular signal transduction pathways which may affect the yields and/or rate of production of one or more fine chemical from *C. glutamicum*. For example, proteins necessary for the import of one or more sugars from the extracellular medium (e.g., HPr, Enzyme I, or a member of an Enzyme II complex) are frequently posttranslationally modified upon the presence of a sufficient quantity of the sugar in the cell, such that they are no longer able to import that sugar. While this quantity of sugar at which the 30 transport system is shut off may be sufficient to sustain the normal functioning of the cell, it may be limiting for the overproduction of the desired fine chemical. Thus, it may be desirable to modify the PTS proteins of the invention such that they are no longer

responsive to such negative regulation, thereby permitting greater intracellular concentrations of one or more sugars to be achieved, and, by extension, more efficient production or greater yields of one or more fine chemicals from organisms containing such mutant PTS proteins.

5 This invention provides novel nucleic acid molecules which encode proteins, referred to herein as phosphoenolpyruvate:sugar phosphotransferase system (PTS) proteins, which are capable of, for example, participating in the import of high-energy carbon molecules (e.g., glucose, fructose, or sucrose) into *C. glutamicum*, and/or of participating in one or more *C. glutamicum* intracellular signal transduction pathways.

10 Nucleic acid molecules encoding a PTS protein are referred to herein as PTS nucleic acid molecules. In a preferred embodiment, the PTS protein participates in the import of high-energy carbon molecules (e.g., glucose, fructose, or sucrose) into *C. glutamicum*, and also may participate in one or more *C. glutamicum* intracellular signal transduction pathways. Examples of such proteins include those encoded by the genes set forth in

15 Table 1.

Accordingly, one aspect of the invention pertains to isolated nucleic acid molecules (e.g., cDNAs, DNAs, or RNAs) comprising a nucleotide sequence encoding a PTS protein or biologically active portions thereof, as well as nucleic acid fragments suitable as primers or hybridization probes for the detection or amplification of PTS-encoding nucleic acid (e.g., DNA or mRNA). In particularly preferred embodiments, the isolated nucleic acid molecule comprises one of the nucleotide sequences set forth in as the odd-numbered SEQ ID NOs in the Sequence Listing (e.g., SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7....) or the coding region or a complement thereof of one of these nucleotide sequences. In other particularly preferred embodiments, the isolated nucleic acid molecule of the invention comprises a nucleotide sequence which hybridizes to or is at least about 50%, preferably at least about 60%, more preferably at least about 70%, 80% or 90%, and even more preferably at least about 95%, 96%, 97%, 98%, 99% or more homologous to a nucleotide sequence set forth, as an odd-numbered SEQ ID NO in the Sequence Listing (e.g., SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7....), or a portion thereof. In other preferred embodiments, the isolated nucleic acid molecule encodes one of the amino acid sequences set forth in as an even-numbered SEQ ID NO in the Sequence Listing (e.g., SEQ ID NO:2, SEQ ID NO:4, SEQ

- 5 -

ID NO:6, SEQ ID NO:8....). The preferred PTS proteins of the present invention also preferably possess at least one of the PTS activities described herein.

In another embodiment, the isolated nucleic acid molecule encodes a protein or portion thereof wherein the protein or portion thereof includes an amino acid sequence which is sufficiently homologous to an amino acid sequence of the invention (e.g., a sequence having an even-numbered SEQ ID NO: in the Sequence Listing), e.g., sufficiently homologous to an amino acid sequence of the invention such that the protein or portion thereof maintains a PTS activity. Preferably, the protein or portion thereof encoded by the nucleic acid molecule maintains the ability to participate in the import of high-energy carbon molecules (e.g., glucose, fructose, or sucrose) into *C. glutamicum*, and/or to participate in one or more *C. glutamicum* intracellular signal transduction pathways. In one embodiment, the protein encoded by the nucleic acid molecule is at least about 50%, preferably at least about 60%, and more preferably at least about 70%, 80%, or 90% and most preferably at least about 95%, 96%, 97%, 98%, or 99% or more homologous to an amino acid sequence of the invention (e.g., an entire amino acid sequence selected from those having an even-numbered SEQ ID NO in the Sequence Listing). In another preferred embodiment, the protein is a full length *C. glutamicum* protein which is substantially homologous to an entire amino acid sequence of the invention (encoded by an open reading frame shown in the corresponding odd-numbered SEQ ID NOs in the Sequence Listing (e.g., SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7....)).

In another preferred embodiment, the isolated nucleic acid molecule is derived from *C. glutamicum* and encodes a protein (e.g., a PTS fusion protein) which includes a biologically active domain which is at least about 50% or more homologous to one of the amino acid sequences of the invention (e.g., a sequence of one of the even-numbered SEQ ID NOs in the Sequence Listing) and is able to participate in the import of high-energy carbon molecules (e.g., glucose, fructose, or sucrose) into *C. glutamicum*, and/or to participate in one or more *C. glutamicum* intracellular signal transduction pathways, or possesses one or more of the activities set forth in Table 1, and which also includes heterologous nucleic acid sequences encoding a heterologous polypeptide or regulatory regions.

In another embodiment, the isolated nucleic acid molecule is at least 15 nucleotides in length and hybridizes under stringent conditions to a nucleic acid molecule comprising a nucleotide sequence of the invention (e.g., a sequence of an odd-numbered SEQ ID NO in the Sequence Listing). Preferably, the isolated nucleic acid molecule corresponds to a naturally-occurring nucleic acid molecule. More preferably, the isolated nucleic acid encodes a naturally-occurring *C. glutamicum* PTS protein, or a biologically active portion thereof.

Another aspect of the invention pertains to vectors, e.g., recombinant expression vectors, containing the nucleic acid molecules of the invention, and host cells into which such vectors have been introduced. In one embodiment, such a host cell is used to produce a PTS protein by culturing the host cell in a suitable medium. The PTS protein can be then isolated from the medium or the host cell.

Yet another aspect of the invention pertains to a genetically altered microorganism in which a PTS gene has been introduced or altered. In one embodiment, the genome of the microorganism has been altered by the introduction of a nucleic acid molecule of the invention encoding wild-type or mutated PTS sequence as a transgene. In another embodiment, an endogenous PTS gene within the genome of the microorganism has been altered, e.g., functionally disrupted, by homologous recombination with an altered PTS gene. In another embodiment, an endogenous or introduced PTS gene in a microorganism has been altered by one or more point mutations, deletions, or inversions, but still encodes a functional PTS protein. In still another embodiment, one or more of the regulatory regions (e.g., a promoter, repressor, or inducer) of a PTS gene in a microorganism has been altered (e.g., by deletion, truncation, inversion, or point mutation) such that the expression of the PTS gene is modulated. In a preferred embodiment, the microorganism belongs to the genus *Corynebacterium* or *Brevibacterium*, with *Corynebacterium glutamicum* being particularly preferred. In a preferred embodiment, the microorganism is also utilized for the production of a desired compound, such as an amino acid, with lysine being particularly preferred.

In another aspect, the invention provides a method of identifying the presence or activity of *Corynebacterium diphtheriae* in a subject. This method includes detection of one or more of the nucleic acid or amino acid sequences of the invention (e.g., the

sequences set forth in the Sequence Listing as SEQ ID NOs 1 through 34)) in a subject, thereby detecting the presence or activity of *Corynebacterium diphtheriae* in the subject.

Still another aspect of the invention pertains to an isolated PTS protein or a portion, *e.g.*, a biologically active portion, thereof. In a preferred embodiment, the 5 isolated PTS protein or portion thereof can participate in the import of high-energy carbon molecules (*e.g.*, glucose, fructose, or sucrose) into *C. glutamicum*, and also may participate in one or more *C. glutamicum* intracellular signal transduction pathways. In another preferred embodiment, the isolated PTS protein or portion thereof is sufficiently homologous to an amino acid sequence of the invention (*e.g.*, a sequence of an even- 10 numbered SEQ ID NO: in the Sequence Listing) such that the protein or portion thereof maintains the ability to participate in the import of high-energy carbon molecules (*e.g.*, glucose, fructose, or sucrose) into *C. glutamicum*, and /or to participate in one or more *C. glutamicum* intracellular signal transduction pathways.

The invention also provides an isolated preparation of a PTS protein. In 15 preferred embodiments, the PTS protein comprises an amino acid sequence of the invention (*e.g.*, a sequence of an even-numbered SEQ ID NO: of the Sequence Listing). In another preferred embodiment, the invention pertains to an isolated full length protein which is substantially homologous to an entire amino acid sequence of the invention (*e.g.*, a sequence of an even-numbered SEQ ID NO: of the Sequence Listing) (encoded 20 by an open reading frame set in a corresponding odd-numbered SEQ ID NO: of the Sequence Listing). In yet another embodiment, the protein is at least about 50%, preferably at least about 60%, and more preferably at least about 70%, 80%, or 90%, and most preferably at least about 95%, 96%, 97%, 98%, or 99% or more homologous to an entire amino acid sequence of the invention (*e.g.*, a sequence of an even-numbered 25 SEQ ID NO: of the Sequence Listing). In other embodiments, the isolated PTS protein comprises an amino acid sequence which is at least about 50% or more homologous to one of the amino acid sequences of the invention (*e.g.*, a sequence of an even-numbered SEQ ID NO: of the Sequence Listing) and is able to participate in the import of high-energy carbon molecules (*e.g.*, glucose, fructose, or sucrose) into *C. glutamicum*, and/or 30 to participate in one or more *C. glutamicum* intracellular signal transduction pathways, or has one or more of the activities set forth in Table 1.

- 8 -

Alternatively, the isolated PTS protein can comprise an amino acid sequence which is encoded by a nucleotide sequence which hybridizes, e.g., hybridizes under stringent conditions, or is at least about 50%, preferably at least about 60%, more preferably at least about 70%, 80%, or 90%, and even more preferably at least about 5 95%, 96%, 97%, 98%, or 99% or more homologous, to a nucleotide sequence of one of the even-numbered SEQ ID NOS set forth in the Sequence Listing. It is also preferred that the preferred forms of PTS proteins also have one or more of the PTS bioactivities described herein.

The PTS polypeptide, or a biologically active portion thereof, can be operatively linked to a non-PTS polypeptide to form a fusion protein. In preferred embodiments, 10 this fusion protein has an activity which differs from that of the PTS protein alone. In other preferred embodiments, this fusion protein results in increased yields, production, and/or efficiency of production of a desired fine chemical from *C. glutamicum*. In particularly preferred embodiments, integration of this fusion protein into a host cell 15 modulates the production of a desired compound from the cell.

In another aspect, the invention provides methods for screening molecules which modulate the activity of a PTS protein, either by interacting with the protein itself or a substrate or binding partner of the PTS protein, or by modulating the transcription or translation of a PTS nucleic acid molecule of the invention.

Another aspect of the invention pertains to a method for producing a fine 20 chemical. This method involves the culturing of a cell containing a vector directing the expression of a PTS nucleic acid molecule of the invention, such that a fine chemical is produced. In a preferred embodiment, this method further includes the step of obtaining a cell containing such a vector, in which a cell is transfected with a vector directing the 25 expression of a PTS nucleic acid. In another preferred embodiment, this method further includes the step of recovering the fine chemical from the culture. In a particularly preferred embodiment, the cell is from the genus *Corynebacterium* or *Brevibacterium*, or is selected from those strains set forth in Table 3.

Another aspect of the invention pertains to methods for modulating production of 30 a molecule from a microorganism. Such methods include contacting the cell with an agent which modulates PTS protein activity or PTS nucleic acid expression such that a cell associated activity is altered relative to this same activity in the absence of the

- 9 -

agent. In a preferred embodiment, the cell is modulated for the uptake of one or more sugars, such that the yields or rate of production of a desired fine chemical by this microorganism is improved. The agent which modulates PTS protein activity can be an agent which stimulates PTS protein activity or PTS nucleic acid expression. Examples 5 of agents which stimulate PTS protein activity or PTS nucleic acid expression include small molecules, active PTS proteins, and nucleic acids encoding PTS proteins that have been introduced into the cell. Examples of agents which inhibit PTS activity or expression include small molecules, and antisense PTS nucleic acid molecules.

Another aspect of the invention pertains to methods for modulating yields of a 10 desired compound from a cell, involving the introduction of a wild-type or mutant PTS gene into a cell, either maintained on a separate plasmid or integrated into the genome of the host cell. If integrated into the genome, such integration can random, or it can take place by homologous recombination such that the native gene is replaced by the introduced copy, causing the production of the desired compound from the cell to be 15 modulated. In a preferred embodiment, said yields are increased. In another preferred embodiment, said chemical is a fine chemical. In a particularly preferred embodiment, said fine chemical is an amino acid. In especially preferred embodiments, said amino acid is L-lysine.

20 **Detailed Description of the Invention**

The present invention provides PTS nucleic acid and protein molecules which are involved in the uptake of high-energy carbon molecules (e.g., sucrose, fructose, or glucose) into *C. glutamicum*, and may also participate in intracellular signal transduction pathways in this microorganism. The molecules of the invention may be utilized in the 25 modulation of production of fine chemicals from microorganisms. Such modulation may be due to increased intracellular levels of high-energy molecules needed to produce, e.g., ATP, GTP and other molecules utilized to drive energetically unfavorable biochemical reactions in the cell, such as the biosynthesis of a fine chemical. This modulation of fine chemical production may also be due to the fact that the breakdown 30 products of many sugars serve as intermediates or precursors for other biosynthetic pathways, including those of certain fine chemicals. Further, PTS proteins are known to participate in certain intracellular signal transduction pathways which may have

- 10 -

regulatory activity for one or more fine chemical metabolic pathways; by manipulating these PTS proteins, one may thereby activate a fine chemical biosynthetic pathways or repress a fine chemical degradation pathway. Aspects of the invention are further explicated below.

5

I. Fine Chemicals

The term 'fine chemical' is art-recognized and includes molecules produced by an organism which have applications in various industries, such as, but not limited to, the pharmaceutical, agriculture, and cosmetics industries. Such compounds include

10 organic acids, such as tartaric acid, itaconic acid, and diaminopimelic acid, both proteinogenic and non-proteinogenic amino acids, purine and pyrimidine bases, nucleosides, and nucleotides (as described *e.g.* in Kuninaka, A. (1996) Nucleotides and related compounds, p. 561-612, in Biotechnology vol. 6, Rehm *et al.*, eds. VCH: Weinheim, and references contained therein), lipids, both saturated and unsaturated fatty acids (*e.g.*, arachidonic acid), diols (*e.g.*, propane diol, and butane diol), carbohydrates (*e.g.*, hyaluronic acid and trehalose), aromatic compounds (*e.g.*, aromatic amines, vanillin, and indigo), vitamins and cofactors (as described in Ullmann's Encyclopedia of Industrial Chemistry, vol. A27, "Vitamins", p. 443-613 (1996) VCH: Weinheim and references therein; and Ong, A.S., Niki, E. & Packer, L. (1995) "Nutrition, Lipids, 15 Health, and Disease" Proceedings of the UNESCO/Confederation of Scientific and Technological Associations in Malaysia, and the Society for Free Radical Research – Asia, held Sept. 1-3, 1994 at Penang, Malaysia, AOCS Press, (1995)), enzymes, polyketides (Cane *et al.* (1998) *Science* 282: 63-68), and all other chemicals described in Gutcho (1983) Chemicals by Fermentation, Noyes Data Corporation, ISBN: 20 0818805086 and references therein. The metabolism and uses of certain of these fine chemicals are further explicated below.

A. *Amino Acid Metabolism and Uses*

Amino acids comprise the basic structural units of all proteins, and as such are 30 essential for normal cellular functioning in all organisms. The term "amino acid" is art-recognized. The proteinogenic amino acids, of which there are 20 species, serve as structural units for proteins, in which they are linked by peptide bonds, while the

- 11 -

nonproteinogenic amino acids (hundreds of which are known) are not normally found in proteins (see Ullmann's Encyclopedia of Industrial Chemistry, vol. A2, p. 57-97 VCH: Weinheim (1985)). Amino acids may be in the D- or L- optical configuration, though L-amino acids are generally the only type found in naturally-occurring proteins.

5 Biosynthetic and degradative pathways of each of the 20 proteinogenic amino acids have been well characterized in both prokaryotic and eukaryotic cells (see, for example, Stryer, L. Biochemistry, 3rd edition, pages 578-590 (1988)). The 'essential' amino acids (histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine), so named because they are generally a nutritional requirement due to the

10 complexity of their biosyntheses, are readily converted by simple biosynthetic pathways to the remaining 11 'nonessential' amino acids (alanine, arginine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, and tyrosine). Higher animals do retain the ability to synthesize some of these amino acids, but the essential amino acids must be supplied from the diet in order for normal protein synthesis to occur.

15 Aside from their function in protein biosynthesis, these amino acids are interesting chemicals in their own right, and many have been found to have various applications in the food, feed, chemical, cosmetics, agriculture, and pharmaceutical industries. Lysine is an important amino acid in the nutrition not only of humans, but also of monogastric animals such as poultry and swine. Glutamate is most commonly

20 used as a flavor additive (mono-sodium glutamate, MSG) and is widely used throughout the food industry, as are aspartate, phenylalanine, glycine, and cysteine. Glycine, L-methionine and tryptophan are all utilized in the pharmaceutical industry. Glutamine, valine, leucine, isoleucine, histidine, arginine, proline, serine and alanine are of use in both the pharmaceutical and cosmetics industries. Threonine, tryptophan, and D/L-

25 methionine are common feed additives. (Leuchtenberger, W. (1996) Amino acids – technical production and use, p. 466-502 in Rehm *et al.* (eds.) Biotechnology vol. 6, chapter 14a, VCH: Weinheim). Additionally, these amino acids have been found to be useful as precursors for the synthesis of synthetic amino acids and proteins, such as N-acetylcysteine, S-carboxymethyl-L-cysteine, (S)-5-hydroxytryptophan, and others

30 described in Ullmann's Encyclopedia of Industrial Chemistry, vol. A2, p. 57-97, VCH: Weinheim, 1985.

- 12 -

The biosynthesis of these natural amino acids in organisms capable of producing them, such as bacteria, has been well characterized (for review of bacterial amino acid biosynthesis and regulation thereof, see Umbarger, H.E.(1978) *Ann. Rev. Biochem.* 47: 533-606). Glutamate is synthesized by the reductive amination of α -ketoglutarate, an intermediate in the citric acid cycle. Glutamine, proline, and arginine are each subsequently produced from glutamate. The biosynthesis of serine is a three-step process beginning with 3-phosphoglycerate (an intermediate in glycolysis), and resulting in this amino acid after oxidation, transamination, and hydrolysis steps. Both cysteine and glycine are produced from serine; the former by the condensation of 5 homocysteine with serine, and the latter by the transferal of the side-chain β -carbon atom to tetrahydrofolate, in a reaction catalyzed by serine transhydroxymethylase. Phenylalanine, and tyrosine are synthesized from the glycolytic and pentose phosphate pathway precursors erythrose 4-phosphate and phosphoenolpyruvate in a 9-step biosynthetic pathway that differ only at the final two steps after synthesis of prephenate. 10 Tryptophan is also produced from these two initial molecules, but its synthesis is an 11-step pathway. Tyrosine may also be synthesized from phenylalanine, in a reaction catalyzed by phenylalanine hydroxylase. Alanine, valine, and leucine are all biosynthetic products of pyruvate, the final product of glycolysis. Aspartate is formed 15 from oxaloacetate, an intermediate of the citric acid cycle. Asparagine, methionine, threonine, and lysine are each produced by the conversion of aspartate. Isoleucine is formed from threonine. A complex 9-step pathway results in the production of histidine 20 from 5-phosphoribosyl-1-pyrophosphate, an activated sugar.

Amino acids in excess of the protein synthesis needs of the cell cannot be stored, and are instead degraded to provide intermediates for the major metabolic pathways of 25 the cell (for review see Stryer, L. *Biochemistry* 3rd ed. Ch. 21 "Amino Acid Degradation and the Urea Cycle" p. 495-516 (1988)). Although the cell is able to convert unwanted amino acids into useful metabolic intermediates, amino acid production is costly in terms of energy, precursor molecules, and the enzymes necessary to synthesize them. Thus it is not surprising that amino acid biosynthesis is regulated by feedback inhibition, 30 in which the presence of a particular amino acid serves to slow or entirely stop its own production (for overview of feedback mechanisms in amino acid biosynthetic pathways, see Stryer, L. *Biochemistry*, 3rd ed. Ch. 24: "Biosynthesis of Amino Acids and Heme" p.

575-600 (1988)). Thus, the output of any particular amino acid is limited by the amount of that amino acid present in the cell.

B. Vitamin, Cofactor, and Nutraceutical Metabolism and Uses

5 Vitamins, cofactors, and nutraceuticals comprise another group of molecules which the higher animals have lost the ability to synthesize and so must ingest, although they are readily synthesized by other organisms, such as bacteria. These molecules are either bioactive substances themselves, or are precursors of biologically active substances which may serve as electron carriers or intermediates in a variety of
10 metabolic pathways. Aside from their nutritive value, these compounds also have significant industrial value as coloring agents, antioxidants, and catalysts or other processing aids. (For an overview of the structure, activity, and industrial applications of these compounds, see, for example, Ullman's Encyclopedia of Industrial Chemistry, "Vitamins" vol. A27, p. 443-613, VCH: Weinheim, 1996.) The term "vitamin" is art-
15 recognized, and includes nutrients which are required by an organism for normal functioning, but which that organism cannot synthesize by itself. The group of vitamins may encompass cofactors and nutraceutical compounds. The language "cofactor" includes nonproteinaceous compounds required for a normal enzymatic activity to occur. Such compounds may be organic or inorganic; the cofactor molecules of the
20 invention are preferably organic. The term "nutraceutical" includes dietary supplements having health benefits in plants and animals, particularly humans. Examples of such molecules are vitamins, antioxidants, and also certain lipids (e.g., polyunsaturated fatty acids).

25 The biosynthesis of these molecules in organisms capable of producing them, such as bacteria, has been largely characterized (Ullman's Encyclopedia of Industrial Chemistry, "Vitamins" vol. A27, p. 443-613, VCH: Weinheim, 1996; Michal, G. (1999) Biochemical Pathways: An Atlas of Biochemistry and Molecular Biology, John Wiley & Sons; Ong, A.S., Niki, E. & Packer, L. (1995) "Nutrition, Lipids, Health, and Disease" Proceedings of the UNESCO/Confederation of Scientific and Technological
30 Associations in Malaysia, and the Society for Free Radical Research – Asia, held Sept. 1-3, 1994 at Penang, Malaysia, AOCS Press: Champaign, IL X, 374 S).

Thiamin (vitamin B₁) is produced by the chemical coupling of pyrimidine and thiazole moieties. Riboflavin (vitamin B₂) is synthesized from guanosine-5'-triphosphate (GTP) and ribose-5'-phosphate. Riboflavin, in turn, is utilized for the synthesis of flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD). The family of

5 compounds collectively termed 'vitamin B₆' (e.g., pyridoxine, pyridoxamine, pyridoxal-5'-phosphate, and the commercially used pyridoxin hydrochloride) are all derivatives of the common structural unit, 5-hydroxy-6-methylpyridine. Pantothenate (pantothenic acid, (R)-(+)-N-(2,4-dihydroxy-3,3-dimethyl-1-oxobutyl)-β-alanine) can be produced either by chemical synthesis or by fermentation. The final steps in pantothenate

10 biosynthesis consist of the ATP-driven condensation of β-alanine and pantoic acid. The enzymes responsible for the biosynthesis steps for the conversion to pantoic acid, to β-alanine and for the condensation to pantothenic acid are known. The metabolically active form of pantothenate is Coenzyme A, for which the biosynthesis proceeds in 5 enzymatic steps. Pantothenate, pyridoxal-5'-phosphate, cysteine and ATP are the

15 precursors of Coenzyme A. These enzymes not only catalyze the formation of panthothante, but also the production of (R)-pantoic acid, (R)-pantolacton, (R)-panthenol (provitamin B₅), pantetheine (and its derivatives) and coenzyme A.

Biotin biosynthesis from the precursor molecule pimeloyl-CoA in microorganisms has been studied in detail and several of the genes involved have been

20 identified. Many of the corresponding proteins have been found to also be involved in Fe-cluster synthesis and are members of the nifS class of proteins. Lipoic acid is derived from octanoic acid, and serves as a coenzyme in energy metabolism, where it becomes part of the pyruvate dehydrogenase complex and the α-ketoglutarate dehydrogenase complex. The folates are a group of substances which are all derivatives

25 of folic acid, which in turn is derived from L-glutamic acid, p-amino-benzoic acid and 6-methylpterin. The biosynthesis of folic acid and its derivatives, starting from the metabolism intermediates guanosine-5'-triphosphate (GTP), L-glutamic acid and p-amino-benzoic acid has been studied in detail in certain microorganisms.

Corrinoids (such as the cobalamines and particularly vitamin B₁₂) and

30 porphyrines belong to a group of chemicals characterized by a tetrapyrrole ring system. The biosynthesis of vitamin B₁₂ is sufficiently complex that it has not yet been completely characterized, but many of the enzymes and substrates involved are now

- 15 -

known. Nicotinic acid (nicotinate), and nicotinamide are pyridine derivatives which are also termed 'niacin'. Niacin is the precursor of the important coenzymes NAD (nicotinamide adenine dinucleotide) and NADP (nicotinamide adenine dinucleotide phosphate) and their reduced forms.

5 The large-scale production of these compounds has largely relied on cell-free chemical syntheses, though some of these chemicals have also been produced by large-scale culture of microorganisms, such as riboflavin, Vitamin B₆, pantothenate, and biotin. Only Vitamin B₁₂ is produced solely by fermentation, due to the complexity of its synthesis. *In vitro* methodologies require significant inputs of materials and time,
10 often at great cost.

C. Purine, Pyrimidine, Nucleoside and Nucleotide Metabolism and Uses

Purine and pyrimidine metabolism genes and their corresponding proteins are important targets for the therapy of tumor diseases and viral infections. The language
15 "purine" or "pyrimidine" includes the nitrogenous bases which are constituents of nucleic acids, co-enzymes, and nucleotides. The term "nucleotide" includes the basic structural units of nucleic acid molecules, which are comprised of a nitrogenous base, a pentose sugar (in the case of RNA, the sugar is ribose; in the case of DNA, the sugar is D-deoxyribose), and phosphoric acid. The language "nucleoside" includes molecules
20 which serve as precursors to nucleotides, but which are lacking the phosphoric acid moiety that nucleotides possess. By inhibiting the biosynthesis of these molecules, or their mobilization to form nucleic acid molecules, it is possible to inhibit RNA and DNA synthesis; by inhibiting this activity in a fashion targeted to cancerous cells, the ability of tumor cells to divide and replicate may be inhibited. Additionally, there are
25 nucleotides which do not form nucleic acid molecules, but rather serve as energy stores (i.e., AMP) or as coenzymes (i.e., FAD and NAD).

Several publications have described the use of these chemicals for these medical indications, by influencing purine and/or pyrimidine metabolism (e.g. Christopherson, R.I. and Lyons, S.D. (1990) "Potent inhibitors of *de novo* pyrimidine and purine
30 biosynthesis as chemotherapeutic agents." *Med. Res. Reviews* 10: 505-548). Studies of enzymes involved in purine and pyrimidine metabolism have been focused on the development of new drugs which can be used, for example, as immunosuppressants or

- 16 -

anti-proliferants (Smith, J.L., (1995) "Enzymes in nucleotide synthesis." *Curr. Opin. Struct. Biol.* 5: 752-757; (1995) *Biochem Soc. Transact.* 23: 877-902). However, purine and pyrimidine bases, nucleosides and nucleotides have other utilities: as intermediates in the biosynthesis of several fine chemicals (e.g., thiamine, S-adenosyl-methionine, 5 folates, or riboflavin), as energy carriers for the cell (e.g., ATP or GTP), and for chemicals themselves, commonly used as flavor enhancers (e.g., IMP or GMP) or for several medicinal applications (see, for example, Kuninaka, A. (1996) Nucleotides and Related Compounds in Biotechnology vol. 6, Rehm *et al.*, eds. VCH: Weinheim, p. 561-612). Also, enzymes involved in purine, pyrimidine, nucleoside, or nucleotide 10 metabolism are increasingly serving as targets against which chemicals for crop protection, including fungicides, herbicides and insecticides, are developed.

The metabolism of these compounds in bacteria has been characterized (for reviews see, for example, Zalkin, H. and Dixon, J.E. (1992) "de novo" purine nucleotide biosynthesis", in: *Progress in Nucleic Acid Research and Molecular Biology*, vol. 42, 15 Academic Press:, p. 259-287; and Michal, G. (1999) "Nucleotides and Nucleosides", Chapter 8 in: *Biochemical Pathways: An Atlas of Biochemistry and Molecular Biology*, Wiley: New York). Purine metabolism has been the subject of intensive research, and is essential to the normal functioning of the cell. Impaired purine metabolism in higher animals can cause severe disease, such as gout. Purine nucleotides are synthesized from 20 ribose-5-phosphate, in a series of steps through the intermediate compound inosine-5'-phosphate (IMP), resulting in the production of guanosine-5'-monophosphate (GMP) or adenosine-5'-monophosphate (AMP), from which the triphosphate forms utilized as nucleotides are readily formed. These compounds are also utilized as energy stores, so their degradation provides energy for many different biochemical processes in the cell. 25 Pyrimidine biosynthesis proceeds by the formation of uridine-5'-monophosphate (UMP) from ribose-5-phosphate. UMP, in turn, is converted to cytidine-5'-triphosphate (CTP). The deoxy- forms of all of these nucleotides are produced in a one step reduction reaction from the diphosphate ribose form of the nucleotide to the diphosphate deoxyribose form of the nucleotide. Upon phosphorylation, these molecules are able to 30 participate in DNA synthesis.

D. Trehalose Metabolism and Uses

Trehalose consists of two glucose molecules, bound in α, α -1,1 linkage. It is commonly used in the food industry as a sweetener, an additive for dried or frozen foods, and in beverages. However, it also has applications in the pharmaceutical, cosmetics and biotechnology industries (see, for example, Nishimoto *et al.*, (1998) U.S. Patent No. 5,759,610; Singer, M.A. and Lindquist, S. (1998) *Trends Biotech.* 16: 460-467; Paiva, C.L.A. and Panek, A.D. (1996) *Biotech. Ann. Rev.* 2: 293-314; and Shiosaka, M. (1997) *J. Japan* 172: 97-102). Trehalose is produced by enzymes from many microorganisms and is naturally released into the surrounding medium, from which it can be collected using methods known in the art.

II. The Phosphoenolpyruvate:Sugar Phosphotransferase System

The ability of cells to grow and divide rapidly in culture is to a great degree dependent on the extent to which the cells are able to take up and utilize high energy molecules, such as glucose and other sugars. Different transporter proteins exist to transport different carbon sources into the cell. There are transport proteins for sugars, such as glucose, fructose, mannose, galactose, ribose, sorbose, ribulose, lactose, maltose, sucrose, or raffinose, and also transport proteins for starch or cellulose degradation products. Other transport systems serve to import alcohols (e.g., methanol or ethanol), alkanes, fatty acids and organic acids like acetic acid or lactic acid. In bacteria, sugars may be transported into the cell across the cellular membrane by a variety of mechanisms. Aside from the symport of sugars with protons, one of the most commonly utilized processes for sugar uptake is the bacterial phosphoenolpyruvate: sugar phosphotransferase system (PTS). This system not only catalyzes the translocation (with concomitant phosphorylation) of sugars and hexitols, but it also regulates cellular metabolism in response to the availability of carbohydrates. Such PTS systems are ubiquitous in bacteria but do not occur in archaebacteria or eukaryotes.

Functionally, the PTS system consists of two cytoplasmic proteins, Enzyme I and HPr, and a variable number of sugar-specific integral and peripheral membrane transport complexes (each termed 'Enzyme II' with a sugar-specific subscript, e.g., 'Enzyme II^{Glu}', for the Enzyme II complex which binds glucose). Enzymes II specific for mono-, di-, or oligosaccharides, like glucose, fructose, mannose, galactose, ribose,

sorbose, ribulose, lactose, maltose, sucrose, raffinose, and others are known. Enzyme I transfers phosphoryl groups from phosphoenolpyruvate (PEP) to the phosphoryl carrier protein, HPr. HPr then transfers the phosphoryl groups to the different Enzyme II transport complexes. While the amino acid sequences of Enzyme I and HPr are quite similar in all bacteria, the sequences for PTS transporters can be grouped into structurally unrelated families. Further, the number and homology between these genes vary from bacteria to bacteria. The *E. coli* genome encodes 38 different PTS proteins, 33 of which are subunits belonging to 22 different transporters. The *M. genitalium* genome contains one gene each for Enzyme I and HPr, and only two genes for PTS transporters. The genomes of *T. palladium* and *C. trachomatis* contain genes for Enzyme I- and HPr-like proteins but no PTS transporters.

All PTS transporters consist of three functional units, IIA, IIB, and IIC, which occur either as protein subunits in a complex (e.g., IIA^{Glc}IICB^{Glc}) or as domains of a single polypeptide chain (e.g., IICBA^{GlcNAc}). IIA and IIB sequentially transfer phosphoryl groups from HPr to the transported sugars. IIC contains the sugar binding site, and spans the inner membrane six or eight times. Sugar translocation is coupled to the transient phosphorylation of the IIB domain. Enzyme I, HPr, and IIA are phosphorylated at histidine residues, while IIB subunits are phosphorylated at either cysteine or histidine residues, depending on the particular transporter involved.

Phosphorylation of the sugar being imported has the advantage of blocking the diffusion of the sugar back through the cellular membrane to the extracellular medium, since the charged phosphate group cannot readily traverse the hydrophobic core of the membrane.

Some PTS proteins play a role in intracellular signal transduction in addition to their function in the active transport of sugars. These subunits regulate their targets either allosterically, or by phosphorylation. Their regulatory activity varies with the degree of their phosphorylation (i.e., the ratio of the non-phosphorylated to the phosphorylated form), which in turn varies with the ratio of sugar-dependent dephosphorylation and phosphoenolpyruvate-dependent rephosphorylation. Examples of such intracellular regulation by PTS proteins in *E. coli* include the inhibition of glycerol kinase by dephosphorylated IIA^{Glc}, and the activation of adenylate cyclase by the phosphorylated version of this protein. Also, the HPr and the IIB domains of some transporters in these microorganisms regulate gene expression by reversible

- 19 -

phosphorylation of transcription antiterminators. In gram-positive bacteria, the activity of HPr is modulated by HPr-specific serine kinases and phosphatases. For example, HPr phosphorylated at serine-46 functions as a co-repressor of the transcriptional repressor CcpA. Lastly, it has been found that unphosphorylated Enzyme I inhibits the sensor

5 kinase CheA of the bacterial chemotaxis machinery, providing a direct link between the sugar binding and transport systems of the bacterium and those systems governing movement of the bacterium (Sonenshein, A. L., *et al.*, eds. *Bacillus subtilis* and other gram-positive bacteria. ASM: Washington, D.C.; Neidhardt, F.C., *et al.*, eds. (1996) *Escherichia coli* and *Salmonella*. ASM Press: Washington, D.C.; Lengeler *et al.*, (1999).

10 Biology of Prokaryotes. Section II, pp. 68-87, Thieme Verlag: Stuttgart).

III. Elements and Methods of the Invention

The present invention is based, at least in part, on the discovery of novel molecules, referred to herein as PTS nucleic acid and protein molecules, which

15 participate in the uptake of high-energy carbon molecules (e.g., glucose, sucrose, and fructose) into *C. glutamicum*, and may also participate in one or more intracellular signal transduction pathways in these microorganisms. In one embodiment, the PTS molecules function to import high-energy carbon molecules into the cell, where the energy produced by their degradation may be utilized to power less energetically favorable

20 biochemical reactions, and their degradation products may serve as intermediates and precursors for a number of other metabolic pathways. In another embodiment, the PTS molecules may participate in one or more intracellular signal transduction pathways, wherein the presence of a modified form of a PTS molecule (e.g., a phosphorylated PTS protein) may participate in a signal transduction cascade which regulates one or more

25 cellular processes. In a preferred embodiment, the activity of the PTS molecules of the present invention has an impact on the production of a desired fine chemical by this organism. In a particularly preferred embodiment, the PTS molecules of the invention are modulated in activity, such that the yield, production or efficiency of production of one or more fine chemicals from *C. glutamicum* is also modulated.

30 The language, "PTS protein" or "PTS polypeptide" includes proteins which participate in the uptake of one or more high-energy carbon compounds (e.g., mono-, di, or oligosaccharides, such as fructose, mannose, sucrose, glucose, raffinose, galactose,

ribose, lactose, maltose, and ribulose) from the extracellular medium to the interior of the cell. Such PTS proteins may also participate in one or more intracellular signal transduction pathways, such as, but not limited to, those governing the uptake of different sugars into the cell. Examples of PTS proteins include those encoded by the 5 PTS genes set forth in Table 1 and by the odd-numbered SEQ ID NOS. For general references pertaining to the PTS system, see: Stryer, L. (1988) Biochemistry. Chapter 37: "Membrane Transport", W.H. Freeman: New York, p. 959-961; Darnell, J. *et al.* (1990) Molecular Cell Biology Scientific American Books: New York, p. 552-553, and Michal, G., ed. (1999) Biochemical Pathways: An Atlas of Biochemistry and Molecular 10 Biology, Chapter 15 "Special Bacterial Metabolism". The terms "PTS gene" or "PTS nucleic acid sequence" include nucleic acid sequences encoding a PTS protein, which consist of a coding region and also corresponding untranslated 5' and 3' sequence regions. Examples of PTS genes include those set forth in Table 1. The terms "production" or "productivity" are art-recognized and include the concentration of the 15 fermentation product (for example, the desired fine chemical) formed within a given time and a given fermentation volume (e.g., kg product per hour per liter). The term "efficiency of production" includes the time required for a particular level of production to be achieved (for example, how long it takes for the cell to attain a particular rate of output of a fine chemical). The term "yield" or "product/carbon yield" is art-recognized 20 and includes the efficiency of the conversion of the carbon source into the product (i.e., fine chemical). This is generally written as, for example, kg product per kg carbon source. By increasing the yield or production of the compound, the quantity of recovered molecules, or of useful recovered molecules of that compound in a given amount of culture over a given amount of time is increased. The terms "biosynthesis" or 25 a "biosynthetic pathway" are art-recognized and include the synthesis of a compound, preferably an organic compound, by a cell from intermediate compounds in what may be a multistep and highly regulated process. The terms "degradation" or a "degradation pathway" are art-recognized and include the breakdown of a compound, preferably an organic compound, by a cell to degradation products (generally speaking, smaller or less 30 complex molecules) in what may be a multistep and highly regulated process. The language "metabolism" is art-recognized and includes the totality of the biochemical reactions that take place in an organism. The metabolism of a particular compound,

then, (e.g., the metabolism of an amino acid such as glycine) comprises the overall biosynthetic, modification, and degradation pathways in the cell related to this compound. The language "transport" or "import" is art-recognized and includes the facilitated movement of one or more molecules across a cellular membrane through 5 which the molecule would otherwise be unable to pass.

In another embodiment, the PTS molecules of the invention are capable of modulating the production of a desired molecule, such as a fine chemical, in a microorganism such as *C. glutamicum*. Using recombinant genetic techniques, one or more of the PTS proteins of the invention may be manipulated such that its function is 10 modulated. For example, a protein involved in the PTS-mediated import of glucose may be altered such that it is optimized in activity, and the PTS system for the importation of glucose may thus be able to translocate increased amounts of glucose into the cell. Since glucose molecules are utilized not only for energy to drive energetically 15 unfavorable biochemical reactions, such as fine chemical biosyntheses, but also as precursors and intermediates in a number of fine chemical biosynthetic pathways (e.g., serine is synthesized from 3-phosphoglycerate). In each case, the overall yield or rate of production of one of these desired fine chemicals may be increased, either by increasing the energy available for such production to occur, or by increasing the availability of compounds necessary for such production to take place.

20 Further, many PTS proteins are known to play key roles in intracellular signal transduction pathways which regulate cellular metabolism and sugar uptake in keeping with the availability of carbon sources. For example, it is known that an increased intracellular level of fructose 1,6-bisphosphate (a compound produced during glycolysis) results in the phosphorylation of a serine residue on HPr which prevents this 25 protein from serving as a phosphoryl donor in any PTS sugar transport process, thereby blocking further sugar uptake. By mutagenizing HPr such that this serine residue cannot be phosphorylated, one may constitutively activate HPr and thereby increase sugar transport into the cell, which in turn will ensure greater intracellular energy stores and intermediate/precursor molecules for the biosynthesis of one or more desired fine 30 chemicals.

The isolated nucleic acid sequences of the invention are contained within the genome of a *Corynebacterium glutamicum* strain available through the American Type

Culture Collection, given designation ATCC 13032. The nucleotide sequence of the isolated *C. glutamicum* PTS DNAs and the predicted amino acid sequences of the *C. glutamicum* PTS proteins are shown in the Sequence Listing as odd-numbered SEQ ID NOS and even-numbered SEQ ID NOS, respectively.

5 Computational analyses were performed which classified and/or identified these nucleotide sequences as sequences which encode metabolic pathway proteins.

The present invention also pertains to proteins which have an amino acid sequence which is substantially homologous to an amino acid sequence of the invention (e.g., the sequence of an even-numbered SEQ ID NO of the Sequence Listing). As used 10 herein, a protein which has an amino acid sequence which is substantially homologous to a selected amino acid sequence is least about 50% homologous to the selected amino acid sequence, e.g., the entire selected amino acid sequence. A protein which has an amino acid sequence which is substantially homologous to a selected amino acid sequence can also be least about 50-60%, preferably at least about 60-70%, and more 15 preferably at least about 70-80%, 80-90%, or 90-95%, and most preferably at least about 96%, 97%, 98%, 99% or more homologous to the selected amino acid sequence.

The PTS protein or a biologically active portion or fragment thereof of the invention can participate in the transport of high-energy carbon-containing molecules such as glucose into *C. glutamicum*, or can participate in intracellular signal transduction 20 in this microorganism, or may have one or more of the activities set forth in Table 1.

Various aspects of the invention are described in further detail in the following subsections:

A. Isolated Nucleic Acid Molecules

25 One aspect of the invention pertains to isolated nucleic acid molecules that encode PTS polypeptides or biologically active portions thereof, as well as nucleic acid fragments sufficient for use as hybridization probes or primers for the identification or amplification of PTS-encoding nucleic acid (e.g., PTS DNA). As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (e.g., cDNA or genomic 30 DNA) and RNA molecules (e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. This term also encompasses untranslated sequence located at both the 3' and 5' ends of the coding region of the gene: at least about 100 nucleotides

of sequence upstream from the 5' end of the coding region and at least about 20 nucleotides of sequence downstream from the 3' end of the coding region of the gene. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA. An "isolated" nucleic acid molecule is one which is separated 5 from other nucleic acid molecules which are present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated PTS nucleic acid molecule can contain less than 10 about 5 kb, 4kb, 3kb, 2kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived (e.g., a *C. glutamicum* cell). Moreover, an "isolated" nucleic acid molecule, such as a DNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or chemical precursors or 15 other chemicals when chemically synthesized.

A nucleic acid molecule of the present invention, e.g., a nucleic acid molecule having a nucleotide sequence of an odd-numbered SEQ ID NO of the Sequence Listing, or a portion thereof, can be isolated using standard molecular biology techniques and the sequence information provided herein. For example, a *C. glutamicum* PTS DNA can be 20 isolated from a *C. glutamicum* library using all or portion of one of the odd-numbered SEQ ID NO sequences of the Sequence Listing as a hybridization probe and standard hybridization techniques (e.g., as described in Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989). 25 Moreover, a nucleic acid molecule encompassing all or a portion of one of the nucleic acid sequences of the invention (e.g., an odd-numbered SEQ ID NO of the Sequence Listing) can be isolated by the polymerase chain reaction using oligonucleotide primers designed based upon this sequence (e.g., a nucleic acid molecule encompassing all or a portion of one of the nucleic acid sequences of the invention (e.g., an odd-numbered 30 SEQ ID NO of the Sequence Listing) can be isolated by the polymerase chain reaction using oligonucleotide primers designed based upon this same sequence). For example, mRNA can be isolated from normal endothelial cells (e.g., by the guanidinium-

thiocyanate extraction procedure of Chirgwin *et al.* (1979) *Biochemistry* 18: 5294-5299) and DNA can be prepared using reverse transcriptase (e.g., Moloney MLV reverse transcriptase, available from Gibco/BRL, Bethesda, MD; or AMV reverse transcriptase, available from Seikagaku America, Inc., St. Petersburg, FL). Synthetic oligonucleotide primers for polymerase chain reaction amplification can be designed based upon one of the nucleotide sequences shown in the Sequence Listing. A nucleic acid of the invention can be amplified using cDNA or, alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to a PTS nucleotide sequence can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.

In a preferred embodiment, an isolated nucleic acid molecule of the invention comprises one of the nucleotide sequences shown in the Sequence Listing. The nucleic acid sequences of the invention, as set forth in the Sequence Listing, correspond to the *Corynebacterium glutamicum* PTS DNAs of the invention. This DNA comprises sequences encoding PTS proteins (i.e., the "coding region", indicated in each odd-numbered SEQ ID NO: sequence in the Sequence Listing), as well as 5' untranslated sequences and 3' untranslated sequences, also indicated in each odd-numbered SEQ ID NO: in the Sequence Listing. Alternatively, the nucleic acid molecule can comprise only the coding region of any of the nucleic acid sequences of the Sequence Listing.

For the purposes of this application, it will be understood that each of the nucleic acid and amino acid sequences set forth in the Sequence Listing has an identifying RXA, RXN, RXS, or RXC number having the designation "RXA", "RXN", "RXS", or "RXC" followed by 5 digits (i.e., RXA01503, RXN01299, RXS00315, or RXC00953). Each of the nucleic acid sequences comprises up to three parts: a 5' upstream region, a coding region, and a downstream region. Each of these three regions is identified by the same RXA, RXN, RXS, or RXC designation to eliminate confusion. The recitation "one of the odd-numbered sequences of the Sequence Listing" then, refers to any of the nucleic acid sequences in the Sequence Listing, which may be also be , distinguished by their differing RXA, RXN, RXS, or RXC designations. The coding region of each of these sequences is translated into a corresponding amino acid sequence, which is also set forth

- 25 -

in the Sequence Listing, as an even-numbered SEQ ID NO: immediately following the corresponding nucleic acid sequence . For example, the coding region for RXA02229 is set forth in SEQ ID NO:1, while the amino acid sequence which it encodes is set forth as SEQ ID NO:2. The sequences of the nucleic acid molecules of the invention are 5 identified by the same RXA, RXN, RXS, or RXC designations as the amino acid molecules which they encode, such that they can be readily correlated. For example, the amino acid sequences designated RXA01503, RXN01299, RXS00315, and RXC00953 are translations of the coding regions of the nucleotide sequence of nucleic acid molecules RXA01503, RXN01299, RXS00315, and RXC00953, respectively. The 10 correspondence between the RXA, RXN, RXS, and RXC nucleotide and amino acid sequences of the invention and their assigned SEQ ID NOs, is set forth in Table 1. For example, as set forth in Table 1, the nucleotide sequence of RXN01299 is SEQ ID NO: 7, and the corresponding amino acid sequence is SEQ ID NO:8.

Several of the genes of the invention are "F-designated genes". An F-designated 15 gene includes those genes set forth in Table 1 which have an 'F' in front of the RXA, RXN, RXS, or RXC designation. For example, SEQ ID NO:3, designated, as indicated on Table 1, as "F RXA00315", is an F-designated gene, as are SEQ ID NOs: 9, 11, and 13 (designated on Table 1 as "F RXA01299", "F RXA01883", and "F RXA01889", respectively).

20 In one embodiment, the nucleic acid molecules of the present invention are not intended to include *C. glutamicum* those compiled in Table 2. In the case of the dapD gene, a sequence for this gene was published in Wehrmann, A., *et al.* (1998) *J. Bacteriol.* 180(12): 3159-3165. However, the sequence obtained by the inventors of the present application is significantly longer than the published version. It is believed that 25 the published version relied on an incorrect start codon, and thus represents only a fragment of the actual coding region.

In another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which is a complement of one of the nucleotide sequences of the invention (e.g., a sequence of an odd-numbered SEQ ID 30 NO: of the Sequence Listing), or a portion thereof. A nucleic acid molecule which is complementary to one of the nucleotide sequences of the invention is one which is sufficiently complementary to one of the nucleotide sequences shown in the Sequence

Listing (e.g., the sequence of an odd-numbered SEQ ID NO:) such that it can hybridize to one of the nucleotide sequences of the invention, thereby forming a stable duplex.

In still another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleotide sequence which is at least about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60%, preferably at least about 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, or 70%, more preferably at least about 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, or 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, or 90%, or 91%, 92%, 93%, 94%, and even more preferably at least about 95%, 96%, 97%, 98%, 99% or more homologous to a nucleotide sequence of the invention (e.g., a sequence of an odd-numbered SEQ ID NO: of the Sequence Listing), or a portion thereof. Ranges and identity values intermediate to the above-recited ranges, (e.g., 70-90% identical or 80-95% identical) are also intended to be encompassed by the present invention. For example, ranges of identity values using a combination of any of the above values recited as upper and/or lower limits are intended to be included. In an additional preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleotide sequence which hybridizes, e.g., hybridizes under stringent conditions, to one of the nucleotide sequences of the invention (e.g., a sequence of an odd-numbered SEQ ID NO: of the Sequence Listing), or a portion thereof.

Moreover, the nucleic acid molecule of the invention can comprise only a portion of the coding region of the sequence of one of the odd-numbered SEQ ID NOs of the Sequence Listing, for example a fragment which can be used as a probe or primer or a fragment encoding a biologically active portion of a PTS protein. The nucleotide sequences determined from the cloning of the PTS genes from *C. glutamicum* allows for the generation of probes and primers designed for use in identifying and/or cloning PTS homologues in other cell types and organisms, as well as PTS homologues from other *Corynebacteria* or related species. The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, preferably about 25, more preferably about 40, 50 or 75 consecutive nucleotides of a sense strand of one of the nucleotide sequences of the invention (e.g., a sequence of one of the odd-numbered SEQ ID NOs of the Sequence Listing, an anti-sense sequence of one of these

sequences, or naturally occurring mutants thereof. Primers based on a nucleotide sequence of the invention can be used in PCR reactions to clone PTS homologues. Probes based on the PTS nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In preferred 5 embodiments, the probe further comprises a label group attached thereto, e.g. the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells which misexpress a PTS protein, such as by measuring a level of a PTS-encoding nucleic acid in a sample of cells e.g., detecting PTS mRNA levels or determining 10 whether a genomic PTS gene has been mutated or deleted.

In one embodiment, the nucleic acid molecule of the invention encodes a protein or portion thereof which includes an amino acid sequence which is sufficiently homologous to an amino acid sequence of the invention (e.g., a sequence of an even-numbered SEQ ID NO of the Sequence Listing), such that the protein or portion thereof 15 maintains the ability to participate in the transport of high-energy carbon molecules (such as glucose) into *C. glutamicum*, and may also participate in one or more intracellular signal transduction pathways. As used herein, the language "sufficiently homologous" refers to proteins or portions thereof which have amino acid sequences which include a minimum number of identical or equivalent (e.g., an amino acid residue 20 which has a similar side chain as an amino acid residue in a sequence of one of the even-numbered SEQ ID NOs of the Sequence Listing) amino acid residues to an amino acid sequence of the invention such that the protein or portion thereof is capable of transporting high-energy carbon-containing molecules such as glucose into *C. glutamicum*, and may also participate in intracellular signal transduction in this 25 microorganism. Protein members of such metabolic pathways, as described herein, function to transport high-energy carbon-containing molecules such as glucose into *C. glutamicum*, and may also participate in intracellular signal transduction in this microorganism. Examples of such activities are also described herein. Thus, "the function of a PTS protein" contributes to the overall functioning and/or regulation of one 30 or more phosphoenolpyruvate-based sugar transport pathway, and /or contributes, either directly or indirectly, to the yield, production, and/or efficiency of production of one or more fine chemicals. Examples of PTS protein activities are set forth in Table 1.

In another embodiment, the protein is at least about 50-60%, preferably at least about 60-70%, and more preferably at least about 70-80%, 80-90%, 90-95%, and most preferably at least about 96%, 97%, 98%, 99% or more homologous to an entire amino acid sequence of the invention (e.g., a sequence of an even-numbered SEQ ID NO: of the Sequence Listing).

Portions of proteins encoded by the PTS nucleic acid molecules of the invention are preferably biologically active portions of one of the PTS proteins. As used herein, the term "biologically active portion of a PTS protein" is intended to include a portion, 10 e.g., a domain/motif, of a PTS protein that is capable of transporting high-energy carbon-containing molecules such as glucose into *C. glutamicum*, or of participating in intracellular signal transduction in this microorganism, or has an activity as set forth in Table 1. To determine whether a PTS protein or a biologically active portion thereof can participate in the transportation of high-energy carbon-containing molecules such as 15 glucose into *C. glutamicum*, or can participate in intracellular signal transduction in this microorganism, an assay of enzymatic activity may be performed. Such assay methods are well known to those of ordinary skill in the art, as detailed in Example 8 of the Exemplification.

Additional nucleic acid fragments encoding biologically active portions of a 20 PTS protein can be prepared by isolating a portion of one of the amino acid sequences of the invention (e.g., a sequence of an even-numbered SEQ ID NO: of the Sequence Listing), expressing the encoded portion of the PTS protein or peptide (e.g., by recombinant expression *in vitro*) and assessing the activity of the encoded portion of the PTS protein or peptide.

25 The invention further encompasses nucleic acid molecules that differ from one of the nucleotide sequences of the invention (e.g., a sequence of an odd-numbered SEQ ID NO: of the Sequence Listing) (and portions thereof) due to degeneracy of the genetic code and thus encode the same PTS protein as that encoded by the nucleotide sequences of the invention. In another embodiment, an isolated nucleic acid molecule of the 30 invention has a nucleotide sequence encoding a protein having an amino acid sequence shown in the Sequence Listing (e.g., an even-numbered SEQ ID NO:). In a still further embodiment, the nucleic acid molecule of the invention encodes a full length *C.*

glutamicum protein which is substantially homologous to an amino acid sequence of the invention (encoded by an open reading frame shown in an odd-numbered SEQ ID NO: of the Sequence Listing).

It will be understood by one of ordinary skill in the art that in one embodiment 5 the sequences of the invention are not meant to include the sequences of the prior art, such as those Genbank sequences set forth in Tables 2 or 4 which were available prior to the present invention. In one embodiment, the invention includes nucleotide and amino acid sequences having a percent identity to a nucleotide or amino acid sequence of the invention which is greater than that of a sequence of the prior art (e.g., a Genbank 10 sequence (or the protein encoded by such a sequence) set forth in Tables 2 or 4). For example, the invention includes a nucleotide sequence which is greater than and/or at least 44% identical to the nucleotide sequence designated RXA01503 (SEQ ID NO:5), a nucleotide sequence which is greater than and/or at least 41% identical to the nucleotide sequence designated RXA00951 (SEQ ID NO:15), and a nucleotide sequence which is 15 greater than and/or at least 38% identical to the nucleotide sequence designated RXA01300 (SEQ ID NO:21). One of ordinary skill in the art would be able to calculate the lower threshold of percent identity for any given sequence of the invention by examining the GAP-calculated percent identity scores set forth in Table 4 for each of the three top hits for the given sequence, and by subtracting the highest GAP-calculated 20 percent identity from 100 percent. One of ordinary skill in the art will also appreciate that nucleic acid and amino acid sequences having percent identities greater than the lower threshold so calculated (e.g., at least 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60%, preferably at least about 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, or 70%, more preferably at least about 71%, 72%, 73%, 74%, 75%, 25 76%, 77%, 78%, 79%, or 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, or 90%, or 91%, 92%, 93%, 94%, and even more preferably at least about 95%, 96%, 97%, 98%, 99% or more identical) are also encompassed by the invention.

In addition to the *C. glutamicum* PTS nucleotide sequences set forth in the Sequence Listing as odd-numbered SEQ ID NOs, it will be appreciated by those of ordinary skill 30 in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of PTS proteins may exist within a population (e.g., the *C. glutamicum* population). Such genetic polymorphism in the PTS gene may exist among individuals

- 30 -

within a population due to natural variation. As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules comprising an open reading frame encoding a PTS protein, preferably a *C. glutamicum* PTS protein. Such natural variations can typically result in 1-5% variance in the nucleotide sequence of the PTS gene. Any and all such nucleotide variations and resulting amino acid polymorphisms in PTS that are the result of natural variation and that do not alter the functional activity of PTS proteins are intended to be within the scope of the invention.

Nucleic acid molecules corresponding to natural variants and non-*C. glutamicum* homologues of the *C. glutamicum* PTS DNA of the invention can be isolated based on their homology to the *C. glutamicum* PTS nucleic acid disclosed herein using the *C. glutamicum* DNA, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions. Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 15 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising a nucleotide sequence of an odd-numbered SEQ ID NO: of the Sequence Listing. In other embodiments, the nucleic acid is at least 30, 50, 100, 250 or more nucleotides in length. As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% homologous to each other typically remain hybridized to each other. Preferably, the conditions are such that sequences at least about 65%, more preferably at least about 70%, and even more preferably at least about 75% or more homologous to each other typically remain hybridized to each other. Such stringent conditions are known to those of ordinary skill in the art and can be found in Ausubel *et al.*, *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. A preferred, non-limiting example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65°C. Preferably, an isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to a nucleotide sequence of the invention corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g.,

encodes a natural protein). In one embodiment, the nucleic acid encodes a natural *C. glutamicum* PTS protein.

In addition to naturally-occurring variants of the PTS sequence that may exist in the population, one of ordinary skill in the art will further appreciate that changes can be 5 introduced by mutation into a nucleotide sequence of the invention, thereby leading to changes in the amino acid sequence of the encoded PTS protein, without altering the functional ability of the PTS protein. For example, nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in a nucleotide sequence of the invention. A "non-essential" amino acid residue is a residue 10 that can be altered from the wild-type sequence of one of the PTS proteins (e.g., an even-numbered SEQ ID NO: of the Sequence Listing) without altering the activity of said PTS protein, whereas an "essential" amino acid residue is required for PTS protein activity. Other amino acid residues, however, (e.g., those that are not conserved or only semi-conserved in the domain having PTS activity) may not be essential for activity and 15 thus are likely to be amenable to alteration without altering PTS activity.

Accordingly, another aspect of the invention pertains to nucleic acid molecules encoding PTS proteins that contain changes in amino acid residues that are not essential for PTS activity. Such PTS proteins differ in amino acid sequence from a sequence of an even-numbered SEQ ID NO: of the Sequence Listing yet retain at least one of the 20 PTS activities described herein. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 50% homologous to an amino acid sequence of the invention and is capable of transporting high-energy carbon-containing molecules such as glucose into *C. glutamicum*, or of participating in intracellular signal transduction in 25 this microorganism, or has one or more activities set forth in Table 1. Preferably, the protein encoded by the nucleic acid molecule is at least about 50-60% homologous to the amino acid sequence of one of the odd-numbered SEQ ID NOs of the Sequence Listing, more preferably at least about 60-70% homologous to one of these sequences, even more preferably at least about 70-80%, 80-90%, 90-95% homologous to one of 30 these sequences, and most preferably at least about 96%, 97%, 98%, or 99% homologous to one of the amino acid sequences of the invention.

example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiacytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

The antisense nucleic acid molecules of the invention are typically administered to a cell or generated *in situ* such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a PTS protein to thereby inhibit expression of the protein, e.g., by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule which binds to DNA duplexes, through specific interactions in the major groove of the double helix. The antisense molecule can

be modified such that it specifically binds to a receptor or an antigen expressed on a selected cell surface, *e.g.*, by linking the antisense nucleic acid molecule to a peptide or an antibody which binds to a cell surface receptor or antigen. The antisense nucleic acid molecule can also be delivered to cells using the vectors described herein. To achieve 5 sufficient intracellular concentrations of the antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong prokaryotic, viral, or eukaryotic promoter are preferred.

In yet another embodiment, the antisense nucleic acid molecule of the invention is an α -anomeric nucleic acid molecule. An α -anomeric nucleic acid molecule forms 10 specific double-stranded hybrids with complementary RNA in which, contrary to the usual β -units, the strands run parallel to each other (Gaultier *et al.* (1987) *Nucleic Acids Res.* 15:6625-6641). The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (Inoue *et al.* (1987) *Nucleic Acids Res.* 15:6131-6148) or a chimeric RNA-DNA analogue (Inoue *et al.* (1987) *FEBS Lett.* 215:327-330).

15 In still another embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (*e.g.*, hammerhead ribozymes (described in Haselhoff and Gerlach (1988) *Nature* 334:585-591)) can be used to 20 catalytically cleave PTS mRNA transcripts to thereby inhibit translation of PTS mRNA. A ribozyme having specificity for a PTS-encoding nucleic acid can be designed based upon the nucleotide sequence of a PTS DNA disclosed herein (*i.e.*, SEQ ID NO:5 (RXA01503)). For example, a derivative of a *Tetrahymena* L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the 25 nucleotide sequence to be cleaved in a PTS-encoding mRNA. See, *e.g.*, Cech *et al.* U.S. Patent No. 4,987,071 and Cech *et al.* U.S. Patent No. 5,116,742. Alternatively, PTS mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, *e.g.*, Bartel, D. and Szostak, J.W. (1993) *Science* 261:1411-1418.

30 Alternatively, PTS gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of a PTS nucleotide sequence (*e.g.*, a PTS promoter and/or enhancers) to form triple helical structures that prevent

To determine the percent homology of two amino acid sequences (e.g., one of the amino acid sequences of the invention and a mutant form thereof) or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of one protein or nucleic acid for optimal alignment with the other protein or nucleic acid). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in one sequence (e.g., one of the amino acid sequences of the invention) is occupied by the same amino acid residue or nucleotide as the corresponding position in the other sequence (e.g., a mutant form of the amino acid sequence), then the molecules are homologous at that position (i.e., as used herein amino acid or nucleic acid "homology" is equivalent to amino acid or nucleic acid "identity"). The percent homology between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % homology = # of identical positions/total # of positions x 100).

An isolated nucleic acid molecule encoding a PTS protein homologous to a protein sequence of the invention (e.g., a sequence of an even-numbered SEQ ID NO: of the Sequence Listing) can be created by introducing one or more nucleotide substitutions, additions or deletions into a nucleotide sequence of the invention such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein. Mutations can be introduced into one of the nucleotide sequences of the invention by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in a PTS protein is preferably replaced with another amino acid residue from the same

side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of a PTS coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for a PTS activity described herein to identify mutants that retain PTS activity. Following mutagenesis of one of the nucleotide 5 sequence of one of the odd-numbered SEQ ID NOs of the Sequence Listing, the encoded protein can be expressed recombinantly and the activity of the protein can be determined using, for example, assays described herein (see Example 8 of the Exemplification).

In addition to the nucleic acid molecules encoding PTS proteins described above, 10 another aspect of the invention pertains to isolated nucleic acid molecules which are antisense thereto. An "antisense" nucleic acid comprises a nucleotide sequence which is complementary to a "sense" nucleic acid encoding a protein, *e.g.*, complementary to the coding strand of a double-stranded DNA molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can hydrogen bond to a sense nucleic 15 acid. The antisense nucleic acid can be complementary to an entire PTS coding strand, or to only a portion thereof. In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding a PTS protein. The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues (*e.g.*, the entire coding 20 region of SEQ ID NO. 5 (RXA01503) comprises nucleotides 1 to 249). In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding PTS. The term "noncoding region" refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids (*i.e.*, also referred to as 5' and 3' untranslated regions).

25 Given the coding strand sequences encoding PTS disclosed herein (*e.g.*, the sequences set forth as odd-numbered SEQ ID NOs in the Sequence Listing), antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of PTS mRNA, but more preferably is an oligonucleotide which is 30 antisense to only a portion of the coding or noncoding region of PTS mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of PTS mRNA. An antisense oligonucleotide can be, for

transcription of a PTS gene in target cells. See generally, Helene, C. (1991) *Anticancer Drug Des.* 6(6):569-84; Helene, C. et al. (1992) *Ann. N.Y. Acad. Sci.* 660:27-36; and Maher, L.J. (1992) *Bioassays* 14(12):807-15.

5 *B. Recombinant Expression Vectors and Host Cells*

Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding a PTS protein (or a portion thereof). As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", 10 which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other 15 vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are 20 often in the form of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

25 The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operatively linked to the nucleic acid sequence to be expressed. Within a recombinant 30 expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (e.g., in an *in vitro* transcription/translation system or in a

host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel; *Gene Expression Technology: Methods in Enzymology* 185, 5 Academic Press, San Diego, CA (1990). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells. Preferred regulatory sequences are, for example, promoters such as cos-, tac-, trp-, tet-, trp-tet-, lpp-, lac-, lpp-lac-, lacI^q-, T7-, T5-, T3-, gal-, trc-, ara-, SP6-, arny, SPO2, λ-Pr- 10 or λ P_L, which are used preferably in bacteria. Additional regulatory sequences are, for example, promoters from yeasts and fungi, such as ADC1, MFα, AC, P-60, CYC1, GAPDH, TEF, rp28, ADH, promoters from plants such as CaMV/35S, SSU, OCS, lib4, usp, STLS1, B33, nos or ubiquitin- or phaseolin-promoters. It is also possible to use artificial promoters. It will be appreciated by one of ordinary skill in the art that the 15 design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., PTS proteins, mutant forms of PTS proteins, fusion proteins, etc.).

20 The recombinant expression vectors of the invention can be designed for expression of PTS proteins in prokaryotic or eukaryotic cells. For example, PTS genes can be expressed in bacterial cells such as *C. glutamicum*, insect cells (using baculovirus expression vectors), yeast and other fungal cells (see Romanos, M.A. *et al.* (1992) "Foreign gene expression in yeast: a review", *Yeast* 8: 423-488; van den Hondel, 25 C.A.M.J.J. *et al.* (1991) "Heterologous gene expression in filamentous fungi" in: *More Gene Manipulations in Fungi*, J.W. Bennet & L.L. Lasure, eds., p. 396-428: Academic Press: San Diego; and van den Hondel, C.A.M.J.J. & Punt, P.J. (1991) "Gene transfer systems and vector development for filamentous fungi, in: *Applied Molecular Genetics of Fungi*, Peberdy, J.F. *et al.*, eds., p. 1-28, Cambridge University Press: Cambridge), 30 algae and multicellular plant cells (see Schmidt, R. and Willmitzer, L. (1988) High efficiency *Agrobacterium tumefaciens* -mediated transformation of *Arabidopsis thaliana* leaf and cotyledon explants" *Plant Cell Rep.*: 583-586), or mammalian cells.

Suitable host cells are discussed further in Goeddel, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

5 Expression of proteins in prokaryotes is most often carried out with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein;
10 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, 15 and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase.

Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith, D.B. and Johnson, K.S. (1988) *Gene* 67:31-40), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant 20 protein. In one embodiment, the coding sequence of the PTS protein is cloned into a pGEX expression vector to create a vector encoding a fusion protein comprising, from the N-terminus to the C-terminus, GST-thrombin cleavage site-X protein. The fusion protein can be purified by affinity chromatography using glutathione-agarose resin. Recombinant PTS protein unfused to GST can be recovered by cleavage of the fusion 25 protein with thrombin.

Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amann *et al.*, (1988) *Gene* 69:301-315) pLG338, pACYC184, pBR322, pUC18, pUC19, pKC30, pRep4, pHs1, pHs2, pPLc236, pMBL24, pLG200, pUR290, pIN-III113-B1, λgt11, pBdCl, and pET 11d (Studier *et al.*, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 60-89 ; and Pouwels *et al.*, eds. (1985) *Cloning Vectors*. Elsevier: New York ISBN 0 444 904018). Target gene expression from the pTrc vector relies on host RNA polymerase

transcription from a hybrid trp-lac fusion promoter. Target gene expression from the pET 11d vector relies on transcription from a T7 gn10-lac fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gn1). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident λ prophage harboring a T7 5 gn1 gene under the transcriptional control of the lacUV 5 promoter. For transformation of other varieties of bacteria, appropriate vectors may be selected. For example, the plasmids pIJ101, pIJ364, pIJ702 and pIJ361 are known to be useful in transforming Streptomyces, while plasmids pUB110, pC194, or pBD214 are suited for transformation of Bacillus species. Several plasmids of use in the transfer of genetic information into 10 Corynebacterium include pHM1519, pBL1, pSA77, or pAJ667 (Pouwels *et al.*, eds. (1985) Cloning Vectors. Elsevier: New York ISBN 0 444 904018).

One strategy to maximize recombinant protein expression is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, S., *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 119-128). Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in the bacterium chosen for expression, such as *C. glutamicum* 15 (Wada *et al.* (1992) *Nucleic Acids Res.* 20:2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques. 20

In another embodiment, the PTS protein expression vector is a yeast expression vector. Examples of vectors for expression in yeast *S. cerevisiae* include pYEPSec1 (Baldari, *et al.*, (1987) *Embo J.* 6:229-234), 2 μ , pAG-1, Yep6, Yep13, pEMBLYe23, pMFA (Kurjan and Herskowitz, (1982) *Cell* 30:933-943), pJRY88 (Schultz *et al.*, (1987) 25 *Gene* 54:113-123), and pYES2 (Invitrogen Corporation, San Diego, CA). Vectors and methods for the construction of vectors appropriate for use in other fungi, such as the filamentous fungi, include those detailed in: van den Hondel, C.A.M.J.J. & Punt, P.J. (1991) "Gene transfer systems and vector development for filamentous fungi, in: 30 Applied Molecular Genetics of Fungi, J.F. Peberdy, *et al.*, eds., p. 1-28, Cambridge University Press: Cambridge, and Pouwels *et al.*, eds. (1985) Cloning Vectors. Elsevier: New York (ISBN 0 444 904018).

Alternatively, the PTS proteins of the invention can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith *et al.* (1983) *Mol. Cell Biol.* 3:2156-2165) and the pVL series (Lucklow and Summers (1989)

5 *Virology* 170:31-39).

In another embodiment, the PTS proteins of the invention may be expressed in unicellular plant cells (such as algae) or in plant cells from higher plants (e.g., the spermatophytes, such as crop plants). Examples of plant expression vectors include those detailed in: Becker, D., Kemper, E., Schell, J. and Masterson, R. (1992) "New 10 plant binary vectors with selectable markers located proximal to the left border", *Plant Mol. Biol.* 20: 1195-1197; and Bevan, M.W. (1984) "Binary *Agrobacterium* vectors for plant transformation", *Nucl. Acid. Res.* 12: 8711-8721, and include pLGV23, pGHIac+, pBIN19, pAK2004, and pDH51 (Pouwels *et al.*, eds. (1985) *Cloning Vectors*. Elsevier: New York ISBN 0 444 904018).

15 In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, B. (1987) *Nature* 329:840) and pMT2PC (Kaufman *et al.* (1987) *EMBO J.* 6:187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. 20 For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see chapters 16 and 17 of Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual*. 2nd, ed., *Cold Spring Harbor Laboratory*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 25 1989.

In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable 30 tissue-specific promoters include the albumin promoter (liver-specific; Pinkert *et al.* (1987) *Genes Dev.* 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) *Adv. Immunol.* 43:235-275), in particular promoters of T cell receptors (Winoto and

- 41 -

Baltimore (1989) *EMBO J.* 8:729-733) and immunoglobulins (Banerji *et al.* (1983) *Cell* 33:729-740; Queen and Baltimore (1983) *Cell* 33:741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle (1989) *PNAS* 86:5473-5477), pancreas-specific promoters (Edlund *et al.* (1985) *Science* 230:912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Patent No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, for example the murine hox promoters (Kessel and Gruss (1990) *Science* 249:374-379) and the α -fetoprotein promoter (Campes and Tilghman (1989) *Genes Dev.* 3:537-546).

10 The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner which allows for expression (by transcription of the DNA molecule) of an RNA molecule which is antisense to PTS mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid
15 or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see Weintraub, H. *et al.*, *Antisense RNA as a molecular tool for genetic analysis, Reviews - Trends in Genetics*, Vol. 1(1) 1986.
20
25 Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due
30 to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

A host cell can be any prokaryotic or eukaryotic cell. For example, a PTS protein can be expressed in bacterial cells such as *C. glutamicum*, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to one of ordinary skill in the art. Microorganisms related 5 to *Corynebacterium glutamicum* which may be conveniently used as host cells for the nucleic acid and protein molecules of the invention are set forth in Table 3.

Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized 10 techniques for introducing foreign nucleic acid (e.g., linear DNA or RNA (e.g., a linearized vector or a gene construct alone without a vector) or nucleic acid in the form of a vector (e.g., a plasmid, phage, phasmid, phagemid, transposon or other DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for 15 transforming or transfecting host cells can be found in Sambrook, *et al.* (*Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), and other laboratory manuals.

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may 20 integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be 25 introduced into a host cell on the same vector as that encoding a PTS protein or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).

To create a homologous recombinant microorganism, a vector is prepared which 30 contains at least a portion of a PTS gene into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the PTS gene. Preferably, this PTS gene is a *Corynebacterium glutamicum* PTS gene, but it can be a

homologue from a related bacterium or even from a mammalian, yeast, or insect source. In a preferred embodiment, the vector is designed such that, upon homologous recombination, the endogenous PTS gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a "knock out" vector). Alternatively, 5 the vector can be designed such that, upon homologous recombination, the endogenous PTS gene is mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous PTS protein). In the homologous recombination vector, the altered portion of the PTS gene is flanked at its 5' and 3' ends by additional nucleic acid of the PTS 10 gene to allow for homologous recombination to occur between the exogenous PTS gene carried by the vector and an endogenous PTS gene in a microorganism. The additional flanking PTS nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5' and 3' ends) are included in the vector (see e.g., Thomas, K.R., and 15 Capecchi, M.R. (1987) Cell 51: 503 for a description of homologous recombination vectors). The vector is introduced into a microorganism (e.g., by electroporation) and cells in which the introduced PTS gene has homologously recombined with the endogenous PTS gene are selected, using art-known techniques.

In another embodiment, recombinant microorganisms can be produced which 20 contain selected systems which allow for regulated expression of the introduced gene. For example, inclusion of a PTS gene on a vector placing it under control of the lac operon permits expression of the PTS gene only in the presence of IPTG. Such regulatory systems are well known in the art.

In another embodiment, an endogenous PTS gene in a host cell is disrupted (e.g., 25 by homologous recombination or other genetic means known in the art) such that expression of its protein product does not occur. In another embodiment, an endogenous or introduced PTS gene in a host cell has been altered by one or more point mutations, deletions, or inversions, but still encodes a functional PTS protein. In still another embodiment, one or more of the regulatory regions (e.g., a promoter, repressor, or 30 inducer) of a PTS gene in a microorganism has been altered (e.g., by deletion, truncation, inversion, or point mutation) such that the expression of the PTS gene is modulated. One of ordinary skill in the art will appreciate that host cells containing

more than one of the described PTS gene and protein modifications may be readily produced using the methods of the invention, and are meant to be included in the present invention.

A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) a PTS protein. Accordingly, the invention further provides methods for producing PTS proteins using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding a PTS protein has been introduced, or into which genome has been introduced a gene encoding a wild-type or altered PTS protein) in a suitable medium until PTS protein is produced. In another embodiment, the method further comprises isolating PTS proteins from the medium or the host cell.

C. Isolated PTS Proteins

Another aspect of the invention pertains to isolated PTS proteins, and biologically active portions thereof. An "isolated" or "purified" protein or biologically active portion thereof is substantially free of cellular material when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of PTS protein in which the protein is separated from cellular components of the cells in which it is naturally or recombinantly produced. In one embodiment, the language "substantially free of cellular material" includes preparations of PTS protein having less than about 30% (by dry weight) of non-PTS protein (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-PTS protein, 20 still more preferably less than about 10% of non-PTS protein, and most preferably less than about 5% non-PTS protein. When the PTS protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the protein 25 preparation. The language "substantially free of chemical precursors or other chemicals" includes preparations of PTS protein in which the protein is separated from chemical precursors or other chemicals which are involved in the synthesis of the 30

protein. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of PTS protein having less than about 30% (by dry weight) of chemical precursors or non-PTS chemicals, more preferably less than about 20% chemical precursors or non-PTS chemicals, still more preferably less than 5 about 10% chemical precursors or non-PTS chemicals, and most preferably less than about 5% chemical precursors or non-PTS chemicals. In preferred embodiments, isolated proteins or biologically active portions thereof lack contaminating proteins from the same organism from which the PTS protein is derived. Typically, such proteins are produced by recombinant expression of, for example, a *C. glutamicum* PTS protein in a 10 microorganism such as *C. glutamicum*.

An isolated PTS protein or a portion thereof of the invention can participate in the transport of high-energy carbon-containing molecules such as glucose into *C. glutamicum*, and may also participate in intracellular signal transduction in this microorganism, or has one or more of the activities set forth in Table 1. In preferred 15 embodiments, the protein or portion thereof comprises an amino acid sequence which is sufficiently homologous to an amino acid sequence of the invention (e.g., a sequence of an even-numbered SEQ ID NO: of the Sequence Listing) such that the protein or portion thereof maintains the ability to transport high-energy carbon-containing molecules such as glucose into *C. glutamicum*, or to participate in intracellular signal transduction in this 20 microorganism. The portion of the protein is preferably a biologically active portion as described herein. In another preferred embodiment, a PTS protein of the invention has an amino acid sequence set forth as an even-numbered SEQ ID NO: of the Sequence Listing. In yet another preferred embodiment, the PTS protein has an amino acid sequence which is encoded by a nucleotide sequence which hybridizes, e.g., hybridizes 25 under stringent conditions, to a nucleotide sequence of the invention (e.g., a sequence of an odd-numbered SEQ ID NO: of the Sequence Listing). In still another preferred embodiment, the PTS protein has an amino acid sequence which is encoded by a nucleotide sequence that is at least about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60%, preferably at least about 61%, 62%, 63%, 64%, 65%, 66%, 67%, 30 68%, 69%, or 70%, more preferably at least about 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, or 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, or 90%, or 91%, 92%, 93%, 94%, and even more preferably at least about 95%, 96%, 97%, 98%,

99% or more homologous to one of the nucleic acid sequences of the invention, or a portion thereof. Ranges and identity values intermediate to the above-recited values, (e.g., 70-90% identical or 80-95% identical) are also intended to be encompassed by the present invention. For example, ranges of identity values using a combination of any of the above values recited as upper and/or lower limits are intended to be included. The preferred PTS proteins of the present invention also preferably possess at least one of the PTS activities described herein. For example, a preferred PTS protein of the present invention includes an amino acid sequence encoded by a nucleotide sequence which hybridizes, e.g., hybridizes under stringent conditions, to a nucleotide sequence of the invention, and which can participate in the transport of high-energy carbon-containing molecules such as glucose into *C. glutamicum*, and may also participate in intracellular signal transduction in this microorganism, or which has one or more of the activities set forth in Table 1.

In other embodiments, the PTS protein is substantially homologous to an amino acid sequence of the invention (e.g., a sequence of an even-numbered SEQ ID NO: of the Sequence Listing) and retains the functional activity of the protein of one of the amino acid sequences of the invention yet differs in amino acid sequence due to natural variation or mutagenesis, as described in detail in subsection I above. Accordingly, in another embodiment, the PTS protein is a protein which comprises an amino acid sequence which is at least about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60%, preferably at least about 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, or 70%, more preferably at least about 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, or 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, or 90%, or 91%, 92%, 93%, 94%, and even more preferably at least about 95%, 96%, 97%, 98%, 99% or more homologous to an entire amino acid sequence of the invention and which has at least one of the PTS activities described herein. Ranges and identity values intermediate to the above-recited values, (e.g., 70-90% identical or 80-95% identical) are also intended to be encompassed by the present invention. For example, ranges of identity values using a combination of any of the above values recited as upper and/or lower limits are intended to be included. In another embodiment, the invention pertains to a full length *C. glutamicum* protein which is substantially homologous to an entire amino acid sequence of the invention.

Biologically active portions of a PTS protein include peptides comprising amino acid sequences derived from the amino acid sequence of a PTS protein, *e.g.*, an amino acid sequence of an even-numbered SEQ ID NO: of the Sequence Listing or the amino acid sequence of a protein homologous to a PTS protein, which include fewer amino acids than a full length PTS protein or the full length protein which is homologous to a PTS protein, and exhibit at least one activity of a PTS protein. Typically, biologically active portions (peptides, *e.g.*, peptides which are, for example, 5, 10, 15, 20, 30, 35, 36, 37, 38, 39, 40, 50, 100 or more amino acids in length) comprise a domain or motif with at least one activity of a PTS protein. Moreover, other biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the activities described herein. Preferably, the biologically active portions of a PTS protein include one or more selected domains/motifs or portions thereof having biological activity.

PTS proteins are preferably produced by recombinant DNA techniques. For example, a nucleic acid molecule encoding the protein is cloned into an expression vector (as described above), the expression vector is introduced into a host cell (as described above) and the PTS protein is expressed in the host cell. The PTS protein can then be isolated from the cells by an appropriate purification scheme using standard protein purification techniques. Alternative to recombinant expression, a PTS protein, polypeptide, or peptide can be synthesized chemically using standard peptide synthesis techniques. Moreover, native PTS protein can be isolated from cells (*e.g.*, endothelial cells), for example using an anti-PTS antibody, which can be produced by standard techniques utilizing a PTS protein or fragment thereof of this invention.

The invention also provides PTS chimeric or fusion proteins. As used herein, a PTS "chimeric protein" or "fusion protein" comprises a PTS polypeptide operatively linked to a non-PTS polypeptide. An "PTS polypeptide" refers to a polypeptide having an amino acid sequence corresponding to PTS, whereas a "non-PTS polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein which is not substantially homologous to the PTS protein, *e.g.*, a protein which is different from the PTS protein and which is derived from the same or a different organism. Within the fusion protein, the term "operatively linked" is intended to indicate that the PTS polypeptide and the non-PTS polypeptide are fused in-frame to each other. The non-

PTS polypeptide can be fused to the N-terminus or C-terminus of the PTS polypeptide. For example, in one embodiment the fusion protein is a GST-PTS fusion protein in which the PTS sequences are fused to the C-terminus of the GST sequences. Such fusion proteins can facilitate the purification of recombinant PTS proteins. In another embodiment, the fusion protein is a PTS protein containing a heterologous signal sequence at its N-terminus. In certain host cells (e.g., mammalian host cells), expression and/or secretion of a PTS protein can be increased through use of a heterologous signal sequence.

Preferably, a PTS chimeric or fusion protein of the invention is produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, for example by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, *Current Protocols in Molecular Biology*, eds. Ausubel *et al.* John Wiley & Sons: 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). A PTS-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the PTS protein.

Homologues of the PTS protein can be generated by mutagenesis, e.g., discrete point mutation or truncation of the PTS protein. As used herein, the term "homologue" refers to a variant form of the PTS protein which acts as an agonist or antagonist of the activity of the PTS protein. An agonist of the PTS protein can retain substantially the same, or a subset, of the biological activities of the PTS protein. An antagonist of the PTS protein can inhibit one or more of the activities of the naturally occurring form of the PTS protein, by, for example, competitively binding to a downstream or upstream member of the PTS system which includes the PTS protein. Thus, the *C. glutamicum*

PTS protein and homologues thereof of the present invention may modulate the activity of one or more sugar transport pathways or intracellular signal transduction pathways in which PTS proteins play a role in this microorganism.

In an alternative embodiment, homologues of the PTS protein can be identified

- 5 by screening combinatorial libraries of mutants, *e.g.*, truncation mutants, of the PTS protein for PTS protein agonist or antagonist activity. In one embodiment, a variegated library of PTS variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of PTS variants can be produced by, for example, enzymatically ligating a mixture of synthetic
- 10 oligonucleotides into gene sequences such that a degenerate set of potential PTS sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (*e.g.*, for phage display) containing the set of PTS sequences therein. There are a variety of methods which can be used to produce libraries of potential PTS homologues from a degenerate oligonucleotide sequence. Chemical synthesis of a
- 15 degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential PTS sequences. Methods for synthesizing degenerate oligonucleotides are known in the art (see, *e.g.*, Narang, S.A. (1983) *Tetrahedron* 39:3;
- 20 Itakura *et al.* (1984) *Annu. Rev. Biochem.* 53:323; Itakura *et al.* (1984) *Science* 198:1056; Ike *et al.* (1983) *Nucleic Acid Res.* 11:477.

In addition, libraries of fragments of the PTS protein coding can be used to generate a variegated population of PTS fragments for screening and subsequent selection of homologues of a PTS protein. In one embodiment, a library of coding

- 25 sequence fragments can be generated by treating a double stranded PCR fragment of a PTS coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by
- 30 treatment with S1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes N-terminal, C-terminal and internal fragments of various sizes of the PTS protein.

- 50 -

Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of PTS homologues. The most widely used techniques, which are amenable to high through-put analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a new technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify PTS homologues (Arkin and Yourvan (1992) *PNAS* 89:7811-7815; Delgrave *et al.* (1993) *Protein Engineering* 6(3):327-331).

In another embodiment, cell based assays can be exploited to analyze a variegated PTS library, using methods well known in the art.

D. Uses and Methods of the Invention

The nucleic acid molecules, proteins, protein homologues, fusion proteins, primers, vectors, and host cells described herein can be used in one or more of the following methods: identification of *C. glutamicum* and related organisms; mapping of genomes of organisms related to *C. glutamicum*; identification and localization of *C. glutamicum* sequences of interest; evolutionary studies; determination of PTS protein regions required for function; modulation of a PTS protein activity; modulation of the activity of a PTS pathway; and modulation of cellular production of a desired compound, such as a fine chemical.

The PTS nucleic acid molecules of the invention have a variety of uses. First, they may be used to identify an organism as being *Corynebacterium glutamicum* or a close relative thereof. Also, they may be used to identify the presence of *C. glutamicum* or a relative thereof in a mixed population of microorganisms. The invention provides the nucleic acid sequences of a number of *C. glutamicum* genes; by probing the extracted genomic DNA of a culture of a unique or mixed population of microorganisms

under stringent conditions with a probe spanning a region of a *C. glutamicum* gene which is unique to this organism, one can ascertain whether this organism is present.

Although *Corynebacterium glutamicum* itself is nonpathogenic, it is related to pathogenic species, such as *Corynebacterium diphtheriae*. *Corynebacterium diphtheriae* is the causative agent of diphtheria, a rapidly developing, acute, febrile infection which involves both local and systemic pathology. In this disease, a local lesion develops in the upper respiratory tract and involves necrotic injury to epithelial cells; the bacilli secrete toxin which is disseminated through this lesion to distal susceptible tissues of the body. Degenerative changes brought about by the inhibition of protein synthesis in these tissues, which include heart, muscle, peripheral nerves, adrenals, kidneys, liver and spleen, result in the systemic pathology of the disease. Diphtheria continues to have high incidence in many parts of the world, including Africa, Asia, Eastern Europe and the independent states of the former Soviet Union. An ongoing epidemic of diphtheria in the latter two regions has resulted in at least 5,000 deaths since 1990.

In one embodiment, the invention provides a method of identifying the presence or activity of *Corynebacterium diphtheriae* in a subject. This method includes detection of one or more of the nucleic acid or amino acid sequences of the invention (e.g., the sequences set forth as odd-numbered or even-numbered SEQ ID NOs, respectively, in the Sequence Listing) in a subject, thereby detecting the presence or activity of *Corynebacterium diphtheriae* in the subject. *C. glutamicum* and *C. diphtheriae* are related bacteria, and many of the nucleic acid and protein molecules in *C. glutamicum* are homologous to *C. diphtheriae* nucleic acid and protein molecules, and can therefore be used to detect *C. diphtheriae* in a subject.

The nucleic acid and protein molecules of the invention may also serve as markers for specific regions of the genome. This has utility not only in the mapping of the genome, but also for functional studies of *C. glutamicum* proteins. For example, to identify the region of the genome to which a particular *C. glutamicum* DNA-binding protein binds, the *C. glutamicum* genome could be digested, and the fragments incubated with the DNA-binding protein. Those which bind the protein may be additionally probed with the nucleic acid molecules of the invention, preferably with readily detectable labels; binding of such a nucleic acid molecule to the genome fragment enables the

localization of the fragment to the genome map of *C. glutamicum*, and, when performed multiple times with different enzymes, facilitates a rapid determination of the nucleic acid sequence to which the protein binds. Further, the nucleic acid molecules of the invention may be sufficiently homologous to the sequences of related species such that 5 these nucleic acid molecules may serve as markers for the construction of a genomic map in related bacteria, such as *Brevibacterium lactofermentum*.

The PTS nucleic acid molecules of the invention are also useful for evolutionary and protein structural studies. The sugar uptake system in which the molecules of the invention participate are utilized by a wide variety of bacteria; by comparing the 10 sequences of the nucleic acid molecules of the present invention to those encoding similar enzymes from other organisms, the evolutionary relatedness of the organisms can be assessed. Similarly, such a comparison permits an assessment of which regions of the sequence are conserved and which are not, which may aid in determining those regions of the protein which are essential for the functioning of the enzyme. This type 15 of determination is of value for protein engineering studies and may give an indication of what the protein can tolerate in terms of mutagenesis without losing function.

Manipulation of the PTS nucleic acid molecules of the invention may result in the production of PTS proteins having functional differences from the wild-type PTS proteins. These proteins may be improved in efficiency or activity, may be present in 20 greater numbers in the cell than is usual, or may be decreased in efficiency or activity.

The invention provides methods for screening molecules which modulate the activity of a PTS protein, either by interacting with the protein itself or a substrate or binding partner of the PTS protein, or by modulating the transcription or translation of a PTS nucleic acid molecule of the invention. In such methods, a microorganism 25 expressing one or more PTS proteins of the invention is contacted with one or more test compounds, and the effect of each test compound on the activity or level of expression of the PTS protein is assessed.

The PTS molecules of the invention may be modified such that the yield, production, and/or efficiency of production of one or more fine chemicals is improved. 30 For example, by modifying a PTS protein involved in the uptake of glucose such that it is optimized in activity, the quantity of glucose uptake or the rate at which glucose is translocated into the cell may be increased. The breakdown of glucose and other sugars

within the cell provides energy that may be used to drive energetically unfavorable biochemical reactions, such as those involved in the biosynthesis of fine chemicals. This breakdown also provides intermediate and precursor molecules necessary for the biosynthesis of certain fine chemicals, such as amino acids, vitamins and cofactors. By 5 increasing the amount of intracellular high-energy carbon molecules through modification of the PTS molecules of the invention, one may therefore increase both the energy available to perform metabolic pathways necessary for the production of one or more fine chemicals, and also the intracellular pools of metabolites necessary for such production. Conversely, by decreasing the importation of a sugar whose breakdown 10 products include a compound which is used solely in metabolic pathways which compete with pathways utilized for the production of a desired fine chemical for enzymes, cofactors, or intermediates, one may downregulate this pathway and thus perhaps increase production through the desired biosynthetic pathway.

Further, the PTS molecules of the invention may be involved in one or more 15 intracellular signal transduction pathways which may affect the yields and/or rate of production of one or more fine chemical from *C. glutamicum*. For example, proteins necessary for the import of one or more sugars from the extracellular medium (e.g., HPr, Enzyme I, or a member of an Enzyme II complex) are frequently posttranslationally modified upon the presence of a sufficient quantity of the sugar in the cell, such that 20 they are no longer able to import that sugar. An example of this occurs in *E. coli*, where high intracellular levels of fructose 1,6-bisphosphate result in the phosphorylation of HPr at serine-46, upon which this molecule is no longer able to participate in the transport of any sugar. While this intracellular level of sugar at which the transport system is shut off may be sufficient to sustain the normal functioning of the cell, it may 25 be limiting for the overproduction of the desired fine chemical. Thus, it may be desirable to modify the PTS proteins of the invention such that they are no longer responsive to such negative regulation, thereby permitting greater intracellular concentrations of one or more sugars to be achieved, and, by extension, more efficient production or greater yields of one or more fine chemicals from organisms containing 30 such mutant PTS proteins.

This aforementioned list of mutagenesis strategies for PTS proteins to result in increased yields of a desired compound is not meant to be limiting; variations on these

- 54 -

mutagenesis strategies will be readily apparent to one of ordinary skill in the art. By these mechanisms, the nucleic acid and protein molecules of the invention may be utilized to generate *C. glutamicum* or related strains of bacteria expressing mutated PTS nucleic acid and protein molecules such that the yield, production, and/or efficiency of

5 production of a desired compound is improved. This desired compound may be any natural product of *C. glutamicum*, which includes the final products of biosynthesis pathways and intermediates of naturally-occurring metabolic pathways, as well as molecules which do not naturally occur in the metabolism of *C. glutamicum*, but which are produced by a *C. glutamicum* strain of the invention.

10 This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patent applications, patents, published patent applications, Tables, and the Sequence Listing cited throughout this application are hereby incorporated by reference.

TABLE 1: Genes Included in the Invention

PHOSPHOENOLPYRUVATE: SUGAR PHOSPHOTRANSFERASE SYSTEM

<u>Nucleotide SEQ ID NO</u>	<u>Amino Acid SEQ ID NO</u>	<u>Identification Code</u>	<u>Contig.</u>	<u>NT Start</u>	<u>NT Stop</u>	<u>Function</u>
1	2	RXS00315				PTS SYSTEM, SUCROSE-SPECIFIC IIABC COMPONENT (EIABC-SCR) (SUCROSE- PERMEASE IIABC COMPONENT) (EC 2.7.1.69)
3	4	F RXA00315	GR00053	6537	5452	PTS SYSTEM, BETA-GLUCOSIDES-SPECIFIC IIABC COMPONENT (EIABC-BGL) (BETA-GLUCOSIDES- PERMEASE IIABC COMPONENT) (PHOSPHOTRANSFERASE ENZYME II, ABC COMPONENT) (EC 2.7.1.69)
5	6	RXA01503	GR00424	10392	10640	PTS SYSTEM, BETA-GLUCOSIDES-SPECIFIC IIABC COMPONENT (EIABC-BGL) (BETA-GLUCOSIDES- PERMEASE IIABC COMPONENT) (PHOSPHOTRANSFERASE ENZYME II, ABC COMPONENT) (EC 2.7.1.69)
7	8	RXN01299	VV0068	11954	9891	PTS SYSTEM, FRUCTOSE-SPECIFIC IIBC COMPONENT (EC 2.7.1.69)
9	10	F RXA01299	GR00375	6	446	PTS SYSTEM, FRUCTOSE-SPECIFIC IIBC COMPONENT (EC 2.7.1.69)
11	12	F RXA01983	GR00538	2154	2633	PTS SYSTEM, FRUCTOSE-SPECIFIC IIBC COMPONENT (EC 2.7.1.69)
13	14	F RXA01989	GR00540	77	631	PTS SYSTEM, FRUCTOSE-SPECIFIC IIIC COMPONENT (EC 2.7.1.69)
15	16	RXA00951	GR00261	564	172	PTS SYSTEM, MANNITOL (CRYPTIC) -SPECIFIC IIA COMPONENT (EIIA-(C)MTL) (MANNITOL (CRYPTIC)- PERMEASE IIA COMPONENT) (PHOSPHOTRANSFERASE ENZYME II, A COMPONENT) (EC 2.7.1.69)
17	18	RXN01244	VV0068	14141	15844	PHOSPHOENOLPYRUVATE-PROTEIN PHOSPHOTRANSFERASE (EC 2.7.3.9)
19	20	F RXA01244	GR00359	4837	3329	PHOSPHOENOLPYRUVATE-PROTEIN PHOSPHOTRANSFERASE (EC 2.7.3.9)
21	22	RXA01300	GR00375	637	903	PHOSPHOCARRIER PROTEIN HPR
23	24	RXN03002	VV0236	1437	1844	PTS SYSTEM, MANNITOL (CRYPTIC) -SPECIFIC IIA COMPONENT (EIIA-(C)MTL) (MANNITOL (CRYPTIC)- PERMEASE IIA COMPONENT) (PHOSPHOTRANSFERASE ENZYME II, A COMPONENT) (EC 2.7.1.69)
25	26	RXC00953	VV0260	1834	1082	Membrane Spanning Protein involved in PTS system
27	28	RXC03001				Membrane Spanning Protein involved in PTS system
29	30	RXN01943	VV0120	4326	6374	PTS SYSTEM, GLUCOSE-SPECIFIC IIABC COMPONENT (EC 2.7.1.69)
31	32	F RXA02191	GR00642	3395	4633	PHOSPHOENOLPYRUVATE SUGAR PHOSPHOTRANSFERASE
33	34	F RXA01943	GR00557	3944	3540	crr gene: phosphotransferase system glucose-specific enzyme III

TABLE 2 - Excluded Genes

GenBank™ Accession No.	Gene Name	Gene Function	Reference
A09073	ppg	Phosphoenol pyruvate carboxylase	Bachmann, B. et al. "DNA fragment coding for phosphoenolpyruvat carboxylase, recombinant DNA carrying said fragment, strains carrying the recombinant DNA and method for producing L-amino acids using said strains," Patent: EP 0358940-A 3 03/21/90
A45579, A45581, A45583, A45585 A45587		Threonine dehydratase	Moekkel, B. et al. "Production of L-isoleucine by means of recombinant micro-organisms with deregulated threonine dehydratase," Patent: WO 9519442-A 5 07/20/95
AB003132	murC; ftsQ; ftsZ		Kobayashi, M. et al. "Cloning, sequencing, and characterization of the ftsZ gene from coryneform bacteria," <i>Biochem. Biophys. Res. Commun.</i> , 236(2):383-388 (1997)
AB015023	murC; ftsQ		Wachi, M. et al. "A murC gene from <i>Coryneform bacteria</i> ," <i>Appl. Microbiol. Biotechnol.</i> , 51(2):223-228 (1999)
AB018530	dtsR		Kimura, E. et al. "Molecular cloning of a novel gene, dtsR, which rescues the detergent sensitivity of a mutant derived from <i>Brevibacterium lactofermentum</i> ," <i>Biosci. Biotechnol. Biochem.</i> , 60(10):1563-1570 (1996)
AB018531	dtsR1; dtsR2		
AB020624	murl	D-glutamate racemase	
AB023377	tkt	transketolase	
AB024708	gltB; gltD	Glutamine 2-oxoglutarate aminotransferase large and small subunits	
AB025424	acn	aconitase	
AB027714	rep	Replication protein	
AB027715	rep; aad	Replication protein; aminoglycoside adenyltransferase	
AF005242	argC	N-acetylglutamate-5-semialdehyde dehydrogenase	
AF005635	glnA	Glutamine synthetase	
AF030405	hisF	cyclase	
AF030520	argG	Argininosuccinate synthetase	
AF031518	argF	Ornithine carbamoyltransferase	
AF036932	aroD	3-dihydroquinate dehydratase	
AF038548	pyc	Pyruvate carboxylase	

Table 2 (continued)

AF038651	dcrA; E; ari; rel	Dipeptide-binding protein; adenine phosphoribosyltransferase; GTP pyrophosphokinase	Wehmeier, L. et al. "The role of the <i>Corynebacterium glutamicum</i> rel gene in (p)ppGpp metabolism," <i>Microbiology</i> , 144:1853-1862 (1998)
AF041436	argR	Arginine repressor	
AF045998	impA	Inositol monophosphate phosphatase	
AF048764	argH	Argininosuccinate lyase	
AF049897	argC; argJ; argB; argD; argF; argR; argG; argH	N-acetylglutamylphosphate reductase; ornithine acetyltransferase; N-acetylglutamate kinase; acetylornithine transminase; ornithine carbamoyltransferase; arginine repressor; argininosuccinate synthase; argininosuccinate lyase	
AF050109	inhA	Enoyl-acyl carrier protein reductase	
AF050166	hisG	ATP phosphoribosyltransferase	
AF051846	hisA	Phosphoribosylformimino-5-amino-1-phosphoribosyl-4-imidazolecarboxamide isomerase	
AF052652	metA	Homoserine O-acetyltransferase	Park, S. et al. "Isolation and analysis of metA, a methionine biosynthetic gene encoding homoserine acetyltransferase in <i>Corynebacterium glutamicum</i> ," <i>Mol. Cells</i> , 8(3):286-294 (1998)
AF053071	aroB	Dehydroquinate synthetase	
AF060558	hisH	Glutamine amidotransferase	
AF086704	hisE	Phosphoribosyl-ATP-pyrophosphohydrolase	
AF114233	aroA	5-enolpyruvylshikimate 3-phosphate synthase	
AF116184	panD	L-aspartate-alpha-decarboxylase precursor	Dusch, N. et al. "Expression of the <i>Corynebacterium glutamicum</i> panD gene encoding L-aspartate-alpha-decarboxylase leads to pantothenate overproduction in <i>Escherichia coli</i> ," <i>Appl. Environ. Microbiol.</i> , 65(4):1530-1539 (1999)
AF124518	aroD; aroE	3-dehydroquinate; shikimate dehydrogenase	
AF124600	aroC; aroK; aroB; pepQ	Chorismate synthase; shikimate kinase; 3-dehydroquinate synthase; putative cytoplasmic peptidase	
AF145897	inhA		
AF145898	inhA		

Table 2 (continued)

Table 2 (continued)			
AJ001436	ectP	Transport of ectoine, glycine betaine, proline	Peter, H. et al. "Corynebacterium glutamicum is equipped with four secondary carriers for compatible solutes: Identification, sequencing, and characterization of the proline/ectoine uptake system, ProP, and the ectoine/proline/glycine betaine carrier, EctP," <i>J. Bacteriol.</i> , 180(22):6005-6012 (1998)
AJ004934	dapD	Tetrahydrodipicolinate succinylase (incomplete)	Wehrmann, A. et al. "Different modes of diaminopimelate synthesis and their role in cell wall integrity: A study with <i>Corynebacterium glutamicum</i> ," <i>J. Bacteriol.</i> , 180(12):3159-3165 (1998)
AJ007732	ppc; secG; amt; ocd; soxA	Phosphoenolpyruvate-carboxylase; ?; high affinity ammonium uptake protein; putative ornithine-cyclodecarboxylase; sarcosine oxidase	Jakoby, M. et al. "Nitrogen regulation in <i>Corynebacterium glutamicum</i> : Isolation of genes involved in biochemical characterization of corresponding proteins," <i>FEMS Microbiol.</i> , 173(2):303-310 (1999)
AJ010319	ftsY; glnB; glnD; sfp; amtP	Involved in cell division; PII protein; uridylyltransferase (uridyl- β -removing enzyme); signal recognition particle; low affinity ammonium uptake protein	
AJ132968	cat	Chloramphenicol acetyl transferase	
AJ224946	mqo	L-malate: quinone oxidoreductase	Molenaar, D. et al. "Biochemical and genetic characterization of the membrane-associated malate dehydrogenase (acceptor) from <i>Corynebacterium glutamicum</i> ," <i>Eur. J. Biochem.</i> , 254(2):395-403 (1998)
AJ238250	ndh	NADH dehydrogenase	
AJ238703	porA	Porin	Lichtinger, T. et al. "Biochemical and biophysical characterization of the cell wall porin of <i>Corynebacterium glutamicum</i> : The channel is formed by a low molecular mass polypeptide," <i>Biochemistry</i> , 37(43):15024-15032 (1998)
D17429		Transposable element IS31831	Vertes et al. "Isolation and characterization of IS31831, a transposable element from <i>Corynebacterium glutamicum</i> ," <i>Mol. Microbiol.</i> , 11(4):739-746 (1994)
D84102	odhA	2-oxoglutarate dehydrogenase	Usuda, Y. et al. "Molecular cloning of the <i>Corynebacterium glutamicum</i> (Brevibacterium laevifermatum A112036) odhA gene encoding a novel type of 2-oxoglutarate dehydrogenase," <i>Microbiology</i> , 142:3347-3354 (1996)
E01358	hdh; hik	Homoserine dehydrogenase; homoserine kinase	Katsumata, R. et al. "Production of L-threonine and L-isoleucine," Patent: JP 1987232392-A 1 10/12/87
E01359		Upstream of the start codon of homoserine kinase gene	Katsumata, R. et al. "Production of L-threonine and L-isoleucine," Patent: JP 1987232392-A 2 10/12/87
E01375		Tryptophan operon	
E01376	trpL; trpE	Leader peptide; anthranilate synthase	Matsui, K. et al. "Tryptophan operon, peptide and protein coded thereby, utilization of tryptophan operon gene expression and production of tryptophan," Patent: JP 1987244382-A 1 10/24/87

Table 2 (continued)

E01377	Promoter and operator regions of tryptophan operon	Matsui, K. et al. "Tryptophan operon, peptide and protein coded thereby, utilization of tryptophan operon gene expression and production of tryptophan," Patent: JP 1987244382-A 1 10/24/87
E03937	Biotin synthase	Hayakeyama, K. et al. "DNA fragment containing gene capable of coding biotin synthetase and its utilization," Patent: JP 1992278088-A 1 10/02/92
E04040	Diamino pelargonic acid aminotransferase	Kohama, K. et al. "Gene coding diamino pelargonic acid aminotransferase and desthiobiotin synthetase and its utilization," Patent: JP 1992330284-A 1 11/18/92
E04041	Desthiobiotinsynthetase	Kohama, K. et al. "Gene coding diamino pelargonic acid aminotransferase and desthiobiotin synthetase and its utilization," Patent: JP 1992330284-A 1 11/18/92
E04307	Flavum aspartase	Kurusu, Y. et al. "Gene DNA coding aspartase and utilization thereof," Patent: JP 1993030977-A 1 02/09/93
E04376	Isocitric acid lyase	Katsumata, R. et al. "Gene manifestation controlling DNA," Patent: JP 1993056782-A 3 03/09/93
E04377	Isocitric acid lyase N-terminal fragment	Katsumata, R. et al. "Gene manifestation controlling DNA," Patent: JP 1993056782-A 3 03/09/93
E04484	Prephenate dehydratase	Sotouchi, N. et al. "Production of L-phenylalanine by fermentation," Patent: JP 1993076352-A 2 03/30/93
E05108	Aspartokinase	Fugono, N. et al. "Gene DNA coding Aspartokinase and its use," Patent: JP 1993184366-A 1 07/27/93
E05112	Dihydro-dipiclorinate synthetase	Hayakeyama, K. et al. "Gene DNA coding dihydrodipicolinic acid synthetase and its use," Patent: JP 1993184371-A 1 07/27/93
E05776	Diaminopimelic acid dehydrogenase	Kobayashi, M. et al. "Gene DNA coding Diaminopimelic acid dehydrogenase and its use," Patent: JP 1993284970-A 1 11/02/93
E05779	Threonine synthase	Kohama, K. et al. "Gene DNA coding threonine synthase and its use," Patent: JP 1993284972-A 1 11/02/93
E06110	Prephenate dehydratase	Kikuchi, T. et al. "Production of L-phenylalanine by fermentation method," Patent: JP 1993344881-A 1 12/27/93
E06111	Mutated Prephenate dehydratase	Imai, M. et al. "Gene capable of coding Acetohydroxy acid synthetase and its use," Patent: JP 1993344893-A 1 12/27/93
E06146	Acetohydroxy acid synthetase	Sugimoto, M. et al. "Mutant aspartokinase gene," patent: JP 1994062866-A 1 03/08/94
E06825	Aspartokinase	Sugimoto, M. et al. "Mutant aspartokinase gene," patent: JP 1994062866-A 1 03/08/94
E06826	Mutated aspartokinase alpha subunit	

Table 2 (continued)

E06827		Mutated aspartokinase alpha subunit	Sugimoto, M. et al. "Mutant aspartokinase gene," patent: JP 1994062866-A 1 03/08/94
E07701	secY		Homma, N. et al. "Gene DNA participating in integration of membranous protein to membrane," Patent: JP 1994 69780-A 1 06/2/94
E08177		Aspartokinase	Sato, Y. et al. "Genetic DNA capable of coding Aspartokinase released from feedback inhibition and its utilization," Patent: JP 1994261766-A 1 09/20/94
E08178, E08179, E08180, E08181, E08182		Feedback inhibition-released Aspartokinase	Sato, Y. et al. "Genetic DNA capable of coding Aspartokinase released from feedback inhibition and its utilization," Patent: JP 1994261766-A 1 09/20/94
E08232		Acetohydroxy-acid isomerase	Inui, M. et al. "Gene DNA coding acetohydroxy acid isomerase," Patent: JP 1994277067-A 1 10/04/94
E08234	secE		Asai, Y. et al. "Gene DNA coding for translocation machinery of protein," Patent: JP 1994277073-A 1 10/04/94
E08643		FT aminotransferase and deshiobiotin synthetase promoter region	Hatakeyama, K. et al. "DNA fragment having promoter function in coryneform bacterium," Patent: JP 1995031476-A 1 02/03/95
E08646		Biotin synthetase	Hatakeyama, K. et al. "DNA fragment having promoter function in coryneform bacterium," Patent: JP 1995031476-A 1 02/03/95
E08649		Aspartase	Kohama, K. et al "DNA fragment having promoter function in coryneform bacterium," Patent: JP 1995031478-A 1 02/03/95
E08900		Dihydropicollinate reductase	Macori, M. et al. "DNA fragment containing gene coding Dihydripicollinate acid reductase and utilization thereof," Patent: JP 1995075578-A 1 03/20/95
E08901		Diaminopimelic acid decarboxylase	Macori, M. et al. "DNA fragment containing gene coding Diaminopimelic acid decarboxylase and utilization thereof," Patent: JP 1995075579-A 1 03/20/95
E12594		Serine hydroxymethyltransferase	Hatakeyama, K. et al. "Production of L-tryptophan," Patent: JP 1997028391-A 1 02/04/97
E12760, E12759, E12758		transposase	Moriya, M. et al. "Amplification of gene using artificial transposon," Patent: JP 1997070291-A 03/18/97
E12764		Arginyl-tRNA synthetase; diaminopimelic acid decarboxylase	Moriya, M. et al. "Amplification of gene using artificial transposon," Patent: JP 1997070291-A 03/18/97
E12767		Dihydropicolic acid synthetase	Moriya, M. et al. "Amplification of gene using artificial transposon," Patent: JP 1997070291-A 03/18/97
E12770		aspartokinase	Moriya, M. et al. "Amplification of gene using artificial transposon," Patent: JP 1997070291-A 03/18/97
E12773		Dihydropicolic acid reductase	Moriya, M. et al. "Amplification of gene using artificial transposon," Patent: JP 1997070291-A 03/18/97

Table 2 (continued)

E13655		Glucose-6-phosphate dehydrogenase	Hatakeyama, K. et al. "Glucose-6-phosphate dehydrogenase and DNA capable of coding the same," Patent: JP 199724661-A 1 09/02/97
L01508	IlvA	Threonine dehydratase	Moekkel, B. et al. "Functional and structural analysis of the threonine dehydratase of <i>Corynebacterium glutamicum</i> ," <i>J. Bacteriol.</i> , 174:8065-8072 (1992)
L07603	EC 4.2.1.15	3-deoxy-D-arabinoheptulosonate-7-phosphate synthase	Chen, C. et al. "The cloning and nucleotide sequence of <i>Corynebacterium glutamicum</i> 3-deoxy-D-arabinoheptulosonate-7-phosphate synthase gene," <i>FEBS Microbiol. Lett.</i> , 107:223-230 (1993)
L09232	IlvB; ilvN; ilvC	Acetohydroxy acid synthase large subunit; Acetohydroxy acid synthase small subunit; Acetohydroxy acid isomero-reductase	Keilhauer, C. et al. "Isoleucine synthesis in <i>Corynebacterium glutamicum</i> : molecular analysis of the ilvB-ilvN-ilvC operon," <i>J. Bacteriol.</i> , 175(17):5595-5603 (1993)
L18874	PtsM	Phosphoenolpyruvate sugar phosphotransferase	Fouet, A et al. "Bacillus subtilis sucrose-specific enzyme II of the phosphotransferase system: expression in <i>Escherichia coli</i> and homology to enzymes II from enteric bacteria," <i>PNAS USA</i> , 84(24):8773-8777 (1987); Lee, J.K. et al. "Nucleotide sequence of the gene encoding the <i>Corynebacterium glutamicum</i> mannose enzyme II and analyses of the deduced protein sequence," <i>FEBS Microbiol. Lett.</i> , 119(1-2):137-145 (1994)
L27123	aceB	Malate synthase	Lee, H.-S. et al. "Molecular characterization of aceB, a gene encoding malate synthase in <i>Corynebacterium glutamicum</i> ," <i>J. Microbiol. Biotechnol.</i> , 4(4):256-263 (1994)
L27126		Pyruvate kinase	Jetten, M. S. et al. "Structural and functional analysis of pyruvate kinase from <i>Corynebacterium glutamicum</i> ," <i>Appl. Environ. Microbiol.</i> , 60(7):2501-2507 (1994)
L28760	aceA	Isocitrate lyase	Ogizawa, J.A. et al. "Molecular cloning, DNA sequence analysis, and characterization of the <i>Corynebacterium diphtheriae</i> dtxR from <i>Brevibacterium lactofermentum</i> ," <i>J. Bacteriol.</i> , 177(2):465-467 (1995)
L35906	dtxR	Diphtheria toxin repressor	Follettie, M.T. et al. "Molecular cloning and nucleotide sequence of the <i>Corynebacterium glutamicum</i> pheA gene," <i>J. Bacteriol.</i> , 167:695-702 (1986)
M13774		Prephenate dehydratase	Park, Y.-H. et al. "Phylogenetic analysis of the coryneform bacteria by 56 rRNA sequences," <i>J. Bacteriol.</i> , 169:1801-1806 (1987)
M16175	5S rRNA		Sano, K. et al. "Structure and function of the trp operon control regions of <i>Brevibacterium lactofermentum</i> , a glutamic-acid-producing bacterium," <i>Gene</i> , 52:191-200 (1987)
M16663	trpE	Antithranilate synthase, 5' end	Sano, K. et al. "Structure and function of the trp operon control regions of <i>Brevibacterium lactofermentum</i> , a glutamic-acid-producing bacterium," <i>Gene</i> , 52:191-200 (1987)
M16664	trpA	Tryptophan synthase, 3' end	

Table 2 (continued)

M25819		Phosphoenolpyruvate carboxylase	O'Regan, M. et al. "Cloning and nucleotide sequence of the Phosphoenolpyruvate carboxylase-coding gene of <i>Corynebacterium glutamicum</i> ATCC13032," <i>Gene</i> , 77(2):237-251 (1989)
M83106		23S rRNA gene insertion sequence	Roller, C. et al. "Gram-positive bacteria with a high DNA G+C content are characterized by a common insertion within their 23S rRNA genes," <i>J. Gen. Microbiol.</i> , 138:1167-1175 (1992)
M85107, M85108		23S rRNA gene insertion sequence	Roller, C. et al. "Gram-positive bacteria with a high DNA G+C content are characterized by a common insertion within their 23S rRNA genes," <i>J. Gen. Microbiol.</i> , 138:1167-1175 (1992)
M89311	aceD; bnmQ; yhbw	Beta C-S lyase; branched-chain amino acid uptake carrier; hypothetical protein yhbw	Rossol, I. et al. "The <i>Corynebacterium glutamicum</i> aecD gene encodes a C-S lyase with alpha, beta-elimination activity that degrades aminothiylcysteine," <i>J. Bacteriol.</i> , 174(9):2968-2977 (1992); Tauch, A. et al. "Isoleucine uptake in <i>Corynebacterium glutamicum</i> ATCC 13032 is directed by the bnmQ gene product," <i>Arch. Microbiol.</i> , 169(4):303-312 (1998)
S59299	trp	Leader gene (promoter)	Henry, D.M. et al. "Cloning of the trp gene cluster from a tryptophan-hyperproducing strain of <i>Corynebacterium glutamicum</i> : identification of a mutation in the trp leader sequence," <i>Appl. Environ. Microbiol.</i> , 59(3):791-799 (1993)
U11545	trpD	Anthranilate phosphoribosyltransferase	O'Gara, J.P. and Dunican, L.K. (1994) Complete nucleotide sequence of the <i>Corynebacterium glutamicum</i> ATCC 21850 trpD gene. "Thesis, Microbiology Department, University College Galway, Ireland.
U13922	cglIM; cglIR; cglIIR	Putative type II 5-cytosine methyltransferase; putative type II restriction endonuclease; putative type I or type III restriction endonuclease	Schafer, A. et al. "Cloning and characterization of a DNA region encoding a stress-sensitive restriction system from <i>Corynebacterium glutamicum</i> ATCC 13032 and analysis of its role in intergeneric conjugation with <i>Escherichia coli</i> ," <i>J. Bacteriol.</i> , 176(23):7309-7319 (1994); Schafer, A. et al. "The <i>Corynebacterium glutamicum</i> cglIM gene encoding a 5-cytosine in an MrBC-deficient <i>Escherichia coli</i> strain," <i>Gene</i> , 203(2):95-101 (1997)
U14965	recA		Ankri, S. et al. "Mutations in the <i>Corynebacterium glutamicum</i> proline biosynthetic pathway: A natural bypass of the proA step," <i>J. Bacteriol.</i> , 178(15):4412-4419 (1996)
U31224	ppx		Ankri, S. et al. "Mutations in the <i>Corynebacterium glutamicum</i> proline biosynthetic pathway: A natural bypass of the proA step," <i>J. Bacteriol.</i> , 178(15):4412-4419 (1996)
U31225	proC	L-proline: NADP+ 5-oxidoreductase	Ankri, S. et al. "Mutations in the <i>Corynebacterium glutamicum</i> proline biosynthetic pathway: A natural bypass of the proA step," <i>J. Bacteriol.</i> , 178(15):4412-4419 (1996)
U31230	obg; proB; unkdh	?gamma glutamyl kinase; similar to D-isomer specific 2-hydroxyacid dehydrogenases	Ankri, S. et al. "Mutations in the <i>Corynebacterium glutamicum</i> proline biosynthetic pathway: A natural bypass of the proA step," <i>J. Bacteriol.</i> , 178(15):4412-4419 (1996)

Table 2 (continued)

U31281	bioB	Biotin synthase	Serebriskii, I.G., "Two new members of the bio B superfamily: Cloning, sequencing and expression of bio B genes of <i>Methyllobacillus flagellatum</i> and <i>Corynebacterium glutamicum</i> ," <i>Gene</i> , 175:15-22 (1996)
U35023	thtR; accBC	Thiosulfate sulfurtransferase; acyl CoA carboxylase	Jager, W. et al. "A <i>Corynebacterium glutamicum</i> gene encoding a two-domain protein similar to biotin carboxylases and biotin-carboxyl-carrier proteins," <i>Arch. Microbiol.</i> , 166(2):76-82 (1996)
U43535	cmr	Multidrug resistance protein	Jager, W. et al. "A <i>Corynebacterium glutamicum</i> gene conferring multidrug resistance in the heterologous host <i>Escherichia coli</i> ," <i>J. Bacteriol.</i> , 179(7):2449-2451 (1997)
U43536	clpB	Heat shock ATP-binding protein	
U53587	aphA-3	3'S'-aminoglycoside phosphotransferase	
U89648		<i>Corynebacterium glutamicum</i> unidentified sequence involved in histidine biosynthesis, partial sequence	
X04960	trpA; trpB; trpC; trpD; trpE; trpG; trpL	Tryptophan operon	Matsui, K. et al. "Complete nucleotide and deduced amino acid sequences of the <i>Brevibacterium lactofermentum</i> tryptophan operon," <i>Nucleic Acids Res.</i> , 14(24):10113-10114 (1986)
X07563	lys A	DAP decarboxylase (meso-diaminopimelate decarboxylase, EC 4.1.1.20)	Yeh, P. et al. "Nucleic sequence of the lysA gene of <i>Corynebacterium glutamicum</i> and possible mechanisms for modulation of its expression," <i>Mol. Gen. Genet.</i> , 212(1):112-119 (1988)
X14234	EC 4.1.1.31	Phosphoenolpyruvate carboxylase	Eikmanns, B.J. et al. "The Phosphoenolpyruvate carboxylase gene of <i>Corynebacterium glutamicum</i> : Molecular cloning, nucleotide sequence, and expression," <i>Mol. Gen. Genet.</i> , 218(2):330-339 (1989); Lepnies, L. et al. "Sorghum Phosphoenolpyruvate carboxylase gene family: structure, function and molecular evolution," <i>Plant. Mol. Biol.</i> , 21 (3):487-502 (1993)
X17313	fda	Fructose-bisphosphate aldolase	Von der Osten, C.H. et al. "Molecular cloning, nucleotide sequence and fine-structural analysis of the <i>Corynebacterium glutamicum</i> fda gene: structural comparison of <i>C. glutamicum</i> fructose-1, 6-biphosphate aldolase to class I and class II aldolases," <i>Mol. Microbiol.</i>
X53993	dapA	L-2, 3-dihydrodipicolinate synthetase (EC 4.2.1.52)	Bonnasse, S. et al. "Nucleic sequence of the dapA gene from <i>Corynebacterium glutamicum</i> ," <i>Nucleic Acids Res.</i> , 18(21):5621 (1990)
X54223		AttB-related site	Cianciotto, N. et al. "DNA sequence homology between att B-related sites of <i>Corynebacterium diphtheriae</i> , <i>Corynebacterium ulcerans</i> , <i>Corynebacterium glutamicum</i> , and the attP site of lambda corynephage," <i>FEBS. Microbiol. Lett.</i> , 66:299-302 (1990)
X54740	argS; lysA	Arginyl-tRNA synthetase; Diaminopimelate decarboxylase	Marcel, T. et al. "Nucleotide sequence and organization of the upstream region of the <i>Corynebacterium glutamicum</i> lysA gene," <i>Mol. Microbiol.</i> , 4(11):1819-1830 (1990)

- 64 -

Table 2 (continued)

X55594	trpL; trpE	Putative leader peptide; anthranilate synthase component 1	Heery, D.M. et al. "Nucleotide sequence of the <i>Corynebacterium glutamicum</i> trpE gene," <i>Nucleic Acids Res.</i> , 18(23):7138 (1990)
X56037	thiC	Threonine synthase	Han, K.S. et al. "The molecular structure of the <i>Corynebacterium glutamicum</i> threonine synthase gene," <i>Mol. Microbiol.</i> , 4(10):1693-1702 (1990)
X56075	attB-related site	Attachment site	Cianciotto, N. et al. "DNA sequence homology between att B-related sites of <i>Corynebacterium diphtheriae</i> , <i>Corynebacterium ulcerans</i> , <i>Corynebacterium glutamicum</i> , and the attP site of lambda <i>corynephage</i> ," <i>FEMS Microbiol. Lett.</i> , 66:299-302 (1990)
X57226	lysC-alpha; lysC-beta; asd	Aspartokinase-alpha subunit; Aspartokinase-beta subunit; aspartate beta semialdehyde dehydrogenase	Kalinowski, J. et al. "Genetic and biochemical analysis of the Aspartokinase from <i>Corynebacterium glutamicum</i> ," <i>Mol. Microbiol.</i> , 5(5):1197-1204 (1991); Kalinowski, J. et al. "Aspartokinase genes lysC alpha and lysC beta overlap and are adjacent to the aspartate beta-semialdehyde dehydrogenase gene and in <i>Corynebacterium glutamicum</i> ," <i>Mol. Gen. Genet.</i> , 224(3):317-324 (1990)
X59403	gap,pgk, lpi	Glyceraldehyde-3-phosphate, phosphoglycerate kinase; triosephosphate isomerase	Eikmanns, B.J. "Identification, sequence analysis, and expression of a <i>Corynebacterium glutamicum</i> gene cluster encoding the three glycolytic enzymes glyceraldehyde-3-phosphate dehydrogenase, 3-phosphoglycerate kinase, and triosephosphate isomerases," <i>J. Bacteriol.</i> , 174(19):6076-6086 (1992)
X59404	gdh	Glutamate dehydrogenase	Bornmann, E.R. et al. "Molecular analysis of the <i>Corynebacterium glutamicum</i> gdh gene encoding glutamate dehydrogenase," <i>Mol. Microbiol.</i> , 6(3):317-326 (1992)
X60312	lysI	L-lysine permease	Seep-Feldhaus, A.H. et al. "Molecular analysis of the <i>Corynebacterium glutamicum</i> lysI gene involved in lysine uptake," <i>Mol. Microbiol.</i> , 5(12):2995-3005 (1991)
X66078	copI	PsI protein	Joliffi, G. et al. "Cloning and nucleotide sequence of the cspI gene encoding PsI, one of the two major secreted proteins of <i>Corynebacterium glutamicum</i> : The deduced N-terminal region of PsI is similar to the <i>Mycobacterium antigen 85</i> complex," <i>Mol. Microbiol.</i> , 6(16):2349-2362 (1992)
X66112	glt	Citrate synthase	Eikmanns, B.J. et al. "Cloning sequence, expression and transcriptional analysis of the <i>Corynebacterium glutamicum</i> gltA gene encoding citrate synthase," <i>Microbiol.</i> , 140:1817-1828 (1994)
X67737	dapB	Dihydrodipicolinate reductase	
X69103	csp2	Surface layer protein PS2	Peyret, J.L. et al. "Characterization of the cspB gene encoding PS2, an ordered surface-layer protein in <i>Corynebacterium glutamicum</i> ," <i>Mol. Microbiol.</i> , 9(1):97-109 (1993)
X69104		IS3 related insertion element	Bonamy, C. et al. "Identification of IS1206, a <i>Corynebacterium glutamicum</i> IS3-related insertion sequence and phylogenetic analysis," <i>Mol. Microbiol.</i> , 14(3):571-581 (1994)

Table 2 (continued)

X70959	leuA	Isopropylmalate synthase	Patek, M. et al. "Leucine synthesis in <i>Corynebacterium glutamicum</i> : enzyme activities, structure of leuA, and effect of leuA inactivation on lysine synthesis," <i>Appl. Environ. Microbiol.</i> , 60(1):133-140 (1994)
X71489	icd	Isocitrate dehydrogenase (NADP+)	Eikmanns, B.J. et al. "Cloning, sequence analysis, expression, and inactivation of the <i>Corynebacterium glutamicum</i> icd gene encoding isocitrate dehydrogenase and biochemical characterization of the enzyme," <i>J. Bacteriol.</i> , 177(3):774-782 (1995)
X72855	GDHA	Glutamate dehydrogenase (NADP+)	Heery, D.M. et al. "A sequence from a tryptophan-hyperproducing strain of <i>Corynebacterium glutamicum</i> encoding resistance to 5-methyltryptophan," <i>Biochem. Biophys. Res. Commun.</i> , 20(3):1255-1262 (1994)
X75083, X70584	mitA	5-methyltryptophan resistance	Fitzpatrick, R. et al. "Construction and characterization of recA mutant strains of <i>Corynebacterium glutamicum</i> and <i>Brevibacterium lactofermentum</i> ," <i>Appl. Microbiol. Biotechnol.</i> , 42(4):575-580 (1994)
X75085	recA		Reinscheid, D.J. et al. "Characterization of the isocitrate lyase gene from <i>Corynebacterium glutamicum</i> and biochemical analysis of the enzyme," <i>J. Bacteriol.</i> , 176(12):3474-3483 (1994)
X75504	aceA; thiX	Partial Isocitrate lyase; ?	Ludwig, W. et al. "Phylogenetic relationships of bacteria based on comparative sequence analysis of elongation factor Tu and ATP-synthase beta-subunit genes," <i>Antonie Van Leeuwenhoek</i> , 64:285-305 (1993)
X76875		ATPase beta-subunit	Ludwig, W. et al. "Phylogenetic relationships of bacteria based on comparative sequence analysis of elongation factor Tu and ATP-synthase beta-subunit genes," <i>Antonie Van Leeuwenhoek</i> , 64:285-305 (1993)
X77034	tuf	Elongation factor Tu	Billman-Jacobe, H. "Nucleotide sequence of a recA gene from <i>Corynebacterium glutamicum</i> ," <i>DNA Seq.</i> , 4(6):403-404 (1994)
X77384	recA		Reinscheid, D.J. et al. "Malate synthase from <i>Corynebacterium glutamicum</i> pta-ack operon encoding phosphotransacetylase: sequence analysis," <i>Microbiology</i> , 140:3099-3108 (1994)
X78491	aceB	Malate synthase	Rainey, F.A. et al. "Phylogenetic analysis of the genera <i>Rhodococcus</i> and <i>Norcardia</i> and evidence for the evolutionary origin of the genus <i>Norcardia</i> from within the radiation of <i>Rhodococcus</i> species," <i>Microbiol.</i> , 141:523-528 (1995)
X80629	16S rDNA	16S ribosomal RNA	Kronemeyer, W. et al. "Structure of the gluABCD cluster encoding the glutamate uptake system of <i>Corynebacterium glutamicum</i> ," <i>J. Bacteriol.</i> , 177(5):1152-1158 (1995)
X81191	gluA; gluB; gluC; gluD	Glutamate uptake system	Wehrmann, A. et al. "Analysis of different DNA fragments of <i>Corynebacterium glutamicum</i> complementing dapE of <i>Escherichia coli</i> ," <i>Microbiology</i> , 40:3349-56 (1994)
X81379	dapE	Succinyldiaminopimelate desuccinylase	

Table 2 (continued)

X82061	16S rDNA	16S ribosomal RNA	Ruimy, R. et al. "Phylogeny of the genus <i>Corynebacterium</i> deduced from analyses of small-subunit ribosomal DNA sequences," <i>Int. J. Syst. Bacteriol.</i> , 45(4):740-746 (1995)
X82928	asd; lysC	Aspartate-semialdehyde dehydrogenase; ?	Serebrijski, I. et al. "Multi-copy suppression by asd gene and osmotic stress-dependent complementation by heterologous proA in proA mutants," <i>J. Bacteriol.</i> , 177(24):7255-7260 (1995)
X82929	proA	Gamma-glutamyl phosphate reductase	Serebrijski, I. et al. "Multi-copy suppression by asd gene and osmotic stress-dependent complementation by heterologous proA in proA mutants," <i>J. Bacteriol.</i> , 177(24):7255-7260 (1995)
X84257	16S rDNA	16S ribosomal RNA	Pascual, C. et al. "Phylogenetic analysis of the genus <i>Corynebacterium</i> based on 16S rRNA gene sequences," <i>Int. J. Syst. Bacteriol.</i> , 45(4):724-728 (1995)
X85965	aroP; dapE	Aromatic amino acid permease; ?	Wehrmann et al. "Functional analysis of sequences adjacent to dapE of <i>C. glutamicum</i> proline reveals the presence of aroP, which encodes the aromatic amino acid transporter," <i>J. Bacteriol.</i> , 177(20):5919-5993 (1995)
X86157	argB; argC; argD; argF; argJ	Acetylglutamate kinase; N-acetyl-gamma-glutamyl-phosphate reductase; acetylornithine aminotransferase; ornithine carbamoyltransferase; glutamate N-acetyltransferase	Sakanyan, V. et al. "Genes and enzymes of the acetyl cycle of arginine biosynthesis in <i>Corynebacterium glutamicum</i> : enzyme evolution in the early steps of the arginine pathway," <i>Microbiology</i> , 142:99-108 (1996)
X89084	pta; ackA	Phosphate acetyltransferase; acetate kinase	Reinscheid, D.J. et al. "Cloning, sequence analysis, expression and inactivation of the <i>Corynebacterium glutamicum</i> pta-ack operon encoding phosphotransacetylase and acetate kinase," <i>Microbiology</i> , 145:503-513 (1999)
X89850	attB	Attachment site	Le Marrec, C. et al. "Genetic characterization of site-specific integration functions of phi AAU2 infecting "Arthrobacter aureus C70," <i>J. Bacteriol.</i> , 178(7):1996-2004 (1996)
X90356		Promoter fragment F1	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90357		Promoter fragment F2	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90358		Promoter fragment F10	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90359		Promoter fragment F13	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)

Table 2 (continued)

X90360	Promoter fragment F22	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90361	Promoter fragment F34	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90362	Promoter fragment F37	Patek, M. et al. "Promoters from <i>C. glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90363	Promoter fragment F45	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90364	Promoter fragment F64	Patek, M. et al. "Promoters from <i>C. glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90365	Promoter fragment F75	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90366	Promoter fragment PF101	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90367	Promoter fragment PF104	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90368	Promoter fragment PF109	Patek, M. et al. "Promoters from <i>C. glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X93513	amt	Siewe, R.M. et al. "Functional and genetic characterization of the (methyl) ammonium uptake carrier of <i>Corynebacterium glutamicum</i> ," <i>J. Biol. Chem.</i> , 271(10):5398-5403 (1996)
X93514	betP	Peter, H. et al. "Isolation, characterization, and expression of the <i>Corynebacterium glutamicum</i> betP gene, encoding the transport system for the compatible solute glycine betaine," <i>J. Bacteriol.</i> , 178(17):5229-5234 (1996)
X95649	orf4	Patek, M. et al. "Identification and transcriptional analysis of the dapB-ORF2-dapA-ORF4 operon of <i>Corynebacterium glutamicum</i> , encoding two enzymes involved in L-lysine synthesis," <i>Biotechnol. Lett.</i> , 19:1113-1117 (1997)
X96471	lysE; lysG	Vrijic, M. et al. "A new type of transporter with a new type of cellular function: L-lysine export from <i>Corynebacterium glutamicum</i> ," <i>Mol. Microbiol.</i> , 22(5):815-826 (1996)

Table 2 (continued)

X96580	panB; panC; xylB	3-methyl-2-oxobutanoate hydroxymethyltransferase; pantoate-beta-alanine ligase; xylulokinase	Sahm, H. et al. "D-pantothenate synthesis in <i>Corynebacterium glutamicum</i> and use of panBC and genes encoding L-valine synthesis for D-pantothenate overproduction," <i>Appl. Environ. Microbiol.</i> , 65(5):1973-1979 (1999)
X96962		Insertion sequence IS1207 and transposase	
X99289		Elongation factor P	Ramos, A. et al. "Cloning, sequencing and expression of the gene encoding elongation factor P in the amino-acid producer <i>Brevibacterium lactofermentum</i> (<i>Corynebacterium glutamicum</i> ATCC 13869)," <i>Gene</i> , 198:217-222 (1997)
Y00140	thrB	Homoserine kinase	Mateos, L.M. et al. "Nucleotide sequence of the homoserine kinase (thrB) gene of the <i>Brevibacterium lactofermentum</i> ," <i>Nucleic Acids Res.</i> , 15(9):3922 (1987)
Y00151	ddh	Meso-diaminopimelate D-dehydrogenase (EC 1.4.1.16)	Ishino, S. et al. "Nucleotide sequence of the meso-diaminopimelate D-dehydrogenase gene from <i>Corynebacterium glutamicum</i> ," <i>Nucleic Acids Res.</i> , 15(9):3917 (1987)
Y00476	thrA	Homoserine dehydrogenase	Mateos, L.M. et al. "Nucleotide sequence of the homoserine dehydrogenase (thrA) gene of the <i>Brevibacterium lactofermentum</i> ," <i>Nucleic Acids Res.</i> , 15(24):10598 (1987)
Y00546	hom; thrB	Homoserine dehydrogenase; homoserine kinase	Peoples, O.P. et al. "Nucleotide sequence and fine structural analysis of the <i>Corynebacterium glutamicum hom-thrB</i> operon," <i>Mol. Microbiol.</i> , 2(1):63-72 (1988)
Y08964	murC; ftsQ/divD; ftsZ	UPD-N-acetylumuramate-alanine ligase; division initiation protein or cell division protein; cell division protein	Honrubia, M.P. et al. "Identification, characterization, and chromosomal organization of the ftsZ gene from <i>Brevibacterium lactofermentum</i> ," <i>Mol. Gen. Genet.</i> , 259(1):97-104 (1998)
Y09163	putP	High affinity proline transport system	Peter, H. et al. "Isolation of the putP gene of <i>Corynebacterium glutamicum</i> and characterization of a low-affinity uptake system for compatible solutes," <i>Arch. Microbiol.</i> , 168(2):143-151 (1997)
Y09548	pyc	Pyruvate carboxylase	Peters-Wendisch, P.G. et al. "Pyruvate carboxylase from <i>Corynebacterium glutamicum</i> : characterization, expression and inactivation of the pyc gene," <i>Microbiology</i> , 144:915-927 (1998)
Y09578	leuB	3-isopropylmalate dehydrogenase	Patek, M. et al. "Analysis of the leuB gene from <i>Corynebacterium glutamicum</i> ," <i>Appl. Microbiol. Biotechnol.</i> , 50(1):42-47 (1998)
Y12472		Attachment site bacteriophage Phi-16	Moreau, S. et al. "Site-specific integration of corynephage Phi-16: The construction of an integration vector," <i>Microbiol.</i> , 145:539-548 (1999)
Y12537	proP	Proline/ectoine uptake system protein	Peter, H. et al. "Corynebacterium glutamicum is equipped with four secondary carriers for compatible solutes: Identification, sequencing, and characterization of the proline/ectoine uptake system, ProP, and the ectoine/proline/glycine betaine carrier, EctP," <i>J. Bacteriol.</i> , 180(22):6005-6012 (1998)

Table 2 (continued)

Y13221	glnA	Glutamine synthetase I	Jakoby, M. et al. "Isolation of <i>Corynebacterium glutamicum</i> glnA gene encoding glutamine synthetase I," <i>FEBS Microbiol. Lett.</i> , 154(1):81-88 (1997)
Y16642	lpd	Dihydrolipoamide dehydrogenase	
Y18059		Attachment site <i>Corynephage 304L</i>	Moreau, S. et al. "Analysis of the integration functions of φ304L: An integrase module among corynephages," <i>Virology</i> , 255(1):150-159 (1999)
Z21501	argS; lysA	Arginyl-tRNA synthetase; diaminopimelate decarboxylase (partial)	Oguiza, J.A. et al. "A gene encoding arginyl-tRNA synthetase is located in the upstream region of the lysA gene in <i>Brevibacterium lactofermentum</i> : Regulation of argS-lysA cluster expression by arginine," <i>J. Bacteriol.</i> , 175(22):7356-7362 (1993)
Z21502	dapA; dapB	Dihydrodipicolinate synthase; dihydrodipicolinate reductase	Pisabarro, A. et al. "A cluster of three genes (dapA, orf2, and dapB) of <i>Brevibacterium lactofermentum</i> encodes dihydrodipicolinate reductase, and a third polypeptide of unknown function," <i>J. Bacteriol.</i> , 175(9):2743-2749 (1993)
Z229563	thrC	Threonine synthase	Malumbres, M. et al. "Analysis and expression of the thrC gene of the encoded threonine synthase," <i>Appl. Environ. Microbiol.</i> , 60(7):2209-2219 (1994)
Z46753	16S rDNA	Gene for 16S ribosomal RNA	Oguiza, J.A. et al "Multiple sigma factor genes in <i>Brevibacterium lactofermentum</i> : Characterization of sigA and sigB," <i>J. Bacteriol.</i> , 178(2):550-553 (1996)
Z49822	sigA	SigA sigma factor	Oguiza, J.A. et al "The galE gene encoding the UDP-galactose 4-epimerase of <i>Brevibacterium lactofermentum</i> is coupled transcriptionally to the dmdR gene," <i>Gene</i> , 177:103-107 (1996)
Z49823	galE; dmxR	Catalytic activity UDP-galactose 4-epimerase; diphtheria toxin regulatory protein	Oguiza, J.A. et al "Multiple sigma factor genes in <i>Brevibacterium lactofermentum</i> : Characterization of sigA and sigB," <i>J. Bacteriol.</i> , 178(2):550-553 (1996)
Z49824	orf1; sigB	?; SigB sigma factor	Correia, A. et al. "Cloning and characterization of an IS-like element present in the genome of <i>Brevibacterium lactofermentum</i> ATCC 13869," <i>Gene</i> , 170(1):91-94 (1996)
Z66534		Transposase	A sequence for this gene was published in the indicated reference. However, the sequence obtained by the inventors of the present application is significantly longer than the published version. It is believed that the published version relied on an incorrect start codon, and thus represents only a fragment of the actual coding region.

TABLE 3: *Corynebacterium* and *Brevibacterium* Strains Which May be Used in the Practice of the Invention

Genus	species	ATCC	FERM	NRRL	CECT	NCIMB	CBS	NCTC	DSMZ
<i>Brevibacterium</i>	ammoniagenes	21054							
<i>Brevibacterium</i>	ammoniagenes	19350							
<i>Brevibacterium</i>	ammoniagenes	19351							
<i>Brevibacterium</i>	ammoniagenes	19352							
<i>Brevibacterium</i>	ammoniagenes	19353							
<i>Brevibacterium</i>	ammoniagenes	19354							
<i>Brevibacterium</i>	ammoniagenes	19355							
<i>Brevibacterium</i>	ammoniagenes	19356							
<i>Brevibacterium</i>	ammoniagenes	21055							
<i>Brevibacterium</i>	ammoniagenes	21077							
<i>Brevibacterium</i>	ammoniagenes	21553							
<i>Brevibacterium</i>	ammoniagenes	21580							
<i>Brevibacterium</i>	ammoniagenes	39101							
<i>Brevibacterium</i>	butanicum	21196							
<i>Brevibacterium</i>	divaricatum	21792	P928						
<i>Brevibacterium</i>	flavum	21474							
<i>Brevibacterium</i>	flavum	21129							
<i>Brevibacterium</i>	flavum	21518							
<i>Brevibacterium</i>	flavum			B11474					
<i>Brevibacterium</i>	flavum			B11472					
<i>Brevibacterium</i>	flavum	21127							
<i>Brevibacterium</i>	flavum	21128							
<i>Brevibacterium</i>	flavum	21427							
<i>Brevibacterium</i>	flavum	21475							
<i>Brevibacterium</i>	flavum	21517							
<i>Brevibacterium</i>	flavum	21528							
<i>Brevibacterium</i>	flavum	21529							
<i>Brevibacterium</i>	flavum			B11477					
<i>Brevibacterium</i>	flavum			B11478					
<i>Brevibacterium</i>	flavum	21127							
<i>Brevibacterium</i>	flavum			B11474					
<i>Brevibacterium</i>	healii	15527							
<i>Brevibacterium</i>	ketoglutamicum	21004							
<i>Brevibacterium</i>	ketoglutamicum	21089							
<i>Brevibacterium</i>	ketosoreductum	21914					70		
<i>Brevibacterium</i>	lactofermentum						74		
<i>Brevibacterium</i>	lactofermentum						77		
<i>Brevibacterium</i>	lactofermentum	21798							
<i>Brevibacterium</i>	lactofermentum	21799							
<i>Brevibacterium</i>	lactofermentum	21800							
<i>Brevibacterium</i>	lactofermentum	21801							
<i>Brevibacterium</i>	lactofermentum			B11470					
<i>Brevibacterium</i>	lactofermentum			B11471					

Brevibacterium	lactofermentum	21086						
Brevibacterium	lactofermentum	21420						
Brevibacterium	lactofermentum	21086						
Brevibacterium	lactofermentum	31269						
Brevibacterium	linens	9174						
Brevibacterium	linens	19391						
Brevibacterium	linens	8377						
Brevibacterium	paraffinolyticum				11160			
Brevibacterium	spec.					717.73		
Brevibacterium	spec.					717.73		
Brevibacterium	spec.	14604						
Brevibacterium	spec.	21860						
Brevibacterium	spec.	21864						
Brevibacterium	spec.	21865						
Brevibacterium	spec.	21866						
Brevibacterium	spec.	19240						
Corynebacterium	acetoacidophilum	21476						
Corynebacterium	acetoacidophilum	13870						
Corynebacterium	acetoglutamicum			B11473				
Corynebacterium	acetoglutamicum			B11475				
Corynebacterium	acetoglutamicum	15806						
Corynebacterium	acetoglutamicum	21491						
Corynebacterium	acetoglutamicum	31270						
Corynebacterium	acetophilum			B3671				
Corynebacterium	ammoniagenes	6872					2399	
Corynebacterium	ammoniagenes	15511						
Corynebacterium	fujikense	21496						
Corynebacterium	glutamicum	14067						
Corynebacterium	glutamicum	39137						
Corynebacterium	glutamicum	21254						
Corynebacterium	glutamicum	21255						
Corynebacterium	glutamicum	31830						
Corynebacterium	glutamicum	13032						
Corynebacterium	glutamicum	14305						
Corynebacterium	glutamicum	15455						
Corynebacterium	glutamicum	13058						
Corynebacterium	glutamicum	13059						
Corynebacterium	glutamicum	13060						
Corynebacterium	glutamicum	21492						
Corynebacterium	glutamicum	21513						
Corynebacterium	glutamicum	21526						
Corynebacterium	glutamicum	21543						
Corynebacterium	glutamicum	13287						
Corynebacterium	glutamicum	21851						
Corynebacterium	glutamicum	21253						
Corynebacterium	glutamicum	21514						
Corynebacterium	glutamicum	21516						
Corynebacterium	glutamicum	21299						
Corynebacterium	glutamicum	21300						

TABLE 4: ALIGNMENT RESULTS

ID #	length [NT]	Genbank Hit [NT]	Length	Accession	Source of Genbank Hit		% homology (GAP)	Date of Deposit
					Name of Genbank Hit	Length		
ra00315	1527	GB_BA1:AB007125	4078	AB007125	Serratia marcescens sfaA gene for surface layer protein, complete Serratia marcescens cds, Isolate 8000.		40,386	26-MAR-1998
		GB_IN1:CELC47D2	17381	U64861	Caenorhabditis elegans cosmid C47D2.		36,207	28-Jul-96
		GB_HTG2:AC006732	159453	AC006732	Caenorhabditis elegans clone Y32G9, *** SEQUENCING IN PROGRESS ***,9 unordered pieces.		36,436	23-Feb-99
ra01503	3772	GB_PRR:AC005019	188362	AC005019	Homo sapiens BAC clone GS250A16 from 7p21-p22, complete RPCI-11-157C9-TJ RPCI-11 Homo sapiens genomic clone RPCI-11-157C9,genomic survey sequence.	Homo sapiens	39,722	27-Aug-98
		GB_GSS12:AQ390040 680		AQ390040	HS_3087_B1_C10_T7C C1T Approved Human Genomic Sperm Library D Homo sapiens genomic clone Plate=3087 Col=19 Row=F, genomic survey sequence.	Homo sapiens	43,137	21-MAY-1999
		GB_GSS5:AQ784231	542	AQ784231	U1-M-BH1-amlh-e-03-0-U1.s1 NIH_BMAP_M_S2 Mus musculus cDNA clone U1-M-BH1-amlh-e-03-0-U1 3', mRNA sequence.	Mus musculus	37,643	3-Aug-99
ra01299	2187	GB_EST38:AW047296 614		AW047296	Rattus norvegicus transcription factor, complete cds.	Rattus norvegicus	41,475	18-Sep-99
		GB_RO:AB004056	1581	AB004056	Rattus norvegicus mRNA for Barth-class homeodomain transcription factor, complete cds.	Rattus norvegicus	41,031	2-Sep-98
		GB_RO:AB004056	1581	AB004056	Rattus norvegicus mRNA for Barth-class homeodomain transcription factor, complete cds.	Rattus norvegicus	40,717	2-Sep-98
ra00951	416	GB_BA1:SCJ21	31717	AL109747	Streptomyces coelicolor A3(2) cosmid J21.	Streptomyces coelicolor A3(2)	34,913	5-Aug-99
		GB_VI:MCU68299	230278	U68299	Mouse cytomegalovirus 1 complete genomic sequence.	Mouse cytomegalovirus 1	40,097	04-DEC-1996
		GB_VI:U93872	133661	U93872	Kaposi's sarcoma-associated herpesvirus glycoprotein M, DNA replication protein, glycoprotein, DNA replication protein, F1/ICE inhibitory protein and v-cyclin genes, complete cds, and tegument genes, complete cds.	Kaposi's sarcoma-associated herpesvirus	36,029	9-Jul-97
ra01244	1827	GB_BA1:AFAPHBH1	4501	M69036	Alcaligenes eutrophus protein H (phbH) and protein I (phbI) genes, complete cds.	Ralstonia eutropha	45,624	26-Apr-93
		GB_PRR:HSJB36E13	78055	AL050326	Human DNA sequence from clone 836E13 on chromosome 20	Homo sapiens	37,303	23-Nov-99
		GB_EST24:AI170227	409	AI170227	Contains ESTs, STS and GSSs, complete sequence.	Rattus sp.	39,098	20-Jan-99
					EST216152 Normalized rat lung, Bento Soares Rattus sp. cDNA clone RLUCF56 3' end, mRNA sequence.			
ra01300	390	GB_PRR:HUMDDODDA	26764	L39874	Homo sapiens deoxyxylidide deaminase gene, complete cds.	Homo sapiens	37,644	11-Aug-95
		GB_PAT:140899	26764	I40899	Sequence 1 from patent US 5622851.	Unknown.	37,644	13-MAY-1997
		GB_PAT:140900	1317	I40900	Sequence 2 from patent US 5622851.	Unknown.	37,644	13-MAY-1997
ra00953	789	GB_BA1:SCJ21	31717	AL109747	Streptomyces coelicolor cosmid J21.	Streptomyces coelicolor A3(2)	39,398	5-Aug-99
		GB_BA1:BLTRP	7725	X04960	Brevibacterium lactofermentum tryptophan operon.	Corynebacterium glutamicum	39,610	10-Feb-99
		GB_PAT:E01375	7726	E01375	DNA sequence of tryptophan operon.	Corynebacterium glutamicum	46,753	29-Sep-97

Table 4 (continued)

ra01943	2172 GB_BA1:CORPTSMA	2656	L18874	Corynebacterium glutamicum phosphoenolpyruvate sugar phosphotransferase (ptsM) mRNA, complete cds.	Corynebacterium glutamicum	100,000	24-Nov-94
GB_BA1:BR1PTSG	3163	L18875		Brevibacterium laevofermentum phosphoenolpyruvate sugar phosphotransferase (ptsG) gene, complete cds.	Brevibacterium	84,963	01-OCT-1993
GB_BA2:AF045481	2841	AF045481		Corynebacterium ammoniagenes glucose permease (ptsG) gene, complete cds.	Corynebacterium ammoniagenes	53,558	29-Jul-98

Corynebacterium	glutamicum	39684									
Corynebacterium	glutamicum	21488									
Corynebacterium	glutamicum	21649									
Corynebacterium	glutamicum	21650									
Corynebacterium	glutamicum	19223									
Corynebacterium	glutamicum	13869									
Corynebacterium	glutamicum	21157									
Corynebacterium	glutamicum	21158									
Corynebacterium	glutamicum	21159									
Corynebacterium	glutamicum	21355									
Corynebacterium	glutamicum	31808									
Corynebacterium	glutamicum	21674									
Corynebacterium	glutamicum	21562									
Corynebacterium	glutamicum	21563									
Corynebacterium	glutamicum	21564									
Corynebacterium	glutamicum	21565									
Corynebacterium	glutamicum	21566									
Corynebacterium	glutamicum	21567									
Corynebacterium	glutamicum	21568									
Corynebacterium	glutamicum	21569									
Corynebacterium	glutamicum	21570									
Corynebacterium	glutamicum	21571									
Corynebacterium	glutamicum	21572									
Corynebacterium	glutamicum	21573									
Corynebacterium	glutamicum	21579									
Corynebacterium	glutamicum	19049									
Corynebacterium	glutamicum	19050									
Corynebacterium	glutamicum	19051									
Corynebacterium	glutamicum	19052									
Corynebacterium	glutamicum	19053									
Corynebacterium	glutamicum	19054									
Corynebacterium	glutamicum	19055									
Corynebacterium	glutamicum	19056									
Corynebacterium	glutamicum	19057									
Corynebacterium	glutamicum	19058									
Corynebacterium	glutamicum	19059									
Corynebacterium	glutamicum	19060									
Corynebacterium	glutamicum	19185									
Corynebacterium	glutamicum	13286									
Corynebacterium	glutamicum	21515									
Corynebacterium	glutamicum	21527									
Corynebacterium	glutamicum	21544									
Corynebacterium	glutamicum	21492									
Corynebacterium	glutamicum						B8183				
Corynebacterium	glutamicum						B8182				
Corynebacterium	glutamicum						B12416				
Corynebacterium	glutamicum						B12417				
Corynebacterium	glutamicum						B12418				
Corynebacterium	glutamicum						B11476				

<i>Corynebacterium</i>	glutamicum	21608							
<i>Corynebacterium</i>	lilium		P973						
<i>Corynebacterium</i>	nitrilophilus	21419				11594			
<i>Corynebacterium</i>	spec.		P4445						
<i>Corynebacterium</i>	spec.		P4446						
<i>Corynebacterium</i>	spec.	31088							
<i>Corynebacterium</i>	spec.	31089							
<i>Corynebacterium</i>	spec.	31090							
<i>Corynebacterium</i>	spec.	31090							
<i>Corynebacterium</i>	spec.	31090							
<i>Corynebacterium</i>	spec.	15954							20145
<i>Corynebacterium</i>	spec.	21857							
<i>Corynebacterium</i>	spec.	21862							
<i>Corynebacterium</i>	spec.	21863							

ATCC: American Type Culture Collection, Rockville, MD, USA

FERM: Fermentation Research Institute, Chiba, Japan

NRRL: ARS Culture Collection, Northern Regional Research Laboratory, Peoria, IL, USA

CECT: Colección Espanola de Cultivos Tipo, Valencia, Spain

NCIMB: National Collection of Industrial and Marine Bacteria Ltd., Aberdeen, UK

CBS: Centraalbureau voor Schimmelcultures, Baarn, NL

NCTC: National Collection of Type Cultures, London, UK

DSMZ: Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braunschweig, Germany

For reference see Sugawara, H. et al. (1993) World directory of collections of cultures of microorganisms: Bacteria, fungi and yeasts (4th edn), World federation for culture collections world data center on microorganisms, Saitama, Japan.

Exemplification**Example 1: Preparation of total genomic DNA of *Corynebacterium glutamicum*****ATCC 13032**

5 A culture of *Corynebacterium glutamicum* (ATCC 13032) was grown overnight at 30°C with vigorous shaking in BHI medium (Difco). The cells were harvested by centrifugation, the supernatant was discarded and the cells were resuspended in 5 ml buffer-I (5% of the original volume of the culture — all indicated volumes have been calculated for 100 ml of culture volume). Composition of buffer-I: 140.34 g/l sucrose, 10 2.46 g/l MgSO₄ x 7H₂O, 10 ml/l KH₂PO₄ solution (100 g/l, adjusted to pH 6.7 with KOH), 50 ml/l M12 concentrate (10 g/l (NH₄)₂SO₄, 1 g/l NaCl, 2 g/l MgSO₄ x 7H₂O, 0.2 g/l CaCl₂, 0.5 g/l yeast extract (Difco), 10 ml/l trace-elements-mix (200 mg/l FeSO₄ x H₂O, 10 mg/l ZnSO₄ x 7 H₂O, 3 mg/l MnCl₂ x 4 H₂O, 30 mg/l H₃BO₃, 20 mg/l CoCl₂ x 6 H₂O, 1 mg/l NiCl₂ x 6 H₂O, 3 mg/l Na₂MoO₄ x 2 H₂O, 500 mg/l complexing agent 15 (EDTA or citric acid), 100 ml/l vitamins-mix (0.2 mg/l biotin, 0.2 mg/l folic acid, 20 mg/l p-amino benzoic acid, 20 mg/l riboflavin, 40 mg/l ca-panthothenate, 140 mg/l nicotinic acid, 40 mg/l pyridoxole hydrochloride, 200 mg/l myo-inositol). Lysozyme was added to the suspension to a final concentration of 2.5 mg/ml. After an approximately 4 h incubation at 37°C, the cell wall was degraded and the resulting 20 protoplasts are harvested by centrifugation. The pellet was washed once with 5 ml buffer-I and once with 5 ml TE-buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8). The pellet was resuspended in 4 ml TE-buffer and 0.5 ml SDS solution (10%) and 0.5 ml NaCl solution (5 M) are added. After adding of proteinase K to a final concentration of 200 µg/ml, the suspension is incubated for ca. 18 h at 37°C. The DNA was purified by 25 extraction with phenol, phenol-chloroform-isoamylalcohol and chloroform-isoamylalcohol using standard procedures. Then, the DNA was precipitated by adding 1/50 volume of 3 M sodium acetate and 2 volumes of ethanol, followed by a 30 min incubation at -20°C and a 30 min centrifugation at 12,000 rpm in a high speed centrifuge using a SS34 rotor (Sorvall). The DNA was dissolved in 1 ml TE-buffer containing 20 30 µg/ml RNaseA and dialysed at 4°C against 1000 ml TE-buffer for at least 3 hours. During this time, the buffer was exchanged 3 times. To aliquots of 0.4 ml of the dialysed DNA solution, 0.4 ml of 2 M LiCl and 0.8 ml of ethanol are added. After a 30

- 77 -

min incubation at -20°C, the DNA was collected by centrifugation (13,000 rpm, Biofuge Fresco, Heraeus, Hanau, Germany). The DNA pellet was dissolved in TE-buffer. DNA prepared by this procedure could be used for all purposes, including southern blotting or construction of genomic libraries.

5

Example 2: Construction of genomic libraries in *Escherichia coli* of *Corynebacterium glutamicum* ATCC13032.

Using DNA prepared as described in Example 1, cosmid and plasmid libraries were constructed according to known and well established methods (see e.g., Sambrook, J. et al.

10 (1989) "Molecular Cloning : A Laboratory Manual", Cold Spring Harbor Laboratory Press, or Ausubel, F.M. et al. (1994) "Current Protocols in Molecular Biology", John Wiley & Sons.)

Any plasmid or cosmid could be used. Of particular use were the plasmids pBR322 (Sutcliffe, J.G. (1979) *Proc. Natl. Acad. Sci. USA*, 75:3737-3741); pACYC177 (Change &

15 Cohen (1978) *J. Bacteriol.* 134:1141-1156), plasmids of the pBS series (pBSSK+, pBSSK- and others; Stratagene, LaJolla, USA), or cosmids as SuperCos1 (Stratagene, LaJolla, USA) or Lorist6 (Gibson, T.J., Rosenthal A. and Waterson, R.H. (1987) *Gene* 53:283-286. Gene libraries specifically for use in *C. glutamicum* may be constructed using plasmid pSL109 (Lee, H.-S. and A. J. Sinskey (1994) *J. Microbiol. Biotechnol.* 4: 256-263).

20

Example 3: DNA Sequencing and Computational Functional Analysis

Genomic libraries as described in Example 2 were used for DNA sequencing according to standard methods, in particular by the chain termination method using ABI377 sequencing machines (see e.g., Fleischman, R.D. et al. (1995) "Whole-genome

25 Random Sequencing and Assembly of *Haemophilus Influenzae* Rd., *Science*, 269:496-512). Sequencing primers with the following nucleotide sequences were used: 5'-GGAAACAGTATGACCATG-3' or 5'-GTAAAACGACGGCCAGT-3'.

Example 4: *In vivo* Mutagenesis

30 *In vivo* mutagenesis of *Corynebacterium glutamicum* can be performed by passage of plasmid (or other vector) DNA through *E. coli* or other microorganisms (e.g. *Bacillus* spp. or yeasts such as *Saccharomyces cerevisiae*) which are impaired in their capabilities to maintain

the integrity of their genetic information. Typical mutator strains have mutations in the genes for the DNA repair system (e.g., mutHLS, mutD, mutT, etc.; for reference, see Rupp, W.D. (1996) DNA repair mechanisms, in: *Escherichia coli* and *Salmonella*, p. 2277-2294, ASM: Washington.) Such strains are well known to one of ordinary skill in the art. The use of such 5 strains is illustrated, for example, in Greener, A. and Callahan, M. (1994) Strategies 7: 32-34.

Example 5: DNA Transfer Between *Escherichia coli* and *Corynebacterium glutamicum*

Several *Corynebacterium* and *Brevibacterium* species contain endogenous 10 plasmids (as e.g., pHM1519 or pBL1) which replicate autonomously (for review see, e.g., Martin, J.F. et al. (1987) Biotechnology, 5:137-146). Shuttle vectors for *Escherichia coli* and *Corynebacterium glutamicum* can be readily constructed by using standard vectors for *E. coli* (Sambrook, J. et al. (1989), "Molecular Cloning: A Laboratory Manual", Cold Spring Harbor Laboratory Press or Ausubel, F.M. et al. (1994) "Current Protocols in 15 Molecular Biology", John Wiley & Sons) to which a origin or replication for and a suitable marker from *Corynebacterium glutamicum* is added. Such origins of replication are preferably taken from endogenous plasmids isolated from *Corynebacterium* and *Brevibacterium* species. Of particular use as transformation markers for these species are genes for kanamycin resistance (such as those derived from the Tn5 or Tn903 20 transposons) or chloramphenicol (Winnacker, E.L. (1987) "From Genes to Clones — Introduction to Gene Technology, VCH, Weinheim). There are numerous examples in the literature of the construction of a wide variety of shuttle vectors which replicate in both *E. coli* and *C. glutamicum*, and which can be used for several purposes, including gene over-expression (for reference, see e.g., Yoshihama, M. et al. (1985) *J. Bacteriol.* 162:591-597, 25 Martin J.F. et al. (1987) *Biotechnology*, 5:137-146 and Eikmanns, B.J. et al. (1991) *Gene*, 102:93-98).

Using standard methods, it is possible to clone a gene of interest into one of the 30 shuttle vectors described above and to introduce such a hybrid vectors into strains of *Corynebacterium glutamicum*. Transformation of *C. glutamicum* can be achieved by protoplast transformation (Kastsumata, R. et al. (1984) *J. Bacteriol.* 159:306-311), electroporation (Liebl, E. et al. (1989) *FEMS Microbiol. Letters*, 53:399-303) and in cases where special vectors are used, also by conjugation (as described e.g. in Schäfer, A et al.

(1990) *J. Bacteriol.* 172:1663-1666). It is also possible to transfer the shuttle vectors for *C. glutamicum* to *E. coli* by preparing plasmid DNA from *C. glutamicum* (using standard methods well-known in the art) and transforming it into *E. coli*. This transformation step can be performed using standard methods, but it is advantageous to use an *Mcr*-deficient

5 *E. coli* strain, such as NM522 (Gough & Murray (1983) *J. Mol. Biol.* 166:1-19).

Genes may be overexpressed in *C. glutamicum* strains using plasmids which comprise pCG1 (U.S. Patent No. 4,617,267) or fragments thereof, and optionally the gene for kanamycin resistance from TN903 (Grindley, N.D. and Joyce, C.M. (1980) *Proc. Natl. Acad. Sci. USA* 77(12): 7176-7180). In addition, genes may be

10 overexpressed in *C. glutamicum* strains using plasmid pSL109 (Lee, H.-S. and A. J. Sinskey (1994) *J. Microbiol. Biotechnol.* 4: 256-263).

Aside from the use of replicative plasmids, gene overexpression can also be achieved by integration into the genome. Genomic integration in *C. glutamicum* or other *Corynebacterium* or *Brevibacterium* species may be accomplished by well-known

15 methods, such as homologous recombination with genomic region(s), restriction endonuclease mediated integration (REMI) (see, e.g., DE Patent 19823834), or through the use of transposons. It is also possible to modulate the activity of a gene of interest by modifying the regulatory regions (e.g., a promoter, a repressor, and/or an enhancer) by sequence modification, insertion, or deletion using site-directed methods (such as

20 homologous recombination) or methods based on random events (such as transposon mutagenesis or REMI). Nucleic acid sequences which function as transcriptional terminators may also be inserted 3' to the coding region of one or more genes of the invention; such terminators are well-known in the art and are described, for example, in Winnacker, E.L. (1987) *From Genes to Clones – Introduction to Gene Technology*. VCH: Weinheim.

25

Example 6: Assessment of the Expression of the Mutant Protein

Observations of the activity of a mutated protein in a transformed host cell rely on the fact that the mutant protein is expressed in a similar fashion and in a similar quantity

30 to that of the wild-type protein. A useful method to ascertain the level of transcription of the mutant gene (an indicator of the amount of mRNA available for translation to the gene product) is to perform a Northern blot (for reference see, for example, Ausubel *et al.*

- 80 -

(1988) *Current Protocols in Molecular Biology*, Wiley: New York), in which a primer designed to bind to the gene of interest is labeled with a detectable tag (usually radioactive or chemiluminescent), such that when the total RNA of a culture of the organism is extracted, run on gel, transferred to a stable matrix and incubated with this probe, the 5 binding and quantity of binding of the probe indicates the presence and also the quantity of mRNA for this gene. This information is evidence of the degree of transcription of the mutant gene. Total cellular RNA can be prepared from *Corynebacterium glutamicum* by several methods, all well-known in the art, such as that described in Bormann, E.R. *et al.* (1992) *Mol. Microbiol.* 6: 317-326.

10 To assess the presence or relative quantity of protein translated from this mRNA, standard techniques, such as a Western blot, may be employed (see, for example, Ausubel *et al.* (1988) *Current Protocols in Molecular Biology*, Wiley: New York). In this process, total cellular proteins are extracted, separated by gel electrophoresis, transferred to a matrix such as nitrocellulose, and incubated with a probe, such as an antibody, which 15 specifically binds to the desired protein. This probe is generally tagged with a chemiluminescent or colorimetric label which may be readily detected. The presence and quantity of label observed indicates the presence and quantity of the desired mutant protein present in the cell.

20 **Example 7: Growth of Genetically Modified *Corynebacterium glutamicum* — Media and Culture Conditions**

Genetically modified *Corynebacteria* are cultured in synthetic or natural growth media. A number of different growth media for *Corynebacteria* are both well-known and readily available (Lieb *et al.* (1989) *Appl. Microbiol. Biotechnol.*, 32:205-210; von der 25 Osten *et al.* (1998) *Biotechnology Letters*, 11:11-16; Patent DE 4,120,867; Liebl (1992) "The Genus *Corynebacterium*, in: *The Prokaryotes*, Volume II, Balows, A. *et al.*, eds. Springer-Verlag). These media consist of one or more carbon sources, nitrogen sources, inorganic salts, vitamins and trace elements. Preferred carbon sources are sugars, such as mono-, di-, or polysaccharides. For example, glucose, fructose, mannose, galactose, 30 ribose, sorbose, ribulose, lactose, maltose, sucrose, raffinose, starch or cellulose serve as very good carbon sources. It is also possible to supply sugar to the media via complex compounds such as molasses or other by-products from sugar refinement. It can also be

advantageous to supply mixtures of different carbon sources. Other possible carbon sources are alcohols and organic acids, such as methanol, ethanol, acetic acid or lactic acid. Nitrogen sources are usually organic or inorganic nitrogen compounds, or materials which contain these compounds. Exemplary nitrogen sources include ammonia gas or 5 ammonia salts, such as NH_4Cl or $(\text{NH}_4)_2\text{SO}_4$, NH_4OH , nitrates, urea, amino acids or complex nitrogen sources like corn steep liquor, soy bean flour, soy bean protein, yeast extract, meat extract and others.

Inorganic salt compounds which may be included in the media include the chloride-, phosphorous- or sulfate- salts of calcium, magnesium, sodium, cobalt, 10 molybdenum, potassium, manganese, zinc, copper and iron. Chelating compounds can be added to the medium to keep the metal ions in solution. Particularly useful chelating compounds include dihydroxyphenols, like catechol or protocatechuate, or organic acids, such as citric acid. It is typical for the media to also contain other growth factors, such as 15 vitamins or growth promoters, examples of which include biotin, riboflavin, thiamin, folic acid, nicotinic acid, pantothenate and pyridoxin. Growth factors and salts frequently originate from complex media components such as yeast extract, molasses, corn steep liquor and others. The exact composition of the media compounds depends strongly on the immediate experiment and is individually decided for each specific case. Information about media optimization is available in the textbook "Applied Microbiol. Physiology, A Practical Approach (eds. P.M. Rhodes, P.F. Stanbury, IRL Press (1997) pp. 53-73, ISBN 0 20 19 963577 3). It is also possible to select growth media from commercial suppliers, like standard 1 (Merck) or BHI (grain heart infusion, DIFCO) or others.

All medium components are sterilized, either by heat (20 minutes at 1.5 bar and 121°C) or by sterile filtration. The components can either be sterilized together or, if 25 necessary, separately. All media components can be present at the beginning of growth, or they can optionally be added continuously or batchwise.

Culture conditions are defined separately for each experiment. The temperature should be in a range between 15°C and 45°C. The temperature can be kept constant or can be altered during the experiment. The pH of the medium should be in the range of 5 to 30 8.5, preferably around 7.0, and can be maintained by the addition of buffers to the media. An exemplary buffer for this purpose is a potassium phosphate buffer. Synthetic buffers such as MOPS, HEPES, ACES and others can alternatively or simultaneously be used. It

is also possible to maintain a constant culture pH through the addition of NaOH or NH₄OH during growth. If complex medium components such as yeast extract are utilized, the necessity for additional buffers may be reduced, due to the fact that many complex compounds have high buffer capacities. If a fermentor is utilized for culturing the micro-organisms, the pH can also be controlled using gaseous ammonia.

The incubation time is usually in a range from several hours to several days. This time is selected in order to permit the maximal amount of product to accumulate in the broth. The disclosed growth experiments can be carried out in a variety of vessels, such as microtiter plates, glass tubes, glass flasks or glass or metal fermentors of different sizes.

10 For screening a large number of clones, the microorganisms should be cultured in microtiter plates, glass tubes or shake flasks, either with or without baffles. Preferably 100 ml shake flasks are used, filled with 10% (by volume) of the required growth medium. The flasks should be shaken on a rotary shaker (amplitude 25 mm) using a speed-range of 100 – 300 rpm. Evaporation losses can be diminished by the maintenance 15 of a humid atmosphere; alternatively, a mathematical correction for evaporation losses should be performed.

If genetically modified clones are tested, an unmodified control clone or a control clone containing the basic plasmid without any insert should also be tested. The medium is inoculated to an OD₆₀₀ of 0.5 – 1.5 using cells grown on agar plates, such as CM plates 20 (10 g/l glucose, 2.5 g/l NaCl, 2 g/l urea, 10 g/l polypeptone, 5 g/l yeast extract, 5 g/l meat extract, 22 g/l NaCl, 2 g/l urea, 10 g/l polypeptone, 5 g/l yeast extract, 5 g/l meat extract, 22 g/l agar, pH 6.8 with 2M NaOH) that had been incubated at 30°C. Inoculation of the media is accomplished by either introduction of a saline suspension of *C. glutamicum* cells from CM plates or addition of a liquid preculture of this bacterium.

25

Example 8 – *In vitro* Analysis of the Function of Mutant Proteins

The determination of activities and kinetic parameters of enzymes is well established in the art. Experiments to determine the activity of any given altered enzyme must be tailored to the specific activity of the wild-type enzyme, which is well 30 within the ability of one of ordinary skill in the art. Overviews about enzymes in general, as well as specific details concerning structure, kinetics, principles, methods, applications and examples for the determination of many enzyme activities may be

- 83 -

found, for example, in the following references: Dixon, M., and Webb, E.C., (1979) Enzymes. Longmans: London; Fersht, (1985) Enzyme Structure and Mechanism. Freeman: New York; Walsh, (1979) Enzymatic Reaction Mechanisms. Freeman: San Francisco; Price, N.C., Stevens, L. (1982) Fundamentals of Enzymology. Oxford Univ. Press: Oxford; Boyer, P.D., ed. (1983) The Enzymes, 3rd ed. Academic Press: New York; Bisswanger, H., (1994) Enzymkinetik, 2nd ed. VCH: Weinheim (ISBN 3527300325); Bergmeyer, H.U., Bergmeyer, J., Graßl, M., eds. (1983-1986) Methods of Enzymatic Analysis, 3rd ed., vol. I-XII, Verlag Chemie: Weinheim; and Ullmann's Encyclopedia of Industrial Chemistry (1987) vol. A9, "Enzymes". VCH: Weinheim, p. 10 352-363.

The activity of proteins which bind to DNA can be measured by several well-established methods, such as DNA band-shift assayss (also called gel retardation assays). The effect of such proteins on the expression of other molecules can be measured using reporter gene assays (such as that described in Kolmar, H. *et al.* (1995) *EMBO J.* 14: 15 3895-3904 and references cited therein). Reporter gene test systems are well known and established for applications in both pro- and eukaryotic cells, using enzymes such as beta-galactosidase, green fluorescent protein, and several others.

The determination of activity of membrane-transport proteins can be performed according to techniques such as those described in Gennis, R.B. (1989) "Pores, 20 Channels and Transporters", in Biomembranes, Molecular Structure and Function, Springer: Heidelberg, p. 85-137; 199-234; and 270-322.

Example 9: Analysis of Impact of Mutant Protein on the Production of the Desired Product

25 The effect of the genetic modification in *C. glutamicum* on production of a desired compound (such as an amino acid) can be assessed by growing the modified microorganism under suitable conditions (such as those described above) and analyzing the medium and/or the cellular component for increased production of the desired product (i.e., an amino acid). Such analysis techniques are well known to one of 30 ordinary skill in the art, and include spectroscopy, thin layer chromatography, staining methods of various kinds, enzymatic and microbiological methods, and analytical chromatography such as high performance liquid chromatography (see, for example,

Ullman, Encyclopedia of Industrial Chemistry, vol. A2, p. 89-90 and p. 443-613, VCH: Weinheim (1985); Fallon, A. *et al.*, (1987) "Applications of HPLC in Biochemistry" in: Laboratory Techniques in Biochemistry and Molecular Biology, vol. 17; Rehm *et al.* (1993) Biotechnology, vol. 3, Chapter III: "Product recovery and purification", page 5 469-714, VCH: Weinheim; Belter, P.A. *et al.* (1988) Bioseparations: downstream processing for biotechnology, John Wiley and Sons; Kennedy, J.F. and Cabral, J.M.S. (1992) Recovery processes for biological materials, John Wiley and Sons; Shaeiwitz, J.A. and Henry, J.D. (1988) Biochemical separations, in: Ullmann's Encyclopedia of Industrial Chemistry, vol. B3, Chapter 11, page 1-27, VCH: Weinheim; and Dechow, 10 F.J. (1989) Separation and purification techniques in biotechnology, Noyes Publications.)

In addition to the measurement of the final product of fermentation, it is also possible to analyze other components of the metabolic pathways utilized for the production of the desired compound, such as intermediates and side-products, to 15 determine the overall productivity of the organism, yield, and/or efficiency of production of the compound. Analysis methods include measurements of nutrient levels in the medium (e.g., sugars, hydrocarbons, nitrogen sources, phosphate, and other ions), measurements of biomass composition and growth, analysis of the production of common metabolites of biosynthetic pathways, and measurement of gasses produced 20 during fermentation. Standard methods for these measurements are outlined in Applied Microbial Physiology, A Practical Approach, P.M. Rhodes and P.F. Stanbury, eds., IRL Press, p. 103-129; 131-163; and 165-192 (ISBN: 0199635773) and references cited therein.

25 **Example 10: Purification of the Desired Product from *C. glutamicum* Culture**

Recovery of the desired product from the *C. glutamicum* cells or supernatant of the above-described culture can be performed by various methods well known in the art. If the desired product is not secreted from the cells, the cells can be harvested from the culture by low-speed centrifugation, the cells can be lysed by standard techniques, such 30 as mechanical force or sonication. The cellular debris is removed by centrifugation, and the supernatant fraction containing the soluble proteins is retained for further purification of the desired compound. If the product is secreted from the *C. glutamicum*

- 85 -

cells, then the cells are removed from the culture by low-speed centrifugation, and the supernate fraction is retained for further purification.

The supernatant fraction from either purification method is subjected to chromatography with a suitable resin, in which the desired molecule is either retained on 5 a chromatography resin while many of the impurities in the sample are not, or where the impurities are retained by the resin while the sample is not. Such chromatography steps may be repeated as necessary, using the same or different chromatography resins. One of ordinary skill in the art would be well-versed in the selection of appropriate chromatography resins and in their most efficacious application for a particular molecule 10 to be purified. The purified product may be concentrated by filtration or ultrafiltration, and stored at a temperature at which the stability of the product is maximized.

There are a wide array of purification methods known to the art and the preceding method of purification is not meant to be limiting. Such purification techniques are described, for example, in Bailey, J.E. & Ollis, D.F. *Biochemical 15 Engineering Fundamentals*, McGraw-Hill: New York (1986).

The identity and purity of the isolated compounds may be assessed by techniques standard in the art. These include high-performance liquid chromatography (HPLC), spectroscopic methods, staining methods, thin layer chromatography, NIRS, enzymatic assay, or microbiologically. Such analysis methods are reviewed in: Patek *et al.* (1994) 20 *Appl. Environ. Microbiol.* 60: 133-140; Malakhova *et al.* (1996) *Biotehnologiya* 11: 27-32; and Schmidt *et al.* (1998) *Bioprocess Engineer.* 19: 67-70. Ulmann's Encyclopedia of Industrial Chemistry, (1996) vol. A27, VCH: Weinheim, p. 89-90, p. 521-540, p. 540-547, p. 559-566, 575-581 and p. 581-587; Michal, G. (1999) *Biochemical Pathways: An 25 Atlas of Biochemistry and Molecular Biology*, John Wiley and Sons; Fallon, A. *et al.* (1987) Applications of HPLC in Biochemistry in: *Laboratory Techniques in Biochemistry and Molecular Biology*, vol. 17.

Example 11: Analysis of the Gene Sequences of the Invention

The comparison of sequences and determination of percent homology between 30 two sequences are art-known techniques, and can be accomplished using a mathematical algorithm, such as the algorithm of Karlin and Altschul (1990) *Proc. Natl. Acad. Sci. USA* 87:2264-68, modified as in Karlin and Altschul (1993) *Proc. Natl. Acad. Sci. USA*

- 86 -

90:5873-77. Such an algorithm is incorporated into the NBLAST and XBLAST programs (version 2.0) of Altschul, *et al.* (1990) *J. Mol. Biol.* 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to PTS nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to PTS protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al.*, (1997) *Nucleic Acids Res.* 25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, one of ordinary skill in the art will know how to optimize the parameters of the program (e.g., XBLAST and NBLAST) for the specific sequence being analyzed.

Another example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Meyers and Miller ((1988) *Comput. Appl. Biosci.* 4: 11-17). Such an algorithm is incorporated into the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used. Additional algorithms for sequence analysis are known in the art, and include ADVANCE and ADAM, described in Torelli and Robotti (1994) *Comput. Appl. Biosci.* 10:3-5; and FASTA, described in Pearson and Lipman (1988) *P.N.A.S.* 85:2444-8.

The percent homology between two amino acid sequences can also be accomplished using the GAP program in the GCG software package (available at <http://www.gcg.com>), using either a Blosum 62 matrix or a PAM250 matrix, and a gap weight of 12, 10, 8, 6, or 4 and a length weight of 2, 3, or 4. The percent homology between two nucleic acid sequences can be accomplished using the GAP program in the GCG software package, using standard parameters, such as a gap weight of 50 and a length weight of 3..

A comparative analysis of the gene sequences of the invention with those present in Genbank has been performed using techniques known in the art (see, e.g., Bexevanis and Ouellette, eds. (1998) *Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins*. John Wiley and Sons: New York). The gene sequences of the invention

were compared to genes present in Genbank in a three-step process. In a first step, a BLASTN analysis (e.g., a local alignment analysis) was performed for each of the sequences of the invention against the nucleotide sequences present in Genbank, and the top 500 hits were retained for further analysis. A subsequent FASTA search (e.g., a 5 combined local and global alignment analysis, in which limited regions of the sequences are aligned) was performed on these 500 hits. Each gene sequence of the invention was subsequently globally aligned to each of the top three FASTA hits, using the GAP program in the GCG software package (using standard parameters). In order to obtain correct results, the length of the sequences extracted from Genbank were adjusted to the 10 length of the query sequences by methods well-known in the art. The results of this analysis are set forth in Table 4. The resulting data is identical to that which would have been obtained had a GAP (global) analysis alone been performed on each of the genes of the invention in comparison with each of the references in Genbank, but required significantly reduced computational time as compared to such a database-wide GAP 15 (global) analysis. Sequences of the invention for which no alignments above the cutoff values were obtained are indicated on Table 4 by the absence of alignment information. It will further be understood by one of ordinary skill in the art that the GAP alignment homology percentages set forth in Table 4 under the heading "% homology (GAP)" are listed in the European numerical format, wherein a ',' represents a decimal point. For 20 example, a value of "40,345" in this column represents "40.345%".

Example 12: Construction and Operation of DNA Microarrays

The sequences of the invention may additionally be used in the construction and application of DNA microarrays (the design, methodology, and uses of DNA arrays are 25 well known in the art, and are described, for example, in Schena, M. *et al.* (1995) *Science* 270: 467-470; Wodicka, L. *et al.* (1997) *Nature Biotechnology* 15: 1359-1367; DeSaizieu, A. *et al.* (1998) *Nature Biotechnology* 16: 45-48; and DeRisi, J.L. *et al.* (1997) *Science* 278: 680-686).

DNA microarrays are solid or flexible supports consisting of nitrocellulose, 30 nylon, glass, silicone, or other materials. Nucleic acid molecules may be attached to the surface in an ordered manner. After appropriate labeling, other nucleic acids or nucleic acid mixtures can be hybridized to the immobilized nucleic acid molecules, and the label

- 90 -

1451-1463). Other separation techniques may also be utilized for protein separation, such as capillary gel electrophoresis; such techniques are well known in the art.

Proteins separated by these methodologies can be visualized by standard techniques, such as by staining or labeling. Suitable stains are known in the art, and 5 include Coomassie Brilliant Blue, silver stain, or fluorescent dyes such as Sypro Ruby (Molecular Probes). The inclusion of radioactively labeled amino acids or other protein precursors (e.g., ³⁵S-methionine, ³⁵S-cysteine, ¹⁴C-labelled amino acids, ¹⁵N-amino acids, ¹⁵NO₃ or ¹⁵NH₄⁺ or ¹³C-labelled amino acids) in the medium of *C. glutamicum* permits the labeling of proteins from these cells prior to their separation. Similarly, 10 fluorescent labels may be employed. These labeled proteins can be extracted, isolated and separated according to the previously described techniques.

Proteins visualized by these techniques can be further analyzed by measuring the amount of dye or label used. The amount of a given protein can be determined 15 quantitatively using, for example, optical methods and can be compared to the amount of other proteins in the same gel or in other gels. Comparisons of proteins on gels can be made, for example, by optical comparison, by spectroscopy, by image scanning and analysis of gels, or through the use of photographic films and screens. Such techniques are well-known in the art.

To determine the identity of any given protein, direct sequencing or other 20 standard techniques may be employed. For example, N- and/or C-terminal amino acid sequencing (such as Edman degradation) may be used, as may mass spectrometry (in particular MALDI or ESI techniques (see, e.g., Langen *et al.* (1997) *Electrophoresis* 18: 1184-1192)). The protein sequences provided herein can be used for the identification of *C. glutamicum* proteins by these techniques.

25 The information obtained by these methods can be used to compare patterns of protein presence, activity, or modification between different samples from various biological conditions (e.g., different organisms, time points of fermentation, media conditions, or different biotopes, among others). Data obtained from such experiments alone, or in combination with other techniques, can be used for various applications, 30 such as to compare the behavior of various organisms in a given (e.g., metabolic) situation, to increase the productivity of strains which produce fine chemicals or to increase the efficiency of the production of fine chemicals.

Equivalents

Those of ordinary skill in the art will recognize, or will be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of 5 the invention described herein. Such equivalents are intended to be encompassed by the following claims.

may be used to monitor and measure the individual signal intensities of the hybridized molecules at defined regions. This methodology allows the simultaneous quantification of the relative or absolute amount of all or selected nucleic acids in the applied nucleic acid sample or mixture. DNA microarrays, therefore, permit an analysis of the 5 expression of multiple (as many as 6800 or more) nucleic acids in parallel (see, e.g., Schena, M. (1996) *BioEssays* 18(5): 427-431).

The sequences of the invention may be used to design oligonucleotide primers which are able to amplify defined regions of one or more *C. glutamicum* genes by a nucleic acid amplification reaction such as the polymerase chain reaction. The choice 10 and design of the 5' or 3' oligonucleotide primers or of appropriate linkers allows the covalent attachment of the resulting PCR products to the surface of a support medium described above (and also described, for example, Schena, M. *et al.* (1995) *Science* 270: 467-470).

Nucleic acid microarrays may also be constructed by *in situ* oligonucleotide synthesis as described by Wodicka, L. *et al.* (1997) *Nature Biotechnology* 15: 1359-1367. By photolithographic methods, precisely defined regions of the matrix are exposed to light. Protective groups which are photolabile are thereby activated and undergo nucleotide addition, whereas regions that are masked from light do not undergo any modification. Subsequent cycles of protection and light activation permit the 20 synthesis of different oligonucleotides at defined positions. Small, defined regions of the genes of the invention may be synthesized on microarrays by solid phase oligonucleotide synthesis.

The nucleic acid molecules of the invention present in a sample or mixture of nucleotides may be hybridized to the microarrays. These nucleic acid molecules can be 25 labeled according to standard methods. In brief, nucleic acid molecules (e.g., mRNA molecules or DNA molecules) are labeled by the incorporation of isotopically or fluorescently labeled nucleotides, e.g., during reverse transcription or DNA synthesis. Hybridization of labeled nucleic acids to microarrays is described (e.g., in Schena, M. *et al.* (1995) *supra*; Wodicka, L. *et al.* (1997), *supra*; and DeSaizieu A. *et al.* (1998), 30 *supra*). The detection and quantification of the hybridized molecule are tailored to the specific incorporated label. Radioactive labels can be detected, for example, as

described in Schena, M. *et al.* (1995) *supra*) and fluorescent labels may be detected, for example, by the method of Shalon *et al.* (1996) *Genome Research* 6: 639-645).

The application of the sequences of the invention to DNA microarray technology, as described above, permits comparative analyses of different strains of *C. glutamicum* or other Corynebacteria. For example, studies of inter-strain variations based on individual transcript profiles and the identification of genes that are important for specific and/or desired strain properties such as pathogenicity, productivity and stress tolerance are facilitated by nucleic acid array methodologies. Also, comparisons of the profile of expression of genes of the invention during the course of a fermentation reaction are possible using nucleic acid array technology.

Example 13: Analysis of the Dynamics of Cellular Protein Populations (Proteomics)

The genes, compositions, and methods of the invention may be applied to study the interactions and dynamics of populations of proteins, termed 'proteomics'. Protein populations of interest include, but are not limited to, the total protein population of *C. glutamicum* (e.g., in comparison with the protein populations of other organisms), those proteins which are active under specific environmental or metabolic conditions (e.g., during fermentation, at high or low temperature, or at high or low pH), or those proteins which are active during specific phases of growth and development.

Protein populations can be analyzed by various well-known techniques, such as gel electrophoresis. Cellular proteins may be obtained, for example, by lysis or extraction, and may be separated from one another using a variety of electrophoretic techniques. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) separates proteins largely on the basis of their molecular weight. Isoelectric focusing polyacrylamide gel electrophoresis (IEF-PAGE) separates proteins by their isoelectric point (which reflects not only the amino acid sequence but also posttranslational modifications of the protein). Another, more preferred method of protein analysis is the consecutive combination of both IEF-PAGE and SDS-PAGE, known as 2-D-gel electrophoresis (described, for example, in Hermann *et al.* (1998) *Electrophoresis* 19: 3217-3221; Fountoulakis *et al.* (1998) *Electrophoresis* 19: 1193-1202; Langen *et al.* (1997) *Electrophoresis* 18: 1184-1192; Antelmann *et al.* (1997) *Electrophoresis* 18:

What is claimed:

1. An isolated nucleic acid molecule from *Corynebacterium glutamicum* encoding a phosphoenolpyruvate: sugar phosphotransferase system protein, or a portion thereof, provided that the nucleic acid molecule does not consist of any of the F-designated genes set forth in Table 1.
2. The isolated nucleic acid molecule of claim 1, wherein said phosphoenolpyruvate: sugar phosphotransferase system protein is selected from the group consisting of proteins involved in the transport of glucose, sucrose, mannose, fructose, mannitol, raffinose, ribulose, ribose, lactose, maltose, sorbose, sorbitol, xylose, and galactose.
3. An isolated *Corynebacterium glutamicum* nucleic acid molecule selected from the group consisting of those sequences set forth as odd-numbered SEQ ID NOs of the Sequence Listing, or a portion thereof, provided that the nucleic acid molecule does not consist of any of the F-designated genes set forth in Table 1.
4. An isolated nucleic acid molecule which encodes a polypeptide sequence selected from the group consisting of those sequences set forth as even-numbered SEQ ID NOs of the Sequence Listing, provided that the nucleic acid molecule does not consist of any of the F-designated genes set forth in Table 1.
5. An isolated nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide selected from the group of amino acid sequences consisting of those sequences set forth as even-numbered SEQ ID NOs of the Sequence Listing, provided that the nucleic acid molecule does not consist of any of the F-designated genes set forth in Table 1.
6. An isolated nucleic acid molecule comprising a nucleotide sequence which is at least 50% homologous to a nucleotide sequence selected from the group consisting of

- 93 -

those sequences set forth as odd-numbered SEQ ID NOs of the Sequence Listing , or a portion thereof, provided that the nucleic acid molecule does not consist of any of the F-designated genes set forth in Table 1.

5 7. An isolated nucleic acid molecule comprising a fragment of at least 15 nucleotides of a nucleic acid comprising a nucleotide sequence selected from the group consisting of those sequences set forth as odd-numbered SEQ ID NOs of the Sequence Listing , provided that the nucleic acid molecule does not consist of any of the F-designated genes set forth in Table 1.

10 8. An isolated nucleic acid molecule which hybridizes to the nucleic acid molecule of any one of claims 1-7 under stringent conditions.

15 9. An isolated nucleic acid molecule comprising the nucleic acid molecule of any one of claims 1-8 or a portion thereof and a nucleotide sequence encoding a heterologous polypeptide.

10. A vector comprising the nucleic acid molecule of any one of claims 1-9.

20 11. The vector of claim 10, which is an expression vector.

12. A host cell transfected with the expression vector of claim 11.

13. The host cell of claim 12, wherein said cell is a microorganism.

25 14. The host cell of claim 13, wherein said cell belongs to the genus *Corynebacterium* or *Brevibacterium*.

30 15. The host cell of claim 12, wherein the expression of said nucleic acid molecule results in the modulation in production of a fine chemical from said cell.

- 94 -

16. The host cell of claim 15, wherein said fine chemical is selected from the group consisting of: organic acids, proteinogenic amino acids, nonproteinogenic amino acids, purine and pyrimidine bases, nucleosides, nucleotides, lipids, saturated and unsaturated fatty acids, diols, carbohydrates, aromatic compounds, vitamins, cofactors, polyketides, 5 and enzymes.

17. A method of producing a polypeptide comprising culturing the host cell of claim 12 in an appropriate culture medium to, thereby, produce the polypeptide.

10 18. An isolated phosphoenolpyruvate: sugar phosphotransferase system polypeptide from *Corynebacterium glutamicum*, or a portion thereof.

15 19. The protein of claim 18, wherein said phosphoenolpyruvate: sugar phosphotransferase system protein is selected from the group consisting of proteins involved in the transport of glucose, sucrose, mannose, fructose, mannitol, raffinose, ribulose, ribose, lactose, maltose, sorbose, and galactose.

20 20. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of those sequences set forth as even-numbered SEQ ID NOs of the Sequence Listing, provided that the amino acid sequence is not encoded by any of the F-designated genes set forth in Table 1.

25 21. An isolated polypeptide comprising a naturally occurring allelic variant of a polypeptide comprising an amino acid sequence selected from the group consisting of those sequences set forth as even-numbered SEQ ID NOs of the Sequence Listing, or a portion thereof, provided that the amino acid sequence is not encoded by any of the F-designated genes set forth in Table 1.

30 22. The isolated polypeptide of any of claims 18-21, further comprising heterologous amino acid sequences.

- 95 -

23. An isolated polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 50% homologous to a nucleic acid selected from the group consisting of those sequences set forth as odd-numbered SEQ ID NOs of the Sequence Listing, provided that the nucleic acid molecule does not consist of any of the 5 F-designated nucleic acid molecules set forth in Table 1.

24. An isolated polypeptide comprising an amino acid sequence which is at least 50% homologous to an amino acid sequence selected from the group consisting of those sequences set forth as even-numbered SEQ ID NOs of the Sequence Listing, provided 10 that the amino acid sequence is not encoded by any of the F-designated genes set forth in Table 1.

25. A method for producing a fine chemical, comprising culturing a cell containing a vector of claim 12 such that the fine chemical is produced.

15 26. The method of claim 25, wherein said method further comprises the step of recovering the fine chemical from said culture.

27. The method of claim 25, wherein said method further comprises the step of 20 transfecting said cell with the vector of claim 11 to result in a cell containing said vector.

28. The method of claim 25, wherein said cell belongs to the genus *Corynebacterium* or *Brevibacterium*.

25 29. The method of claim 25, wherein said cell is selected from the group consisting of: *Corynebacterium glutamicum*, *Corynebacterium herculis*, *Corynebacterium lilium*, *Corynebacterium acetoacidophilum*, *Corynebacterium acetoglutamicum*, *Corynebacterium acetophilum*, *Corynebacterium ammoniagenes*, *Corynebacterium fujikense*, *Corynebacterium nitrilophilus*, *Brevibacterium ammoniagenes*, 30 *Brevibacterium butanicum*, *Brevibacterium divaricatum*, *Brevibacterium flavum*, *Brevibacterium healii*, *Brevibacterium ketoglutamicum*, *Brevibacterium*

ketosoreductum, *Brevibacterium lactofermentum*, *Brevibacterium linens*, *Brevibacterium paraffinolyticum*, and those strains set forth in Table 3.

30. The method of claim 25, wherein expression of the nucleic acid molecule from
5 said vector results in modulation of production of said fine chemical.

31. The method of claim 25, wherein said fine chemical is selected from the group
consisting of: organic acids, proteinogenic amino acids, nonproteinogenic amino acids,
purine and pyrimidine bases, nucleosides, nucleotides, lipids, saturated and unsaturated
10 fatty acids, diols, carbohydrates, aromatic compounds, vitamins, cofactors, polyketides,
and enzymes.

32. The method of claim 25, wherein said fine chemical is an amino acid.
15 33. The method of claim 32, wherein said amino acid is drawn from the group
consisting of: lysine, glutamate, glutamine, alanine, aspartate, glycine, serine, threonine,
methionine, cysteine, valine, leucine, isoleucine, arginine, proline, histidine, tyrosine,
phenylalanine, and tryptophan.
20 34. A method for producing a fine chemical, comprising culturing a cell whose
genomic DNA has been altered by the inclusion of a nucleic acid molecule of any one of
claims 1-9.

35. A method for diagnosing the presence or activity of *Corynebacterium*
25 *diphtheriae* in a subject, comprising detecting the presence of one or more of SEQ ID
NOS 1 through 34 of the Sequence Listing in the subject, provided that the sequences are
not or are not encoded by any of the F-designated sequences set forth in Table 1, thereby
diagnosing the presence or activity of *Corynebacterium diphtheriae* in the subject.

30 36. A host cell comprising a nucleic acid molecule selected from the group
consisting of the nucleic acid molecules set forth as odd-numbered SEQ ID NOS of the
Sequence Listing, wherein the nucleic acid molecule is disrupted.

- 97 -

37. A host cell comprising a nucleic acid molecule selected from the group consisting of the nucleic acid molecules set forth as odd-numbered SEQ ID NOS of the Sequence Listing, wherein the nucleic acid molecule comprises one or more nucleic acid modifications from the sequence set forth in as odd-numbered SEQ ID NOS of the Sequence Listing.

5

38. A host cell comprising a nucleic acid molecule selected from the group consisting of the nucleic acid molecules set forth as odd-numbered SEQ ID NOS of the Sequence Listing, wherein the regulatory region of the nucleic acid molecule is modified relative to the wild-type regulatory region of the molecule.

10

SEQUENCE LISTING

<110> BASF Aktiengesellschaft
 <120> CORYNEBACTERIUM GLUTAMICUM GENES ENCODING
 PHOSPHOENOLPYRUVATE:SUGAR PHOSPHOTRANSFERASE
 SYSTEM PROTEINS
 <130> BGI-122CPPC
 <140>
 <141>
 <160> 34

 <210> 1
 <211> 1527
 <212> DNA
 <213> Corynebacterium glutamicum

 <220>
 <221> CDS
 <222> (101)..(1504)
 <223> RXS00315

 <400> 1
 ctcatggcat ctgcgccgtt cgcgttcttg ccagtgttgg ttggttcac cgcaaccaag 60
 cgtttcggcg gcaatgagtt cctggcgcc gcgtatttgtt atg gcg atg gtg ttc 115
 Met Ala Met Val Phe
 1 5

 ccg agc ttg gtg aac ggc tac gac gtg gcc gcc acc atg gct gcg ggc 163
 Pro Ser Leu Val Asn Gly Tyr Asp Val Ala Ala Thr Met Ala Ala Gly
 10 15 20

 gaa atg cca atg tgg tcc ctg ttt ggt tta gat gtt gcc caa gcc ggt 211
 Glu Met Pro Met Trp Ser Leu Phe Gly Leu Asp Val Ala Gln Ala Gly
 25 30 35

 tac cag ggc acc gtg ctt cct gtg ctg gtg gtt tct tgg att ctg gca 259
 Tyr Gln Gly Thr Val Leu Pro Val Leu Val Val Ser Trp Ile Leu Ala
 40 45 50

 acg atc gag aag ttc ctg cac aag cga ctc aag ggc act gca gac ttc 307
 Thr Ile Glu Lys Phe Leu His Lys Arg Leu Lys Gly Thr Ala Asp Phe
 55 60 65

 ctg atc act cca gtg ctg acg ttg ctg ctc acc gga ttc ctt aca ttc 355
 Leu Ile Thr Pro Val Leu Thr Leu Leu Thr Gly Phe Leu Thr Phe
 70 75 80 85

 atc gcc att ggc cca gca atg cgc tgg gtg ggc gat gtg ctg gca cac 403
 Ile Ala Ile Gly Pro Ala Met Arg Trp Val Gly Asp Val Leu Ala His
 90 95 100

 ggt cta cag gga ctt tat gat ttc ggt ggt cca gtc ggc ggt ctg ctc 451
 Gly Leu Gln Gly Leu Tyr Asp Phe Gly Gly Pro Val Gly Leu Leu
 105 110 115

 ttc ggt ctg gtc tac tca cca atc gtc atc act ggt ctg cac cag tcc 499
 Phe Gly Leu Val Tyr Ser Pro Ile Val Ile Thr Gly Leu His Gln Ser
 120 125 130

 ttc ccg cca att gag ctg gag ctg ttt aac cag ggt gga tcc ttc atc 547

Phe	Pro	Pro	Ile	Glu	Leu	Glu	Leu	Phe	Asn	Gln	Gly	Gly	Ser	Phe	Ile	
135				140						145						
ttc	gca	acg	gca	tct	atg	gct	aat	atc	gcc	cag	ggt	gcf	gca	tgt	ttg	595
Phe	Ala	Thr	Ala	Ser	Met	Ala	Asn	Ile	Ala	Gln	Gly	Ala	Ala	Cys	Leu	
150				155						160				165		
gca	gtg	ttc	ttc	ctg	gcf	aag	agt	gaa	aag	ctc	aag	ggc	ctt	gca	ggt	643
Ala	Val	Phe	Phe	Leu	Ala	Lys	Ser	Glu	Lys	Leu	Lys	Gly	Leu	Ala	Gly	
				170					175				180			
gct	tca	ggt	gtc	tcc	gct	gtt	ctt	ggt	att	acg	gag	cct	gcf	atc	ttc	691
Ala	Ser	Gly	Val	Ser	Ala	Val	Leu	Gly	Ile	Thr	Glu	Pro	Ala	Ile	Phe	
				185					190			195				
ggt	gtg	aac	ctt	cgc	ctg	cgc	tgg	ccg	ttc	atc	ggt	atc	ggt	acc	739	
Gly	Val	Asn	Leu	Arg	Leu	Arg	Trp	Pro	Phe	Phe	Ile	Gly	Ile	Gly	Thr	
				200				205			210					
gca	gct	atc	ggt	ggc	gct	ttg	att	gca	ctc	ttt	aat	atc	aag	gca	gtt	787
Ala	Ala	Ile	Gly	Gly	Ala	Leu	Ile	Ala	Leu	Phe	Asn	Ile	Lys	Ala	Val	
				215				220			225					
gcg	ttg	ggc	gct	gca	ggt	ttc	ttg	ggt	gtt	gtt	tct	att	gat	gct	cca	835
Ala	Leu	Gly	Ala	Ala	Gly	Phe	Leu	Gly	Val	Val	Ser	Ile	Asp	Ala	Pro	
				230				235			240			245		
gat	atg	gtc	atg	ttc	ttg	gtg	tgt	gca	gtt	gtt	acc	ttc	ttc	atc	gca	883
Asp	Met	Val	Met	Phe	Leu	Val	Cys	Ala	Val	Val	Thr	Phe	Phe	Ile	Ala	
				250				255			260					
ttc	ggc	gca	gcf	att	gct	tat	ggc	ctt	tac	ttg	gtt	ccg	ccg	aac	ggc	931
Phe	Gly	Ala	Ala	Ile	Ala	Tyr	Gly	Leu	Tyr	Leu	Val	Arg	Arg	Asn	Gly	
				265				270			275					
agc	att	gat	cca	gat	gca	acc	gct	gct	cca	gtg	cct	gca	gga	acg	acc	979
Ser	Ile	Asp	Pro	Asp	Ala	Thr	Ala	Ala	Pro	Val	Pro	Ala	Gly	Thr	Thr	
				280				285			290					
aaa	gcc	gaa	gca	gaa	gca	ccc	gca	gaa	ttt	tca	aac	gat	tcc	acc	atc	1027
Lys	Ala	Glu	Ala	Glu	Ala	Pro	Ala	Glu	Ala	Pro	Asn	Asp	Ser	Thr	Ile	
				295				300			305					
atc	cag	gca	cct	ttg	acc	ggt	gaa	gct	att	gca	ctg	agc	agc	gtc	agc	1075
Ile	Gln	Ala	Pro	Leu	Thr	Gly	Glu	Ala	Ile	Ala	Leu	Ser	Ser	Val	Ser	
				310				315			320			325		
gat	gcc	atg	ttt	gcc	agc	gga	aag	ctt	ggc	tcg	ggc	gtt	gcc	atc	gtc	1123
Asp	Ala	Met	Phe	Ala	Ser	Gly	Lys	Leu	Gly	Ser	Gly	Val	Ala	Ile	Val	
				330				335			340					
cca	acc	aag	ggg	cag	tta	gtt	tct	ccg	gtg	agt	gga	aag	att	gtg	gtg	1171
Pro	Thr	Lys	Gly	Gln	Leu	Val	Ser	Pro	Val	Ser	Gly	Lys	Ile	Val	Val	
				345				350			355					
gca	tcc	cca	tct	ggc	cat	gct	ttc	gca	gtt	ccg	acc	aag	gct	gag	gat	1219
Ala	Phe	Pro	Ser	Gly	His	Ala	Phe	Ala	Val	Arg	Thr	Lys	Ala	Glu	Asp	
				360				365			370					
ggt	tcc	aat	gtg	gat	atc	ttg	atg	cac	att	ggt	ttc	gac	aca	gta	aac	1267
Gly	Ser	Asn	Val	Asp	Ile	Leu	Met	His	Ile	Gly	Phe	Asp	Thr	Val	Asn	

375	380	385	
ctc aac ggc acg cac ttt aac ccg ctg aag aag cag ggc gat gaa gtc			1315
Leu Asn Gly Thr His Phe Asn Pro Leu Lys Lys Gln Gly Asp Glu Val			
390	395	400	405
aaa gca ggg gag ctg ctg tgt gaa ttc gat att gat gcc att aag gct			1363
Lys Ala Gly Glu Leu Leu Cys Glu Phe Asp Ile Asp Ala Ile Lys Ala			
410	415	420	
gca ggt tat gag gta acc acg ccg att gtt gtt tcg aat tac aag aaa			1411
Ala Gly Tyr Glu Val Thr Pro Ile Val Val Ser Asn Tyr Lys Lys			
425	430	435	
acc gga cct gta aac act tac ggt ttg ggc gaa att gaa gcg gga gcc			1459
Thr Gly Pro Val Asn Thr Tyr Gly Leu Gly Glu Ile Glu Ala Gly Ala			
440	445	450	
aac ctg ctc aac gtc gca aag aaa gaa gcg gtg cca gca aca cca			1504
Asn Leu Leu Asn Val Ala Lys Lys Glu Ala Val Pro Ala Thr Pro			
455	460	465	
taagttgaaa ccttgagtgt tcg			1527
<210> 2			
<211> 468			
<212> PRT			
<213> Corynebacterium glutamicum			
<400> 2			
Met Ala Met Val Phe Pro Ser Leu Val Asn Gly Tyr Asp Val Ala Ala			
1	5	10	15
Thr Met Ala Ala Gly Glu Met Pro Met Trp Ser Leu Phe Gly Leu Asp			
20	25	30	
Val Ala Gln Ala Gly Tyr Gln Gly Thr Val Leu Pro Val Leu Val Val			
35	40	45	
Ser Trp Ile Leu Ala Thr Ile Glu Lys Phe Leu His Lys Arg Leu Lys			
50	55	60	
Gly Thr Ala Asp Phe Leu Ile Thr Pro Val Leu Thr Leu Leu Thr			
65	70	75	80
Gly Phe Leu Thr Phe Ile Ala Ile Gly Pro Ala Met Arg Trp Val Gly			
85	90	95	
Asp Val Leu Ala His Gly Leu Gln Gly Leu Tyr Asp Phe Gly Gly Pro			
100	105	110	
Val Gly Gly Leu Leu Phe Gly Leu Val Tyr Ser Pro Ile Val Ile Thr			
115	120	125	
Gly Leu His Gln Ser Phe Pro Pro Ile Glu Leu Glu Leu Phe Asn Gln			
130	135	140	
Gly Gly Ser Phe Ile Phe Ala Thr Ala Ser Met Ala Asn Ile Ala Gln			
145	150	155	160

Gly Ala Ala Cys Leu Ala Val Phe Phe Leu Ala Lys Ser Glu Lys Leu
 165 170 175
 Lys Gly Leu Ala Gly Ala Ser Gly Val Ser Ala Val Leu Gly Ile Thr
 180 185 190
 Glu Pro Ala Ile Phe Gly Val Asn Leu Arg Leu Arg Trp Pro Phe Phe
 195 200 205
 Ile Gly Ile Gly Thr Ala Ala Ile Gly Gly Ala Leu Ile Ala Leu Phe
 210 215 220
 Asn Ile Lys Ala Val Ala Leu Gly Ala Ala Gly Phe Leu Gly Val Val
 225 230 235 240
 Ser Ile Asp Ala Pro Asp Met Val Met Phe Leu Val Cys Ala Val Val
 245 250 255
 Thr Phe Phe Ile Ala Phe Gly Ala Ala Ile Ala Tyr Gly Leu Tyr Leu
 260 265 270
 Val Arg Arg Asn Gly Ser Ile Asp Pro Asp Ala Thr Ala Ala Pro Val
 275 280 285
 Pro Ala Gly Thr Thr Lys Ala Glu Ala Glu Ala Pro Ala Glu Phe Ser
 290 295 300
 Asn Asp Ser Thr Ile Ile Gln Ala Pro Leu Thr Gly Glu Ala Ile Ala
 305 310 315 320
 Leu Ser Ser Val Ser Asp Ala Met Phe Ala Ser Gly Lys Leu Gly Ser
 325 330 335
 Gly Val Ala Ile Val Pro Thr Lys Gly Gln Leu Val Ser Pro Val Ser
 340 345 350
 Gly Lys Ile Val Val Ala Phe Pro Ser Gly His Ala Phe Ala Val Arg
 355 360 365
 Thr Lys Ala Glu Asp Gly Ser Asn Val Asp Ile Leu Met His Ile Gly
 370 375 380
 Phe Asp Thr Val Asn Leu Asn Gly Thr His Phe Asn Pro Leu Lys Lys
 385 390 395 400
 Gln Gly Asp Glu Val Lys Ala Gly Glu Leu Leu Cys Glu Phe Asp Ile
 405 410 415
 Asp Ala Ile Lys Ala Ala Gly Tyr Glu Val Thr Thr Pro Ile Val Val
 420 425 430
 Ser Asn Tyr Lys Lys Thr Gly Pro Val Asn Thr Tyr Gly Leu Gly Glu
 435 440 445
 Ile Glu Ala Gly Ala Asn Leu Leu Asn Val Ala Lys Lys Glu Ala Val
 450 455 460
 Pro Ala Thr Pro
 465

<210> 3
 <211> 1109
 <212> DNA
 <213> Corynebacterium glutamicum

 <220>
 <221> CDS
 <222> (1)..(1086)
 <223> FRXA00315

 <400> 3 48
 tat gat ttc ggc ggt cca gtc ggc ggt ctg ctc ttc ggt ctg gtc tac
 Tyr Asp Phe Gly Gly Pro Val Gly Gly Leu Leu Phe Gly Leu Val Tyr
 1 5 10 15

 tca cca atc gtc atc act ggt ctg cac cag tcc ttc ccg cca att gag 96
 Ser Pro Ile Val Ile Thr Gly Leu His Gln Ser Phe Pro Pro Ile Glu
 20 25 30

 ctg gag ctg ttt aac cag ggt gga tcc ttc atc ttc gca acg gca tct 144
 Leu Glu Leu Phe Asn Gln Gly Gly Ser Phe Ile Phe Ala Thr Ala Ser
 35 40 45

 atg gct aat atc gcc cag ggt gcg gca tgt ttg gca gtg ttc ttc ctg 192
 Met Ala Asn Ile Ala Gln Gly Ala Ala Cys Leu Ala Val Phe Phe Leu
 50 55 60

 gcg aag agt gaa aag ctc aag ggc ctt gca ggt gct tca ggt gtc tcc 240
 Ala Lys Ser Glu Lys Leu Lys Gly Leu Ala Gly Ala Ser Gly Val Ser
 65 70 75 80

 gct gtt ctt ggt att acg gag cct gcg atc ttc ggt gtg aac ctt cgc 288
 Ala Val Leu Gly Ile Thr Glu Pro Ala Ile Phe Gly Val Asn Leu Arg
 85 90 95

 ctg cgc tgg ccg ttc ttc atc ggt atc ggt acc gca gct atc ggt ggc 336
 Leu Arg Trp Pro Phe Phe Ile Gly Ile Gly Thr Ala Ala Ile Gly Gly
 100 105 110

 gct ttg att gca ctc ttt aat atc aag gca gtt gcg ttg ggc gct gca 384
 Ala Leu Ile Ala Leu Phe Asn Ile Lys Ala Val Ala Leu Gly Ala Ala
 115 120 125

 ggt ttc ttg ggt gtt tct att gat gct cca gat atg gtc atg ttc 432
 Gly Phe Leu Gly Val Val Ser Ile Asp Ala Pro Asp Met Val Met Phe
 130 135 140

 ttg gtg tgt gca gtt gtt acc ttc ttc atc gca ttc ggc gca gcg att 480
 Leu Val Cys Ala Val Val Thr Phe Phe Ile Ala Phe Gly Ala Ala Ile
 145 150 155 160

 gct tat ggc ctt tac ttg gtt cgc cgc aac ggc agc att gat cca gat 528
 Ala Tyr Gly Leu Tyr Leu Val Arg Arg Asn Gly Ser Ile Asp Pro Asp
 165 170 175

 gca acc gct gct cca gtg cct gca gga acg acc aaa gcc gaa gca gaa 576
 Ala Thr Ala Ala Pro Val Pro Ala Gly Thr Thr Lys Ala Glu Ala Glu
 180 185 190

 gca ccc gca gaa ttt tca aac gat tcc acc atc atc cag gca cct ttg 624
 Ala Pro Ala Glu Phe Ser Asn Asp Ser Thr Ile Ile Gln Ala Pro Leu

195	200	205	
acc ggt gaa gct att gca ctg agc agc gtc agc gat gcc atg ttt gcc			672
Thr Gly Glu Ala Ile Ala Leu Ser Ser Val Ser Asp Ala Met Phe Ala			
210	215	220	
agc gga aag ctt ggc tcg ggc gtt gcc atc gtc cca acc aag ggg cag			720
Ser Gly Lys Leu Gly Ser Gly Val Ala Ile Val Pro Thr Lys Gly Gln			
225	230	235	240
tta gtt tct ccg gtg agt gga aag att gtg gtg gca ttc cca tct ggc			768
Leu Val Ser Pro Val Ser Gly Lys Ile Val Val Ala Phe Pro Ser Gly			
245	250	255	
cat gct ttc gca gtt cgc acc aag gct gag gat ggt tcc aat gtg gat			816
His Ala Phe Ala Val Arg Thr Lys Ala Glu Asp Gly Ser Asn Val Asp			
260	265	270	
atc ttg atg cac att ggt ttc gac aca gta aac ctc aac ggc acg cac			864
Ile Leu Met His Ile Gly Phe Asp Thr Val Asn Leu Asn Gly Thr His			
275	280	285	
ttt aac ccg ctg aag aag cag ggc gat gaa gtc aaa gca ggg gag ctg			912
Phe Asn Pro Leu Lys Lys Gln Gly Asp Glu Val Lys Ala Gly Glu Leu			
290	295	300	
ctg tgt gaa ttc gat att gat gcc att aag gct gca ggt tat gag gta			960
Leu Cys Glu Phe Asp Ile Asp Ala Ile Lys Ala Ala Gly Tyr Glu Val			
305	310	315	320
acc acg ccg att gtt gtt tcg aat tac aag aaa acc gga cct gta aac			1008
Thr Thr Pro Ile Val Val Ser Asn Tyr Lys Lys Thr Gly Pro Val Asn			
325	330	335	
act tac ggt ttg ggc gaa att gaa gcg gga gcc aac ctg ctc aac gtc			1056
Thr Tyr Gly Leu Gly Glu Ile Glu Ala Gly Ala Asn Leu Leu Asn Val			
340	345	350	
gca aag aaa gaa gcg gtg cca gca aca cca taagttgaaa ccttgagtgt			1106
Ala Lys Glu Ala Val Pro Ala Thr Pro			
355	360		
tcg			1109
 <210> 4			
<211> 362			
<212> PRT			
<213> Corynebacterium glutamicum			
 <400> 4			
Tyr Asp Phe Gly Gly Pro Val Gly Gly Leu Leu Phe Gly Leu Val Tyr			
1	5	10	15
Ser Pro Ile Val Ile Thr Gly Leu His Gln Ser Phe Pro Pro Ile Glu			
20	25	30	
Leu Glu Leu Phe Asn Gln Gly Ser Phe Ile Phe Ala Thr Ala Ser			
35	40	45	
Met Ala Asn Ile Ala Gln Gly Ala Ala Cys Leu Ala Val Phe Phe Leu			

50	55	60
Ala Lys Ser Glu Lys Leu Lys Gly Leu Ala Gly Ala Ser Gly Val Ser		
65	70	75
Ala Val Leu Gly Ile Thr Glu Pro Ala Ile Phe Gly Val Asn Leu Arg		
85	90	95
Leu Arg Trp Pro Phe Phe Ile Gly Ile Gly Thr Ala Ala Ile Gly Gly		
100	105	110
Ala Leu Ile Ala Leu Phe Asn Ile Lys Ala Val Ala Leu Gly Ala Ala		
115	120	125
Gly Phe Leu Gly Val Val Ser Ile Asp Ala Pro Asp Met Val Met Phe		
130	135	140
Leu Val Cys Ala Val Val Thr Phe Phe Ile Ala Phe Gly Ala Ala Ile		
145	150	155
160		
Ala Tyr Gly Leu Tyr Leu Val Arg Arg Asn Gly Ser Ile Asp Pro Asp		
165	170	175
Ala Thr Ala Ala Pro Val Pro Ala Gly Thr Thr Lys Ala Glu Ala Glu		
180	185	190
Ala Pro Ala Glu Phe Ser Asn Asp Ser Thr Ile Ile Gln Ala Pro Leu		
195	200	205
Thr Gly Glu Ala Ile Ala Leu Ser Ser Val Ser Asp Ala Met Phe Ala		
210	215	220
Ser Gly Lys Leu Gly Ser Gly Val Ala Ile Val Pro Thr Lys Gly Gln		
225	230	235
240		
Leu Val Ser Pro Val Ser Gly Lys Ile Val Val Ala Phe Pro Ser Gly		
245	250	255
His Ala Phe Ala Val Arg Thr Lys Ala Glu Asp Gly Ser Asn Val Asp		
260	265	270
Ile Leu Met His Ile Gly Phe Asp Thr Val Asn Leu Asn Gly Thr His		
275	280	285
Phe Asn Pro Leu Lys Lys Gln Gly Asp Glu Val Lys Ala Gly Glu Leu		
290	295	300
Leu Cys Glu Phe Asp Ile Asp Ala Ile Lys Ala Ala Gly Tyr Glu Val		
305	310	315
320		
Thr Thr Pro Ile Val Val Ser Asn Tyr Lys Lys Thr Gly Pro Val Asn		
325	330	335
Thr Tyr Gly Leu Gly Glu Ile Glu Ala Gly Ala Asn Leu Leu Asn Val		
340	345	350
Ala Lys Lys Glu Ala Val Pro Ala Thr Pro		
355	360	

<211> 372

<212> DNA

<213> Corynebacterium glutamicum

<220>

<221> CDS

<222> (101)..(349)

<223> RXA01503

<400> 5

gtatcccaa aggcccttcta gctgttgcag ctgcagcgca ctcggatggat acgacatcca 60

cgacctatca aattcttat gctgcaggcg atgcctttc atg ttc ttg gca gtc 115
Met Phe Leu Ala Val
1 5att ttg gcg att act gct cgt aaa ttc ggt gcc aat gtc ttt aca 163
Ile Leu Ala Ile Thr Ala Ala Arg Lys Phe Gly Ala Asn Val Phe Thr
10 15 20tca gtc gca ctc gct ggt gca ttg ctg cac aca cag ctt cag gca gta 211
Ser Val Ala Leu Ala Gly Ala Leu Leu His Thr Gln Leu Gln Ala Val
25 30 35acc gtg ttg gtt gac ggt gaa ctc cag tcg atg act ctg gtg gct ttc 259
Thr Val Leu Val Asp Gly Glu Leu Gln Ser Met Thr Leu Val Ala Phe
40 45 50caa aag gct ggt aat gac gtc acc ttc ctg ggc att cca gtg gtg ctg 307
Gln Lys Ala Gly Asn Asp Val Thr Phe Leu Gly Ile Pro Val Val Leu
55 60 65cag ttg gcg ttg cat gta gcg agt ttg atg aag ttg tcg cga 349
Gln Leu Ala Leu His Val Ala Ser Leu Met Lys Leu Ser Arg
70 75 80

taagaggagg ggcgtgtcgg tct 372

<210> 6

<211> 83

<212> PRT

<213> Corynebacterium glutamicum

<400> 6

Met Phe Leu Ala Val Ile Leu Ala Ile Thr Ala Ala Arg Lys Phe Gly
1 5 10 15Ala Asn Val Phe Thr Ser Val Ala Leu Ala Gly Ala Leu Leu His Thr
20 25 30Gln Leu Gln Ala Val Thr Val Leu Val Asp Gly Glu Leu Gln Ser Met
35 40 45Thr Leu Val Ala Phe Gln Lys Ala Gly Asn Asp Val Thr Phe Leu Gly
50 55 60Ile Pro Val Val Leu Gln Leu Ala Leu His Val Ala Ser Leu Met Lys
65 70 75 80

Leu Ser Arg

<210> 7
 <211> 2187
 <212> DNA
 <213> *Corynebacterium glutamicum*

<220>
 <221> CDS
 <222> (101)..(2164)
 <223> RXN01299

<400> 7
 cgactgcggc gtctttcctt ggcactacca ttcctcggtcc tgaccaactc gccacagctg 60
 gtgcaacggt cacccaaagtc aaaggattga aagaatcagc atg aat agc gta aat 115
 Met Asn Ser Val Asn
 1 5

aat tcc tcg ctt gtc cgg ctg gat gtc gat ttc ggc gac tcc acc acg 163
 Asn Ser Ser Leu Val Arg Leu Asp Val Asp Phe Gly Asp Ser Thr Thr
 10 15 20

gat gtc atc aac aac ctt gcc act gtt att ttc gac gct ggc cga gct 211
 Asp Val Ile Asn Asn Leu Ala Thr Val Ile Phe Asp Ala Gly Arg Ala
 25 30 35

tcc tcc gcc gac gcc ctt gcc aaa gac gcg ctg gat cgt gaa gca aag 259
 Ser Ser Ala Asp Ala Leu Ala Lys Asp Ala Leu Asp Arg Glu Ala Lys
 40 45 50

tcc ggc acc ggc gtt cct ggt caa gtt gct atc ccc cac tgc cgt tcc 307
 Ser Gly Thr Gly Val Pro Gly Gln Val Ala Ile Pro His Cys Arg Ser
 55 60 65

gaa gcc gta tct gtc cct acc ttg ggc ttt gct cgc ctg agc aag ggt 355
 Glu Ala Val Ser Val Pro Thr Leu Gly Phe Ala Arg Leu Ser Lys Gly
 70 75 80 85

gtg gac ttc agc gga cct gat ggc gat gcc aac ttg gtg ttc ctc att 403
 Val Asp Phe Ser Gly Pro Asp Gly Asp Ala Asn Leu Val Phe Leu Ile
 90 95 100

gca gca cct gct ggc ggc aaa gag cac ctg aag atc ctg tcc aag 451
 Ala Ala Pro Ala Gly Gly Lys Glu His Leu Lys Ile Leu Ser Lys
 105 110 115

ctt gct cgc tcc ttg gtg aag aag gat ttc atc aag gct ctg cag gaa 499
 Leu Ala Arg Ser Leu Val Lys Lys Asp Phe Ile Lys Ala Leu Gln Glu
 120 125 130

gcc acc acc gag cag gaa atc gtc gac gtt gtc gat gcc gtg ctc aac 547
 Ala Thr Thr Glu Gln Glu Ile Val Asp Val Val Asp Ala Val Leu Asn
 135 140 145

cca gca cca aaa acc acc gag cca gct gca gct ccg gct gcg gcg gcg 595
 Pro Ala Pro Lys Thr Thr Glu Pro Ala Ala Ala Pro Ala Ala Ala Ala
 150 155 160 165

gtt gct gag agt ggg gcg gcg tcg aca agc gtt act cgt atc gtg gca 643

Val Ala Glu Ser Gly Ala Ala Ser Thr Ser Val Thr Arg Ile Val Ala
 170 175 180
 atc acc gca tgc cca acc ggt atc gca cac acc tac atg gct ggc gat 691
 Ile Thr Ala Cys Pro Thr Gly Ile Ala His Thr Tyr Met Ala Ala Asp
 185 190 195
 tcc ctg acg caa aac gcg gaa ggc cgc gat gat gtg gaa ctc gtt gtg 739
 Ser Leu Thr Gln Asn Ala Glu Gly Arg Asp Asp Val Glu Leu Val Val
 200 205 210
 gag act cag ggc tct tcc gct gtc acc cca gtc gat ccg aag atc atc 787
 Glu Thr Gln Gly Ser Ser Ala Val Thr Pro Val Asp Pro Lys Ile Ile
 215 220 225
 gaa gct gcc gac gcc gtc atc ttc gcc acc gac gtg gga gtt aaa gac 835
 Glu Ala Ala Asp Ala Val Ile Phe Ala Thr Asp Val Gly Val Lys Asp
 230 235 240 245
 cgc gag cgt ttc gct ggc aag cca gtc att gaa tcc ggc gtc aag cgc 883
 Arg Glu Arg Phe Ala Gly Lys Pro Val Ile Glu Ser Gly Val Lys Arg
 250 255 260
 gcg atc aat gag cca gcc aag atg atc gac gag gcc atc gca gcc tcc 931
 Ala Ile Asn Glu Pro Ala Lys Met Ile Asp Glu Ala Ile Ala Ser
 265 270 275
 aag aac cca aac gcc cgc aag gtt tcc ggt tcc ggt gtc gcg gca tct 979
 Lys Asn Pro Asn Ala Arg Lys Val Ser Gly Ser Gly Val Ala Ala Ser
 280 285 290
 gct gaa acc acc ggc gag aag ctc ggc tgg ggc aag cgc atc cag cag 1027
 Ala Glu Thr Thr Gly Glu Lys Leu Gly Trp Gly Lys Arg Ile Gln Gln
 295 300 305
 gca gtc atg acc ggc gtg tcc tac atg gtt cca ttc gta gct gcc ggc 1075
 Ala Val Met Thr Gly Val Ser Tyr Met Val Pro Phe Val Ala Ala Gly
 310 315 320 325
 ggc ctc ctg ttg gct ctc ggc ttc gca ttc ggt gga tac gac atg gcg 1123
 Gly Leu Leu Leu Ala Leu Gly Phe Ala Phe Gly Gly Tyr Asp Met Ala
 330 335 340
 aac ggc tgg caa gca atc gcc acc cag ttc tct ctg acc aac ctg cca 1171
 Asn Gly Trp Gln Ala Ile Ala Thr Gln Phe Ser Leu Thr Asn Leu Pro
 345 350 355
 ggc aac acc gtc gat gtt gac ggc gtg gcc atg acc ttc gag cgt tca 1219
 Gly Asn Thr Val Asp Val Asp Gly Val Ala Met Thr Phe Glu Arg Ser
 360 365 370
 ggc ttc ctg ttg tac ttc ggc gca gtc ctg ttc gcc acc ggc caa gca 1267
 Gly Phe Leu Leu Tyr Phe Gly Ala Val Leu Phe Ala Thr Gly Gln Ala
 375 380 385
 gcc atg ggc ttc atc gtg gca gcc ctg tct ggc tac acc gca tac gca 1315
 Ala Met Gly Phe Ile Val Ala Ala Leu Ser Gly Tyr Thr Ala Tyr Ala
 390 395 400 405
 ctt gct gga cgc cca ggc atc gcg ccg ggc ttc gtc ggt ggc gcc atc 1363
 Leu Ala Gly Arg Pro Gly Ile Ala Pro Gly Phe Val Gly Gly Ala Ile

WO 01/02583

410	415	420	
tcc gtc acc atc ggc gct ggc ttc att ggt ggt ctg gtt acc ggt atc			1411
Ser Val Thr Ile Gly Ala Gly Phe Ile Gly Gly Leu Val Thr Gly Ile			
425	430	435	
ttg gct ggt ctc att gcc ctg tgg att ggc tcc tgg aag gtt cca cgc			1459
Leu Ala Gly Leu Ile Ala Leu Trp Ile Gly Ser Trp Lys Val Pro Arg			
440	445	450	
gtg gtt cag tca ctg atg cct gtg gtc atc atc ccg cta ctt acc tca			1507
Val Val Gln Ser Leu Met Pro Val Val Ile Pro Leu Leu Thr Ser			
455	460	465	
gtg gtt ggt ctc gtc atg tac ctc ctg ctg ggt cgc cca ctc gca			1555
Val Val Val Gly Leu Val Met Tyr Leu Leu Leu Gly Arg Pro Leu Ala			
470	475	480	485
tcc atc atg act ggt ttg cag gac tgg cta tcg tca atg tcc gga agc			1603
Ser Ile Met Thr Gly Leu Gln Asp Trp Leu Ser Ser Met Ser Gly Ser			
490	495	500	
tcc gcc atc ttg ctg ggt atc atc ttg ggc ctc atg atg tgt ttc gac			1651
Ser Ala Ile Leu Leu Gly Ile Ile Leu Gly Leu Met Met Cys Phe Asp			
505	510	515	
ctc ggc gga cca gta aac aag gca gcc tac ctc ttt ggt acc gca ggc			1699
Leu Gly Gly Pro Val Asn Lys Ala Ala Tyr Leu Phe Gly Thr Ala Gly			
520	525	530	
ctg tct acc ggc gac caa gct tcc atg gaa atc atg gcc gcg atc atg			1747
Leu Ser Thr Gly Asp Gln Ala Ser Met Glu Ile Met Ala Ala Ile Met			
535	540	545	
gca gct ggc atg gtc cca cca atc gcg ttg tcc att gct acc ctg ctg			1795
Ala Ala Gly Met Val Pro Pro Ile Ala Leu Ser Ile Ala Thr Leu Leu			
550	555	560	565
cgc aag aag ctg ttc acc cca gca gag caa gaa aac ggc aag tct tcc			1843
Arg Lys Lys Leu Phe Thr Pro Ala Glu Gln Glu Asn Gly Lys Ser Ser			
570	575	580	
tgg ctg ctt ggc ctg gca ttc gtc tcc gaa ggt gcc atc cca ttc gcc			1891
Trp Leu Leu Gly Leu Ala Phe Val Ser Glu Gly Ala Ile Pro Phe Ala			
585	590	595	
gca gct gac cca ttc cgt gtg atc cca gca atg atg gct ggc ggt gca			1939
Ala Ala Asp Pro Phe Arg Val Ile Pro Ala Met Met Ala Gly Gly Ala			
600	605	610	
acc act ggt gca atc tcc atg gca ctg ggc gtc ggc tct cgg gct cca			1987
Thr Thr Gly Ala Ile Ser Met Ala Leu Gly Val Gly Ser Arg Ala Pro			
615	620	625	
cac ggc ggt atc ttc gtg gtc tgg gca atc gaa cca tgg tgg ggc tgg			2035
His Gly Gly Ile Phe Val Val Trp Ala Ile Glu Pro Trp Trp Gly Trp			
630	635	640	645
ctc atc gca ctt gca gca ggc acc atc gtg tcc acc atc gtt gtc atc			2083
Leu Ile Ala Leu Ala Ala Gly Thr Ile Val Ser Thr Ile Val Val Ile			
650	655	660	

gca ctg aag cag ttc tgg cca aac aag gcc gtc gct gca gaa gtc gcg 2131
 Ala Leu Lys Gln Phe Trp Pro Asn Lys Ala Val Ala Ala Glu Val Ala
 665 670 675

aag caa gaa gca caa caa gca gct gta aac gca taatcgacc ttgaccgat 2184
 Lys Gln Glu Ala Gln Ala Ala Val Asn Ala
 680 685

gtc 2187

<210> 8
 <211> 688
 <212> PRT
 <213> *Corynebacterium glutamicum*

<400> 8
 Met Asn Ser Val Asn Asn Ser Ser Leu Val Arg Leu Asp Val Asp Phe
 1 5 10 15

Gly Asp Ser Thr Thr Asp Val Ile Asn Asn Leu Ala Thr Val Ile Phe
 20 25 30

Asp Ala Gly Arg Ala Ser Ser Ala Asp Ala Leu Ala Lys Asp Ala Leu
 35 40 45

Asp Arg Glu Ala Lys Ser Gly Thr Gly Val Pro Gly Gln Val Ala Ile
 50 55 60

Pro His Cys Arg Ser Glu Ala Val Ser Val Pro Thr Leu Gly Phe Ala
 65 70 75 80

Arg Leu Ser Lys Gly Val Asp Phe Ser Gly Pro Asp Gly Asp Ala Asn
 85 90 95

Leu Val Phe Leu Ile Ala Ala Pro Ala Gly Gly Lys Glu His Leu
 100 105 110

Lys Ile Leu Ser Lys Leu Ala Arg Ser Leu Val Lys Lys Asp Phe Ile
 115 120 125

Lys Ala Leu Gln Glu Ala Thr Thr Glu Gln Glu Ile Val Asp Val Val
 130 135 140

Asp Ala Val Leu Asn Pro Ala Pro Lys Thr Thr Glu Pro Ala Ala Ala
 145 150 155 160

Pro Ala Ala Ala Val Ala Glu Ser Gly Ala Ala Ser Thr Ser Val
 165 170 175

Thr Arg Ile Val Ala Ile Thr Ala Cys Pro Thr Gly Ile Ala His Thr
 180 185 190

Tyr Met Ala Ala Asp Ser Leu Thr Gln Asn Ala Glu Gly Arg Asp Asp
 195 200 205

Val Glu Leu Val Val Glu Thr Gln Gly Ser Ser Ala Val Thr Pro Val
 210 215 220

Asp Pro Lys Ile Ile Glu Ala Ala Asp Ala Val Ile Phe Ala Thr Asp

225	230	235	240
Val Gly Val Lys Asp Arg Glu Arg Phe Ala Gly Lys Pro Val Ile Glu			
245		250	255
Ser Gly Val Lys Arg Ala Ile Asn Glu Pro Ala Lys Met Ile Asp Glu			
260	265		270
Ala Ile Ala Ala Ser Lys Asn Pro Asn Ala Arg Lys Val Ser Gly Ser			
275	280	285	
Gly Val Ala Ala Ser Ala Glu Thr Thr Gly Glu Lys Leu Gly Trp Gly			
290	295	300	
Lys Arg Ile Gln Gln Ala Val Met Thr Gly Val Ser Tyr Met Val Pro			
305	310	315	320
Phe Val Ala Ala Gly Gly Leu Leu Leu Ala Leu Gly Phe Ala Phe Gly			
325	330	335	
Gly Tyr Asp Met Ala Asn Gly Trp Gln Ala Ile Ala Thr Gln Phe Ser			
340	345	350	
Leu Thr Asn Leu Pro Gly Asn Thr Val Asp Val Asp Gly Val Ala Met			
355	360	365	
Thr Phe Glu Arg Ser Gly Phe Leu Leu Tyr Phe Gly Ala Val Leu Phe			
370	375	380	
Ala Thr Gly Gln Ala Ala Met Gly Phe Ile Val Ala Ala Leu Ser Gly			
385	390	395	400
Tyr Thr Ala Tyr Ala Leu Ala Gly Arg Pro Gly Ile Ala Pro Gly Phe			
405	410	415	
Val Gly Gly Ala Ile Ser Val Thr Ile Gly Ala Gly Phe Ile Gly Gly			
420	425	430	
Leu Val Thr Gly Ile Leu Ala Gly Leu Ile Ala Leu Trp Ile Gly Ser			
435	440	445	
Trp Lys Val Pro Arg Val Val Gln Ser Leu Met Pro Val Val Ile Ile			
450	455	460	
Pro Leu Leu Thr Ser Val Val Val Gly Leu Val Met Tyr Leu Leu Leu			
465	470	475	480
Gly Arg Pro Leu Ala Ser Ile Met Thr Gly Leu Gln Asp Trp Leu Ser			
485	490	495	
Ser Met Ser Gly Ser Ser Ala Ile Leu Leu Gly Ile Ile Leu Gly Leu			
500	505	510	
Met Met Cys Phe Asp Leu Gly Gly Pro Val Asn Lys Ala Ala Tyr Leu			
515	520	525	
Phe Gly Thr Ala Gly Leu Ser Thr Gly Asp Gln Ala Ser Met Glu Ile			
530	535	540	
Met Ala Ala Ile Met Ala Ala Gly Met Val Pro Pro Ile Ala Leu Ser			
545	550	555	560

```
<210> 9
<211> 464
<212> DNA
<213> Corynebacterium glutamicum
```

<220>
<221> CDS
<222> (1)..(441)
<223> FRXA01299

```

<400> 9
atg gaa atc atg gcc gcg atc atg gca gct ggc atg gtc cca cca atc 48
Met Glu Ile Met Ala Ala Ile Met Ala Ala Gly Met Val Pro Pro Ile
1 5 10 15

gct ttc tcc att gct acc ctg ctg cgc aag aag ctg ttc acc cca gca 96
Ala Leu Ser Ile Ala Thr Leu Leu Arg Lys Lys Leu Phe Thr Pro Ala
20 25 30

gag caa gaa aac ggc aag tct tcc tgg ctg ctt ggc ctg gca ttc gtc 144
Glu Gln Glu Asn Gly Lys Ser Ser Trp Leu Leu Gly Leu Ala Phe Val
35 40 45

tcc gaa ggt gcc atc cca ttc gcc gca gct gac cca ttc cgt gtg atc 192
Ser Glu Gly Ala Ile Pro Phe Ala Ala Ala Asp Pro Phe Arg Val Ile
50 55 60

cca gca atg atg gct ggc ggt gca acc act ggt gca atc tcc atg gca 240
Pro Ala Met Met Ala Gly Gly Ala Thr Thr Gly Ala Ile Ser Met Ala
65 70 75 80

ctg ggc gtc ggc tct cgg gct cca cac ggc ggt atc ttc gtg gtc tgg 288

```

WO 01/02583

Leu	Gly	Val	Gly	Ser	Arg	Ala	Pro	His	Gly	Gly	Ile	Phe	Val	Val	Trp	
															95	
85																
gca	atc	gaa	cca	tgg	tgg	ggc	tgg	ctc	atc	gca	ctt	gca	gca	ggc	acc	336
Ala	Ile	Glu	Pro	Trp	Trp	Gly	Trp	Leu	Ile	Ala	Leu	Ala	Ala	Gly	Thr	
100															110	
atc	gtg	tcc	acc	atc	gtt	gtc	atc	gca	ctg	aag	cag	ttc	tgg	cca	aac	384
Ile	Val	Ser	Thr	Ile	Val	Val	Ile	Ala	Leu	Lys	Gln	Phe	Trp	Pro	Asn	
115															125	
aag	gcc	gct	gca	gaa	gtc	gct	aag	caa	gaa	gca	caa	caa	gca	gct		432
Lys	Ala	Val	Ala	Ala	Glu	Val	Ala	Lys	Gln	Glu	Ala	Gln	Gln	Ala	Ala	
130															140	
gta	aac	gca	taatcgacc	ttgacccgat	gtc											464
Val	Asn	Ala														
145																

<210> 10

<211> 147

<212> PRT

<213> Corynebacterium glutamicum

<400> 10

Met	Glu	Ile	Met	Ala	Ala	Ile	Met	Ala	Ala	Gly	Met	Val	Pro	Pro	Ile
1															15

Ala	Leu	Ser	Ile	Ala	Thr	Leu	Leu	Arg	Lys	Lys	Leu	Phe	Thr	Pro	Ala
20															30

Glu	Gln	Glu	Asn	Gly	Lys	Ser	Ser	Trp	Leu	Leu	Gly	Leu	Ala	Phe	Val
35															45

Ser	Glu	Gly	Ala	Ile	Pro	Phe	Ala	Ala	Ala	Asp	Pro	Phe	Arg	Val	Ile
50															60

Pro	Ala	Met	Met	Ala	Gly	Gly	Ala	Thr	Thr	Gly	Ala	Ile	Ser	Met	Ala
65															80

Leu	Gly	Val	Gly	Ser	Arg	Ala	Pro	His	Gly	Gly	Ile	Phe	Val	Val	Trp
85															95

Ala	Ile	Glu	Pro	Trp	Trp	Gly	Trp	Leu	Ile	Ala	Leu	Ala	Ala	Gly	Thr
100															110

Ile	Val	Ser	Thr	Ile	Val	Val	Ile	Ala	Leu	Lys	Gln	Phe	Trp	Pro	Asn
115															125

Lys	Ala	Val	Ala	Ala	Glu	Val	Ala	Lys	Gln	Glu	Ala	Gln	Gln	Ala	Ala
130															140

Val Asn Ala
145

<210> 11
<211> 580
<212> DNA
<213> Corynebacterium glutamicum

<220>

<221> CDS

<222> (101)..(580)

<223> FRXA01883

<400> 11

cgactgcggc gtctttcctt ggcactacca ttcctcggtcc tgaccaactc gccacagctg 60

gtgcaacggt cacccaaatgc aaaggattga aagaatcagc atg aat agc gta aat 115
Met Asn Ser Val Asn
1 5aat tcc tcg ctt gtc cgg ctg gat gtc gat ttc ggc gac tcc acc acg 163
Asn Ser Ser Leu Val Arg Leu Asp Val Asp Phe Gly Asp Ser Thr Thr
10 15 20gat gtc atc aac aac ctt gcc act gtt att ttc gac gct ggc cga gct 211
Asp Val Ile Asn Asn Leu Ala Thr Val Ile Phe Asp Ala Gly Arg Ala
25 30 35tcc tcc gcc gac gcc ctt gcc aaa gac gcg ctg gat cgt gaa gca aag 259
Ser Ser Ala Asp Ala Leu Ala Lys Asp Ala Leu Asp Arg Glu Ala Lys
40 45 50tcc ggc acc ggc gtt cct ggt caa gtt gct atc ccc cac tgc cgt tcc 307
Ser Gly Thr Gly Val Pro Gly Gln Val Ala Ile Pro His Cys Arg Ser
55 60 65gaa gcc gta tct gtc cct acc ttg ggc ttt gct cgc ctg agc aag ggt 355
Glu Ala Val Ser Val Pro Thr Leu Gly Phe Ala Arg Leu Ser Lys Gly
70 75 80 85gtg gac ttc agc gga cct gat ggc gat gcc aac ttg gtg ttc ctc att 403
Val Asp Phe Ser Gly Pro Asp Gly Asp Ala Asn Leu Val Phe Leu Ile
90 95 100gca gca cct gct ggc ggc aaa gag cac ctg aag atc ctg tcc aag 451
Ala Ala Pro Ala Gly Gly Lys Glu His Leu Lys Ile Leu Ser Lys
105 110 115ctt gct cgc tcc ttg gtg aag aag gat ttc atc aag gct ctg cag gaa 499
Leu Ala Arg Ser Leu Val Lys Lys Asp Phe Ile Lys Ala Leu Gln Glu
120 125 130gcc acc acc gag cag gaa atc gtc gac gtt gtc gat gcc gtg ctc aac 547
Ala Thr Thr Glu Gln Glu Ile Val Asp Val Val Asp Ala Val Leu Asn
135 140 145cca gca cca aaa aac cac cga gcc agc tgc agc 580
Pro Ala Pro Lys Asn His Arg Ala Ser Cys Ser
150 155 160

<210> 12

<211> 160

<212> PRT

<213> Corynebacterium glutamicum

<400> 12

Met Asn Ser Val Asn Asn Ser Leu Val Arg Leu Asp Val Asp Phe

1	5	10	15
Gly Asp Ser Thr Thr Asp Val Ile Asn Asn Leu Ala Thr Val Ile Phe			
20	25	30	
Asp Ala Gly Arg Ala Ser Ser Ala Asp Ala Leu Ala Lys Asp Ala Leu			
35	40	45	
Asp Arg Glu Ala Lys Ser Gly Thr Gly Val Pro Gly Gln Val Ala Ile			
50	55	60	
Pro His Cys Arg Ser Glu Ala Val Ser Val Pro Thr Leu Gly Phe Ala			
65	70	75	80
Arg Leu Ser Lys Gly Val Asp Phe Ser Gly Pro Asp Gly Asp Ala Asn			
85	90	95	
Leu Val Phe Leu Ile Ala Ala Pro Ala Gly Gly Lys Glu His Leu			
100	105	110	
Lys Ile Leu Ser Lys Leu Ala Arg Ser Leu Val Lys Lys Asp Phe Ile			
115	120	125	
Lys Ala Leu Gln Glu Ala Thr Thr Glu Gln Glu Ile Val Asp Val Val			
130	135	140	
Asp Ala Val Leu Asn Pro Ala Pro Lys Asn His Arg Ala Ser Cys Ser			
145	150	155	160

<210> 13
 <211> 631
 <212> DNA
 <213> *Corynebacterium glutamicum*

<220>
 <221> CDS
 <222> (77)..(631)
 <223> FRXA01889

<400> 13
 accgagccag ctgcagctcc ggctgcggcg gccgggttgtt aagagtgggg cggcgctcgac 60
 aagcgttact cgtatcgta gca atc acc gca tgc cca acc ggt atc gca cac 112
 Val Ala Ile Thr Ala Cys Pro Thr Gly Ile Ala His
 1 5 10
 acc tac atg gct gcg gat tcc ctg acg caa aac gcg gaa ggc cgc gat 160
 Thr Tyr Met Ala Ala Asp Ser Leu Thr Gln Asn Ala Glu Gly Arg Asp
 15 20 25
 gat gtg gaa ctc gtt gtg gag act cag ggc tct tcc gct gtc acc cca 208
 Asp Val Glu Leu Val Val Glu Thr Gln Gly Ser Ser Ala Val Thr Pro
 30 35 40
 gtc gat ccg aag atc atc gaa gct gcc gac gcc gtc atc ttc gcc acc 256
 Val Asp Pro Lys Ile Ile Glu Ala Ala Asp Ala Val Ile Phe Ala Thr
 45 50 55 60

gac gtg gga gtt aaa gac cgc gag cgt ttc gct ggc aag cca gtc att 304
 Asp Val Gly Val Lys Asp Arg Glu Arg Phe Ala Gly Lys Pro Val Ile
 65 70 75

 gaa tcc ggc gtc aag cgc gcg atc aat gag cca gcc aag atg atc gac 352
 Glu Ser Gly Val Lys Arg Ala Ile Asn Glu Pro Ala Lys Met Ile Asp
 80 85 90

 gag gcc atc gca gcc tcc aag aac cca aac gcc cgc aag gtt tcc ggt 400
 Glu Ala Ile Ala Ala Ser Lys Asn Pro Asn Ala Arg Lys Val Ser Gly
 95 100 105

 tcc ggt gtc gcg gca tct gct gaa acc acc ggc gag aag ctc ggc tgg 448
 Ser Gly Val Ala Ala Ser Ala Glu Thr Thr Gly Glu Lys Leu Gly Trp
 110 115 120

 ggc aag cgc atc cag cag gca gtc atg acc ggc gtc tcc tac atg gtt 496
 Gly Lys Arg Ile Gln Gln Ala Val Met Thr Gly Val Ser Tyr Met Val
 125 130 135 140

 cca ttc gta gct gcc ggc ctc ctg ttg gct ctc ggc ttc gca ttc 544
 Pro Phe Val Ala Ala Gly Gly Leu Leu Leu Ala Leu Gly Phe Ala Phe
 145 150 155

 ggt gga tac gac atg gcg aac ggc tgg caa gca atc gcc acc cag ttc 592
 Gly Gly Tyr Asp Met Ala Asn Gly Trp Gln Ala Ile Ala Thr Gln Phe
 160 165 170

 tct ctg acc aac ctg cca ggc aac acc gtc gat gtt gac 631
 Ser Leu Thr Asn Leu Pro Gly Asn Thr Val Asp Val Asp
 175 180 185

<210> 14
 <211> 185
 <212> PRT
 <213> *Corynebacterium glutamicum*

<400> 14
 Val Ala Ile Thr Ala Cys Pro Thr Gly Ile Ala His Thr Tyr Met Ala
 1 5 10 15

 Ala Asp Ser Leu Thr Gln Asn Ala Glu Gly Arg Asp Asp Val Glu Leu
 20 25 30

 Val Val Glu Thr Gln Gly Ser Ser Ala Val Thr Pro Val Asp Pro Lys
 35 40 45

 Ile Ile Glu Ala Ala Asp Ala Val Ile Phe Ala Thr Asp Val Gly Val
 50 55 60

 Lys Asp Arg Glu Arg Phe Ala Gly Lys Pro Val Ile Glu Ser Gly Val
 65 70 75 80

 Lys Arg Ala Ile Asn Glu Pro Ala Lys Met Ile Asp Glu Ala Ile Ala
 85 90 95

 Ala Ser Lys Asn Pro Asn Ala Arg Lys Val Ser Gly Ser Gly Val Ala
 100 105 110

Ala Ser Ala Glu Thr Thr Gly Glu Lys Leu Gly Trp Gly Lys Arg Ile
 115 120 125
 Gln Gln Ala Val Met Thr Gly Val Ser Tyr Met Val Pro Phe Val Ala
 130 135 140
 Ala Gly Gly Leu Leu Ala Leu Gly Phe Ala Phe Gly Gly Tyr Asp
 145 150 155 160
 Met Ala Asn Gly Trp Gln Ala Ile Ala Thr Gln Phe Ser Leu Thr Asn
 165 170 175
 Leu Pro Gly Asn Thr Val Asp Val Asp
 180 185

<210> 15
 <211> 416
 <212> DNA
 <213> Corynebacterium glutamicum

<220>
 <221> CDS
 <222> (1)..(393)
 <223> RXA00951

<400> 15 48
 atc caa gca atc tta gag aag gca gca gcg ccg gcg aag cag aag gct
 Ile Gln Ala Ile Leu Glu Lys Ala Ala Pro Ala Lys Gln Lys Ala
 1 5 10 15
 cct gct gtg gct cct gct gta aca ccc act gac gct cct gca gcc tca 96
 Pro Ala Val Ala Pro Ala Val Thr Pro Thr Asp Ala Pro Ala Ala Ser
 20 25 30
 gtc caa tcc aaa acc cac gac aag atc ctc acc gtc tgt ggc aac ggc 144
 Val Gln Ser Lys Thr His Asp Lys Ile Leu Thr Val Cys Gly Asn Gly
 35 40 45
 ttg ggt acc tcc ctc ttc ctc aaa aac acc ctt gag caa gtt ttc gac 192
 Leu Gly Thr Ser Leu Phe Leu Lys Asn Thr Leu Glu Gln Val Phe Asp
 50 55 60
 acc tgg ggt tgg ggt cca tac atg acg gtg gag gca acc gac act atc 240
 Thr Trp Gly Trp Gly Pro Tyr Met Thr Val Glu Ala Thr Asp Thr Ile
 65 70 75 80
 tcc gcc aag ggc aaa gcc aag gaa gct gat ctc atc atg acc tct ggt 288
 Ser Ala Lys Gly Lys Ala Lys Glu Ala Asp Leu Ile Met Thr Ser Gly
 85 90 95
 gaa atc gcc cgc acg ttg ggt gat gtt gga atc ccg gtt cac gtg atc 336
 Glu Ile Ala Arg Thr Leu Gly Asp Val Gly Ile Pro Val His Val Ile
 100 105 110
 aat gac ttc acg agc acc gat gaa atc gat gct gcg ctt cgt gaa cgc 384
 Asn Asp Phe Thr Ser Thr Asp Glu Ile Asp Ala Ala Leu Arg Glu Arg
 115 120 125
 tac gac atc taactacttt aaaaggacga aaa 416
 Tyr Asp Ile

130

<210> 16
 <211> 131
 <212> PRT
 <213> *Corynebacterium glutamicum*

<400> 16
 Ile Gln Ala Ile Leu Glu Lys Ala Ala Ala Pro Ala Lys Gln Lys Ala
 1 5 10 15
 Pro Ala Val Ala Pro Ala Val Thr Pro Thr Asp Ala Pro Ala Ala Ser
 20 25 30
 Val Gln Ser Lys Thr His Asp Lys Ile Leu Thr Val Cys Gly Asn Gly
 35 40 45
 Leu Gly Thr Ser Leu Phe Leu Lys Asn Thr Leu Glu Gln Val Phe Asp
 50 55 60
 Thr Trp Gly Trp Gly Pro Tyr Met Thr Val Glu Ala Thr Asp Thr Ile
 65 70 75 80
 Ser Ala Lys Gly Lys Ala Lys Glu Ala Asp Leu Ile Met Thr Ser Gly
 85 90 95
 Glu Ile Ala Arg Thr Leu Gly Asp Val Gly Ile Pro Val His Val Ile
 100 105 110
 Asn Asp Phe Thr Ser Thr Asp Glu Ile Asp Ala Ala Leu Arg Glu Arg
 115 120 125
 Tyr Asp Ile
 130

<210> 17
 <211> 1827
 <212> DNA
 <213> *Corynebacterium glutamicum*

<220>
 <221> CDS
 <222> (101)..(1804)
 <223> RXN01244

<400> 17
 gatatgtgtt tgtttgtcaa tatccaaatg tttgaatagt tgcacaactg ttgggtttgt 60
 ggtgatcttg aggaaattaa ctcaatgatt gtgaggatgg gtg gct act gtg gct 115
 Val Ala Thr Val Ala
 1 5
 gat gtg aat caa gac act gta ctg aag ggc acc ggc gtt gtc ggt gga 163
 Asp Val Asn Gln Asp Thr Val Leu Lys Gly Thr Gly Val Val Gly Gly
 10 15 20
 gtc cgt tat gca agc gcg gtg tgg att acc cca cgc ccc gaa cta ccc 211
 Val Arg Tyr Ala Ser Ala Val Trp Ile Thr Pro Arg Pro Glu Leu Pro
 25 30 35

caa gca ggc gaa gtc gtc gcc gaa gaa aac cgt gaa gca gag cag gag	259
Gln Ala Gly Glu Val Val Ala Glu Glu Asn Arg Glu Ala Glu Gln Glu	
40 45 50	
cgt ttc gac gcc gct gca gcc aca gtc tct tct cgt ttg ctt gag cgc	307
Arg Phe Asp Ala Ala Ala Ala Thr Val Ser Ser Arg Leu Leu Glu Arg	
55 60 65	
tcc gaa gct gct gaa gga cca gca gct gag gtg ctt aaa gct act gct	355
Ser Glu Ala Ala Glu Gly Pro Ala Ala Glu Val Leu Lys Ala Thr Ala	
70 75 80 85	
ggc atg gtc aat gac cgt ggc tgg cgt aag gct gtc atc aag ggt gtc	403
Gly Met Val Asn Asp Arg Gly Trp Arg Lys Ala Val Ile Lys Gly Val	
90 95 100	
aag ggt ggt cac cct gcg gaa tac gcc gtg gtt gca gca aca acc aag	451
Lys Gly Gly His Pro Ala Glu Tyr Ala Val Val Ala Ala Thr Thr Lys	
105 110 115	
tcc atc tcc atg ttc gaa gcc gca ggc ggc ctg atc gcg gag cgc acc	499
Phe Ile Ser Met Phe Glu Ala Ala Gly Gly Leu Ile Ala Glu Arg Thr	
120 125 130	
aca gac ttg cgc gac atc cgc gac cgc gtc atc gca gaa ctt cgt ggc	547
Thr Asp Leu Arg Asp Ile Arg Asp Arg Val Ile Ala Glu Leu Arg Gly	
135 140 145	
gat gaa gag cca ggt ctg cca gct gtt tcc gga cag gtc att ctc ttt	595
Asp Glu Glu Pro Gly Leu Pro Ala Val Ser Gly Gln Val Ile Leu Phe	
150 155 160 165	
gca gat gac ctc tcc cca gca gac acc gcg gca cta gac aca gat ctc	643
Ala Asp Asp Leu Ser Pro Ala Asp Thr Ala Ala Leu Asp Thr Asp Leu	
170 175 180	
ttt gtg gga ctt gtc act gag ctg ggt ggc cca acg agc cac acc gcg	691
Phe Val Gly Leu Val Thr Glu Leu Gly Gly Pro Thr Ser His Thr Ala	
185 190 195	
atc atc gca cgc cag ctc aac gtg cct tgc atc gtc gca tcc ggc gcc	739
Ile Ile Ala Arg Gln Leu Asn Val Pro Cys Ile Val Ala Ser Gly Ala	
200 205 210	
ggc atc aag gac atc aag tcc ggc gaa aag gtg ctt atc gac ggc agc	787
Gly Ile Lys Asp Ile Lys Ser Gly Glu Lys Val Leu Ile Asp Gly Ser	
215 220 225	
ctc ggc acc att gac cgc aac gcg gac gaa gct gaa gca acc aag ctc	835
Leu Gly Thr Ile Asp Arg Asn Ala Asp Glu Ala Glu Ala Thr Lys Leu	
230 235 240 245	
gtc tcc gag tcc ctc gag cgc gct gct cgc atc gcc gag tgg aag ggt	883
Val Ser Glu Ser Leu Glu Arg Ala Ala Arg Ile Ala Glu Trp Lys Gly	
250 255 260	
cct gca caa acc aag gac ggc tac cgc gtt cag ctg ttg gcc aac gtc	931
Pro Ala Gln Thr Lys Asp Gly Tyr Arg Val Gln Leu Leu Ala Asn Val	
265 270 275	

caa gac ggc aac tct gca cag cag gct gca cag acc gaa gca gaa ggc 979
 Gln Asp Gly Asn Ser Ala Gln Gln Ala Ala Gln Thr Glu Ala Glu Gly
 280 285 290

atc ggc ctg ttc cgc acc gaa ctg tgc ttc ctt tcc gcc acc gaa gag 1027
 Ile Gly Leu Phe Arg Thr Glu Leu Cys Phe Leu Ser Ala Thr Glu Glu
 295 300 305

cca agc gtt gat gag cag gct gcg gtc tac tca aag gtg ctt gaa gca 1075
 Pro Ser Val Asp Glu Gln Ala Ala Val Tyr Ser Lys Val Leu Glu Ala
 310 315 320 325

ttc cca gag tcc aag gtc gtt gtc cgc tcc ctc gac gca ggt tct gac 1123
 Phe Pro Glu Ser Lys Val Val Val Arg Ser Leu Asp Ala Gly Ser Asp
 330 335 340

aag cca gtt cca ttc gca tcg atg gct gat gag atg aac cca gca ctg 1171
 Lys Pro Val Pro Phe Ala Ser Met Ala Asp Glu Met Asn Pro Ala Leu
 345 350 355

ggt gtt cgt ggc ctg cgt atc gca cgt gga cag gtt gat ctg ctg act 1219
 Gly Val Arg Gly Leu Arg Ile Ala Arg Gly Gln Val Asp Leu Leu Thr
 360 365 370

cgc cag ctc gac gca att gcg aag gcc agc gaa gaa ctc ggc cgt ggc 1267
 Arg Gln Leu Asp Ala Ile Ala Lys Ala Ser Glu Glu Leu Gly Arg Gly
 375 380 385

gac gac gcc cca acc tgg gtt atg gct cca atg gtg gct acc gct tat 1315
 Asp Asp Ala Pro Thr Trp Val Met Ala Pro Met Val Ala Thr Ala Tyr
 390 395 400 405

gaa gca aag tgg ttt gct gac atg tgc cgt gag cgt ggc cta atc gcc 1363
 Glu Ala Lys Trp Phe Ala Asp Met Cys Arg Glu Arg Gly Leu Ile Ala
 410 415 420

ggc gcc atg atc gaa gtt cca gca gca tcc ctg atg gca gac aag atc 1411
 Gly Ala Met Ile Glu Val Pro Ala Ala Ser Leu Met Ala Asp Lys Ile
 425 430 435

atg cct cac ctg gac ttt gtt tcc atc ggt acc aac gac ctg acc cag 1459
 Met Pro His Leu Asp Phe Val Ser Ile Gly Thr Asn Asp Leu Thr Gln
 440 445 450

tac acc atg gca gcg gac cgc atg tct cct gag ctt gcc tac ctg acc 1507
 Tyr Thr Met Ala Ala Asp Arg Met Ser Pro Glu Leu Ala Tyr Leu Thr
 455 460 465

gat cct tgg cag cca gca gtc ctg cgc ctg atc aag cac acc tgt gac 1555
 Asp Pro Trp Gln Pro Ala Val Leu Arg Leu Ile Lys His Thr Cys Asp
 470 475 480 485

gaa ggt gct cgc ttt aac acc ccg gtc ggt gtt tgt ggt gaa gca gca 1603
 Glu Gly Ala Arg Phe Asn Thr Pro Val Gly Val Cys Gly Glu Ala Ala
 490 495 500

gca gac cca ctg ttg gca act gtc ctc acc ggt ctt ggc gtg aac tcc 1651
 Ala Asp Pro Leu Leu Ala Thr Val Leu Thr Gly Leu Gly Val Asn Ser
 505 510 515

ctg tcc gca gca tcc act gct ctc gca gca gtc ggt gca aag ctg tca 1699

Leu Ser Ala Ala Ser Thr Ala Leu Ala Ala Val Gly Ala Lys Leu Ser
 520 525 530
 gag gtc acc ctg gaa acc tgt aag aag gca gca gaa gca gca ctt gac 1747
 Glu Val Thr Leu Glu Thr Cys Lys Ala Ala Glu Ala Ala Leu Asp
 535 540 545
 gct gaa ggt gca act gaa gca cgc gat gct gta cgc gca gtg atc gac 1795
 Ala Glu Gly Ala Thr Glu Ala Arg Asp Ala Val Arg Ala Val Ile Asp
 550 555 560 565
 gca gca gtc taaaccactg ttgagctaaa aag 1827
 Ala Ala Val

<210> 18
 <211> 568
 <212> PRT
 <213> *Corynebacterium glutamicum*

<400> 18
 Val Ala Thr Val Ala Asp Val Asn Gln Asp Thr Val Leu Lys Gly Thr
 1 5 10 15
 Gly Val Val Gly Gly Val Arg Tyr Ala Ser Ala Val Trp Ile Thr Pro
 20 25 30
 Arg Pro Glu Leu Pro Gln Ala Gly Glu Val Val Ala Glu Glu Asn Arg
 35 40 45
 Glu Ala Glu Gln Glu Arg Phe Asp Ala Ala Ala Thr Val Ser Ser
 50 55 60
 Arg Leu Leu Glu Arg Ser Glu Ala Ala Glu Gly Pro Ala Ala Glu Val
 65 70 75 80
 Leu Lys Ala Thr Ala Gly Met Val Asn Asp Arg Gly Trp Arg Lys Ala
 85 90 95
 Val Ile Lys Gly Val Lys Gly Gly His Pro Ala Glu Tyr Ala Val Val
 100 105 110
 Ala Ala Thr Thr Lys Phe Ile Ser Met Phe Glu Ala Ala Gly Gly Leu
 115 120 125
 Ile Ala Glu Arg Thr Thr Asp Leu Arg Asp Ile Arg Asp Arg Val Ile
 130 135 140
 Ala Glu Leu Arg Gly Asp Glu Glu Pro Gly Leu Pro Ala Val Ser Gly
 145 150 155 160
 Gln Val Ile Leu Phe Ala Asp Asp Leu Ser Pro Ala Asp Thr Ala Ala
 165 170 175
 Leu Asp Thr Asp Leu Phe Val Gly Leu Val Thr Glu Leu Gly Gly Pro
 180 185 190
 Thr Ser His Thr Ala Ile Ile Ala Arg Gln Leu Asn Val Pro Cys Ile
 195 200 205

Val Ala Ser Gly Ala Gly Ile Lys Asp Ile Lys Ser Gly Glu Lys Val
 210 215 220
 Leu Ile Asp Gly Ser Leu Gly Thr Ile Asp Arg Asn Ala Asp Glu Ala
 225 230 235 240
 Glu Ala Thr Lys Leu Val Ser Glu Ser Leu Glu Arg Ala Ala Arg Ile
 245 250 255
 Ala Glu Trp Lys Gly Pro Ala Gln Thr Lys Asp Gly Tyr Arg Val Gln
 260 265 270
 Leu Leu Ala Asn Val Gln Asp Gly Asn Ser Ala Gln Gln Ala Ala Gln
 275 280 285
 Thr Glu Ala Glu Gly Ile Gly Leu Phe Arg Thr Glu Leu Cys Phe Leu
 290 295 300
 Ser Ala Thr Glu Glu Pro Ser Val Asp Glu Gln Ala Ala Val Tyr Ser
 305 310 315 320
 Lys Val Leu Glu Ala Phe Pro Glu Ser Lys Val Val Val Arg Ser Leu
 325 330 335
 Asp Ala Gly Ser Asp Lys Pro Val Pro Phe Ala Ser Met Ala Asp Glu
 340 345 350
 Met Asn Pro Ala Leu Gly Val Arg Gly Leu Arg Ile Ala Arg Gly Gln
 355 360 365
 Val Asp Leu Leu Thr Arg Gln Leu Asp Ala Ile Ala Lys Ala Ser Glu
 370 375 380
 Glu Leu Gly Arg Gly Asp Asp Ala Pro Thr Trp Val Met Ala Pro Met
 385 390 395 400
 Val Ala Thr Ala Tyr Glu Ala Lys Trp Phe Ala Asp Met Cys Arg Glu
 405 410 415
 Arg Gly Leu Ile Ala Gly Ala Met Ile Glu Val Pro Ala Ala Ser Leu
 420 425 430
 Met Ala Asp Lys Ile Met Pro His Leu Asp Phe Val Ser Ile Gly Thr
 435 440 445
 Asn Asp Leu Thr Gln Tyr Thr Met Ala Ala Asp Arg Met Ser Pro Glu
 450 455 460
 Leu Ala Tyr Leu Thr Asp Pro Trp Gln Pro Ala Val Leu Arg Leu Ile
 465 470 475 480
 Lys His Thr Cys Asp Glu Gly Ala Arg Phe Asn Thr Pro Val Gly Val
 485 490 495
 Cys Gly Glu Ala Ala Ala Asp Pro Leu Leu Ala Thr Val Leu Thr Gly
 500 505 510
 Leu Gly Val Asn Ser Leu Ser Ala Ala Ser Thr Ala Leu Ala Ala Val
 515 520 525
 Gly Ala Lys Leu Ser Glu Val Thr Leu Glu Thr Cys Lys Lys Ala Ala

530

535

540

Glu Ala Ala Leu Asp Ala Glu Gly Ala Thr Glu Ala Arg Asp Ala Val
 545 550 555 560

Arg Ala Val Ile Asp Ala Ala Val
 565

<210> 19

<211> 1629

<212> DNA

<213> Corynebacterium glutamicum

<220>

<221> CDS

<222> (98)..(1606)

<223> FRXA01244

<400> 19

agatgtcgat ttctcgagga agaagttaac gccgaagaaa accgtgaatc agagcaggag 60
 cgcttcgacg ccgctgcagc cacagtctct tcttcgtttg ctt gag cgc tcc gaa 115
 Leu Leu Glu Arg Ser Glu
 1 5

gct gct gaa gga cca gca gct gag gtg ctt aaa gct act gct ggc atg 163
 Ala Ala Glu Gly Pro Ala Ala Glu Val Leu Lys Ala Thr Ala Gly Met
 10 15 20

gtc aat gac cgt ggc tgg cgt aag gct gtc atc aag ggt gtc aag ggt 211
 Val Asn Asp Arg Gly Trp Arg Lys Ala Val Ile Lys Gly Val Lys Gly
 25 30 35

ggt cac cct gcg gaa tac gcc gtg gtt gca gca aca acc aag ttc atc 259
 Gly His Pro Ala Glu Tyr Ala Val Val Ala Ala Thr Thr Lys Phe Ile
 40 45 50

tcc atg ttc gaa gcc gca ggc ggc ctg atc gcg gag cgc acc aca gac 307
 Ser Met Phe Glu Ala Ala Gly Gly Leu Ile Ala Glu Arg Thr Thr Asp
 55 60 65 70

ttg cgc gac atc cgc gac cgc gtc atc gca gaa ctt cgt ggc gat gaa 355
 Leu Arg Asp Ile Arg Asp Arg Val Ile Ala Glu Leu Arg Gly Asp Glu
 75 80 85

gag cca ggt ctg cca gct gtt tcc gga cag gtc att ctc ttt gca gat 403
 Glu Pro Gly Leu Pro Ala Val Ser Gly Gln Val Ile Leu Phe Ala Asp
 90 95 100

gac ctc tcc cca gca gac acc gcg gca cta gac aca gat ctc ttt gtg 451
 Asp Leu Ser Pro Ala Asp Thr Ala Ala Leu Asp Thr Asp Leu Phe Val
 105 110 115

gga ctt gtc act gag ctg ggt ggc cca acg agc cac acc gcg atc atc 499
 Gly Leu Val Thr Glu Leu Gly Gly Pro Thr Ser His Thr Ala Ile Ile
 120 125 130

gca cgc cag ctc aac gtg cct tgc atc gtc gca tcc ggc ggc atc 547
 Ala Arg Gln Leu Asn Val Pro Cys Ile Val Ala Ser Gly Ala Gly Ile
 135 140 145 150

aag gac atc aag tcc ggc gaa aag gtg ctt atc gac ggc agc ctc ggc	595
Lys Asp Ile Lys Ser Gly Glu Lys Val Leu Ile Asp Gly Ser Leu Gly	
155 160 165	
acc att gac cgc aac gcg gac gaa gct gaa gca acc aag ctc gtc tcc	643
Thr Ile Asp Arg Asn Ala Asp Glu Ala Glu Ala Thr Lys Leu Val Ser	
170 175 180	
gag tcc ctc gag cgc gct gct cgc atc gcc gag tgg aag ggt cct gca	691
Glu Ser Leu Glu Arg Ala Ala Arg Ile Ala Glu Trp Lys Gly Pro Ala	
185 190 195	
caa acc aag gac ggc tac cgc gtt cag ctg ttg gcc aac gtc caa gac	739
Gln Thr Lys Asp Gly Tyr Arg Val Gln Leu Leu Ala Asn Val Gln Asp	
200 205 210	
ggc aac tct gca cag cag gct gca cag acc gaa gca gaa ggc atc ggc	787
Gly Asn Ser Ala Gln Gln Ala Ala Gln Thr Glu Ala Glu Gly Ile Gly	
215 220 225 230	
ctg ttc cgc acc gaa ctg tgc ttc ctt tcc gcc acc gaa gag cca agc	835
Leu Phe Arg Thr Glu Leu Cys Phe Leu Ser Ala Thr Glu Glu Pro Ser	
235 240 245	
gtt gat gag cag gct gcg gtc tac tca aag gtg ctt gaa gca ttc cca	883
Val Asp Glu Gln Ala Ala Val Tyr Ser Lys Val Leu Glu Ala Phe Pro	
250 255 260	
gag tcc aag gtc gtt gtc cgc tcc ctc gac gca ggt tct gac aag cca	931
Glu Ser Lys Val Val Val Arg Ser Leu Asp Ala Gly Ser Asp Lys Pro	
265 270 275	
gtt cca ttc gca tcg atg gct gat gag atg aac cca gca ctg ggt gtt	979
Val Pro Phe Ala Ser Met Ala Asp Glu Met Asn Pro Ala Leu Gly Val	
280 285 290	
cgt ggc ctg cgt atc gca cgt gga cag gtt gat ctg ctg act cgc cag	1027
Arg Gly Leu Arg Ile Ala Arg Gly Gln Val Asp Leu Leu Thr Arg Gln	
295 300 305 310	
ctc gac gca att gcg aag gcc agc gaa gaa ctc ggc cgt ggc gac gac	1075
Leu Asp Ala Ile Ala Lys Ala Ser Glu Glu Leu Gly Arg Gly Asp Asp	
315 320 325	
gcc cca acc tgg gtt atg gct cca atg gtg gct acc gct tat gaa gca	1123
Ala Pro Thr Trp Val Met Ala Pro Met Val Ala Thr Ala Tyr Glu Ala	
330 335 340	
aag tgg ttt gct gac atg tgc cgt gag cgt ggc cta atc gcc ggc gcc	1171
Lys Trp Phe Ala Asp Met Cys Arg Glu Arg Gly Leu Ile Ala Gly Ala	
345 350 355	
atg atc gaa gtt cca gca gca tcc ctg atg gca gac aag atc atg cct	1219
Met Ile Glu Val Pro Ala Ala Ser Leu Met Ala Asp Lys Ile Met Pro	
360 365 370	
cac ctg gac ttt gtt tcc atc ggt acc aac gac ctg acc cag tac acc	1267
His Leu Asp Phe Val Ser Ile Gly Thr Asn Asp Leu Thr Gln Tyr Thr	
375 380 385 390	

atg gca gcg gac cgc atg tct cct gag ctt gcc tac ctg acc gat cct 1315
 Met Ala Ala Asp Arg Met Ser Pro Glu Leu Ala Tyr Leu Thr Asp Pro
 395 400 405
 tgg cag cca gca gtc ctg cgc ctg atc aag cac acc tgt gac gaa ggt 1363
 Trp Gln Pro Ala Val Leu Arg Leu Ile Lys His Thr Cys Asp Glu Gly
 410 415 420
 gct cgc ttt aac acc ccg gtc ggt gtt tgt ggt gaa gca gca gac 1411
 Ala Arg Phe Asn Thr Pro Val Gly Val Cys Gly Glu Ala Ala Ala Asp
 425 430 435
 cca ctg ttg gca act gtc ctc acc ggt ctt ggc gtg aac tcc ctg tcc 1459
 Pro Leu Leu Ala Thr Val Leu Thr Gly Leu Gly Val Asn Ser Leu Ser
 440 445 450
 gca gca tcc act gct ctc gca gca gtc ggt gca aag ctg tca gag gtc 1507
 Ala Ala Ser Thr Ala Leu Ala Ala Val Gly Ala Lys Leu Ser Glu Val
 455 460 465 470
 acc ctg gaa acc tgt aag aag gca gca gaa gca ctt gac gct gaa 1555
 Thr Leu Glu Thr Cys Lys Lys Ala Ala Glu Ala Ala Leu Asp Ala Glu
 475 480 485
 ggt gca act gaa gca cgc gat gct gta cgc gca gtg atc gac gca gca 1603
 Gly Ala Thr Glu Ala Arg Asp Ala Val Arg Ala Val Ile Asp Ala Ala
 490 495 500
 gtc taaaccactg ttgagctaaa aag 1629
 Val

<210> 20
 <211> 503
 <212> PRT
 <213> *Corynebacterium glutamicum*

<400> 20
 Leu Leu Glu Arg Ser Glu Ala Ala Glu Gly Pro Ala Ala Glu Val Leu
 1 5 10 15
 Lys Ala Thr Ala Gly Met Val Asn Asp Arg Gly Trp Arg Lys Ala Val
 20 25 30
 Ile Lys Gly Val Lys Gly Gly His Pro Ala Glu Tyr Ala Val Val Ala
 35 40 45
 Ala Thr Thr Lys Phe Ile Ser Met Phe Glu Ala Ala Gly Gly Leu Ile
 50 55 60
 Ala Glu Arg Thr Thr Asp Leu Arg Asp Ile Arg Asp Arg Val Ile Ala
 65 70 75 80
 Glu Leu Arg Gly Asp Glu Glu Pro Gly Leu Pro Ala Val Ser Gly Gln
 85 90 95
 Val Ile Leu Phe Ala Asp Asp Leu Ser Pro Ala Asp Thr Ala Ala Leu
 100 105 110
 Asp Thr Asp Leu Phe Val Gly Leu Val Thr Glu Leu Gly Gly Pro Thr

115	120	125
Ser His Thr Ala Ile Ile Ala Arg Gln Leu Asn Val Pro Cys Ile Val		
130	135	140
Ala Ser Gly Ala Gly Ile Lys Asp Ile Lys Ser Gly Glu Lys Val Leu		
145	150	155
Ile Asp Gly Ser Leu Gly Thr Ile Asp Arg Asn Ala Asp Glu Ala Glu		
165	170	175
Ala Thr Lys Leu Val Ser Glu Ser Leu Glu Arg Ala Ala Arg Ile Ala		
180	185	190
Glu Trp Lys Gly Pro Ala Gln Thr Lys Asp Gly Tyr Arg Val Gln Leu		
195	200	205
Leu Ala Asn Val Gln Asp Gly Asn Ser Ala Gln Gln Ala Ala Gln Thr		
210	215	220
Glu Ala Glu Gly Ile Gly Leu Phe Arg Thr Glu Leu Cys Phe Leu Ser		
225	230	235
Ala Thr Glu Glu Pro Ser Val Asp Glu Gln Ala Ala Val Tyr Ser Lys		
245	250	255
Val Leu Glu Ala Phe Pro Glu Ser Lys Val Val Val Arg Ser Leu Asp		
260	265	270
Ala Gly Ser Asp Lys Pro Val Pro Phe Ala Ser Met Ala Asp Glu Met		
275	280	285
Asn Pro Ala Leu Gly Val Arg Gly Leu Arg Ile Ala Arg Gly Gln Val		
290	295	300
Asp Leu Leu Thr Arg Gln Leu Asp Ala Ile Ala Lys Ala Ser Glu Glu		
305	310	315
Leu Gly Arg Gly Asp Asp Ala Pro Thr Trp Val Met Ala Pro Met Val		
325	330	335
Ala Thr Ala Tyr Glu Ala Lys Trp Phe Ala Asp Met Cys Arg Glu Arg		
340	345	350
Gly Leu Ile Ala Gly Ala Met Ile Glu Val Pro Ala Ala Ser Leu Met		
355	360	365
Ala Asp Lys Ile Met Pro His Leu Asp Phe Val Ser Ile Gly Thr Asn		
370	375	380
Asp Leu Thr Gln Tyr Thr Met Ala Ala Asp Arg Met Ser Pro Glu Leu		
385	390	395
Ala Tyr Leu Thr Asp Pro Trp Gln Pro Ala Val Leu Arg Leu Ile Lys		
405	410	415
His Thr Cys Asp Glu Gly Ala Arg Phe Asn Thr Pro Val Gly Val Cys		
420	425	430
Gly Glu Ala Ala Ala Asp Pro Leu Leu Ala Thr Val Leu Thr Gly Leu		
435	440	445

WO 01/02583

Gly Val Asn Ser Leu Ser Ala Ala Ser Thr Ala Leu Ala Ala Val Gly
 450 455 460
 Ala Lys Leu Ser Glu Val Thr Leu Glu Thr Cys Lys Lys Ala Ala Glu
 465 470 475 480
 Ala Ala Leu Asp Ala Glu Gly Ala Thr Glu Ala Arg Asp Ala Val Arg
 485 490 495
 Ala Val Ile Asp Ala Ala Val
 500

<210> 21
 <211> 390
 <212> DNA
 <213> Corynebacterium glutamicum

<220>
 <221> CDS
 <222> (101)..(367)
 <223> RXA01300

<400> 21
 gatcgacatt aaatccccctc ccttgggggg tttaactaac aaatcgctgc gccctaattcc 60
 gttcggattt acggcgtagc aacacgaaag gacactttcc atg gct tcc aag act 115
 Met Ala Ser Lys Thr
 1 5
 gta acc gtc ggt tcc tcc gtt ggc ctg cac gca cgt cca gca tcc atc 163
 Val Thr Val Gly Ser Ser Val Gly Leu His Ala Arg Pro Ala Ser Ile
 10 15 20
 atc gct gaa gcg gct gct gag tac gac gac gaa atc ttg ctg acc ctg 211
 Ile Ala Glu Ala Ala Glu Tyr Asp Asp Glu Ile Leu Leu Thr Leu
 25 30 35
 gtt ggc tcc gat gat gac gaa gag acc gac gcg tcc tct tcc ctc atg 259
 Val Gly Ser Asp Asp Asp Glu Glu Thr Asp Ala Ser Ser Leu Met
 40 45 50
 atc atg gcg ctg ggc gca gag cac ggc aac gaa gtt acc gtc acc tcc 307
 Ile Met Ala Leu Gly Ala Glu His Gly Asn Glu Val Thr Val Thr Ser
 55 60 65
 gac aac gct gaa gct gtt gag aag atc gct gcg ctt atc gca cag gac 355
 Asp Asn Ala Glu Ala Val Glu Lys Ile Ala Ala Leu Ile Ala Gln Asp
 70 75 80 85
 ctt gac gct gag taaacaacgc tctgcttggaa 390
 Leu Asp Ala Glu

<210> 22
 <211> 89
 <212> PRT
 <213> Corynebacterium glutamicum

<400> 22
 Met Ala Ser Lys Thr Val Thr Val Gly Ser Ser Val Gly Leu His Ala
 1 5 10 15
 Arg Pro Ala Ser Ile Ile Ala Glu Ala Ala Ala Glu Tyr Asp Asp Glu
 20 25 30
 Ile Leu Leu Thr Leu Val Gly Ser Asp Asp Asp Glu Glu Thr Asp Ala
 35 40 45
 Ser Ser Ser Leu Met Ile Met Ala Leu Gly Ala Glu His Gly Asn Glu
 50 55 60
 Val Thr Val Thr Ser Asp Asn Ala Glu Ala Val Glu Lys Ile Ala Ala
 65 70 75 80
 Leu Ile Ala Gln Asp Leu Asp Ala Glu
 85

 <210> 23
 <211> 508
 <212> DNA
 <213> *Corynebacterium glutamicum*

<220>
 <221> CDS
 <222> (101)..(508)
 <223> RXN03002

<400> 23
 ggaaccttcga ggtgtcttcg tggggcgtag ggagatctag caagtgtggc tttatgtttg 60
 accctatccg aatcaacatg cagtgaatata acatctactt atg ttt gta ctc aaa 115
 Met Phe Val Leu Lys
 1 5
 gat ctg cta aag gca gaa cgc ata gaa ctc gac cgc acg gtc acc gat 163
 Asp Leu Leu Lys Ala Glu Arg Ile Glu Leu Asp Arg Thr Val Thr Asp
 10 15 20
 tgg cgt gaa ggc atc cgc gcc gca ggt gta ctc cta gaa aag aca aac 211
 Trp Arg Glu Gly Ile Arg Ala Ala Gly Val Leu Leu Glu Lys Thr Asn
 25 30 35
 agc att gat tcc gcc tac acc gat gcc atg atc gcc agc gtg gaa gaa 259
 Ser Ile Asp Ser Ala Tyr Thr Asp Ala Met Ile Ala Ser Val Glu Glu
 40 45 50
 aaa ggc ccc tac att gtg gtc gct cca ggt ttc gct ttc gcg cac gcc 307
 Lys Gly Pro Tyr Ile Val Val Ala Pro Gly Phe Ala Phe Ala His Ala
 55 60 65
 cgc ccc agc aga gca gtc cgc gag acc gct atg tcg tgg gtg cgc ctg 355
 Arg Pro Ser Arg Ala Val Arg Glu Thr Ala Met Ser Trp Val Arg Leu
 70 75 80 85
 gcc tcc cct gtt tcc ttc ggt cac agt aag aat gat ccc ctc aat ctc 403
 Ala Ser Pro Val Ser Phe Gly His Ser Lys Asn Asp Pro Leu Asn Leu
 90 95 100

atc gtt gct ctc gct gcc aaa gat gcc acc gca cat acc caa gcg atg 451
 Ile Val Ala Leu Ala Ala Lys Asp Ala Thr Ala His Thr Gln Ala Met
 105 110 115

gcg gca ttg gct aaa gct tta gga aaa tac cga aag gat ctc gac gag 499
 Ala Ala Leu Ala Lys Ala Leu Gly Lys Tyr Arg Lys Asp Leu Asp Glu
 120 125 130

gca caa agt 508
 Ala Gln Ser
 135

<210> 24
 <211> 136
 <212> PRT
 <213> Corynebacterium glutamicum

<400> 24
 Met Phe Val Leu Lys Asp Leu Leu Lys Ala Glu Arg Ile Glu Leu Asp
 1 5 10 15

Arg Thr Val Thr Asp Trp Arg Glu Gly Ile Arg Ala Ala Gly Val Leu
 20 25 30

Leu Glu Lys Thr Asn Ser Ile Asp Ser Ala Tyr Thr Asp Ala Met Ile
 35 40 45

Ala Ser Val Glu Glu Lys Gly Pro Tyr Ile Val Val Ala Pro Gly Phe
 50 55 60

Ala Phe Ala His Ala Arg Pro Ser Arg Ala Val Arg Glu Thr Ala Met
 65 70 75 80

Ser Trp Val Arg Leu Ala Ser Pro Val Ser Phe Gly His Ser Lys Asn
 85 90 95

Asp Pro Leu Asn Leu Ile Val Ala Leu Ala Ala Lys Asp Ala Thr Ala
 100 105 110

His Thr Gln Ala Met Ala Ala Leu Ala Lys Ala Leu Gly Lys Tyr Arg
 115 120 125

Lys Asp Leu Asp Glu Ala Gln Ser
 130 135

<210> 25
 <211> 789
 <212> DNA
 <213> Corynebacterium glutamicum

<220>
 <221> CDS
 <222> (14)..(766)
 <223> RXC00953

<400> 25
 cttgcattcc ccaatg gcg cca cca acg gta ggc aac tac atc atg cag tcc 52
 Met Ala Pro Pro Thr Val Gly Asn Tyr Ile Met Gln Ser
 1 5 10

ttc actcaa ggt ctg cag ttc ggc gtt gca gtt gcc gtg att ctc ttt 100
 Phe Thr Gln Gly Leu Gln Phe Gly Val Ala Val Ala Val Ile Leu Phe
 15 20 25

ggt gtc cgc acc att ctt ggt gaa ctg gtc ccc gca ttc caa ggt att 148
 Gly Val Arg Thr Ile Leu Gly Glu Leu Val Pro Ala Phe Gln Gly Ile
 30 35 40 45

gct gcg aag gtt gtt ccc gga gct atc ccc gca ttg gat gca ccg atc 196
 Ala Ala Lys Val Val Pro Gly Ala Ile Pro Ala Leu Asp Ala Pro Ile
 50 55 60

gtg ttc ccc tac gcg cag aac gcc gtt ctc att ggt ttc ttg tct tcc 244
 Val Phe Pro Tyr Ala Gln Asn Ala Val Leu Ile Gly Phe Leu Ser Ser
 65 70 75

ttc gtc ggt ggc ttg gtt ggc ctg act gtt ctt gca tcg tgg ctg aac 292
 Phe Val Gly Gly Leu Val Gly Leu Thr Val Leu Ala Ser Trp Leu Asn
 80 85 90

cca gct ttt ggt gtc gcg ttg att ctg cct ggt ttg gtc ccc cac ttc 340
 Pro Ala Phe Gly Val Ala Leu Ile Leu Pro Gly Leu Val Pro His Phe
 95 100 105

ttc act ggt ggc gcg ggc gtt tac ggt aat gcc acg ggt ggt cgt 388
 Phe Thr Gly Gly Ala Ala Gly Val Tyr Gly Asn Ala Thr Gly Gly Arg
 110 115 120 125

cga gga gca gta ttt ggc gcc ttt gcc aac ggt ctt ctg att acc ttc 436
 Arg Gly Ala Val Phe Gly Ala Phe Ala Asn Gly Leu Leu Ile Thr Phe
 130 135 140

ctc cct gct ttc ctg ctt ggt gtg ctt ggt tcc ttc ggg tca gag aac 484
 Leu Pro Ala Phe Leu Leu Gly Val Leu Gly Ser Phe Gly Ser Glu Asn
 145 150 155

acc act ttc ggt gat gcg gac ttt ggt tgg ttc gga atc gtt gtt ggt 532
 Thr Thr Phe Gly Asp Ala Asp Phe Gly Trp Phe Gly Ile Val Val Gly
 160 165 170

tct gca gcc aag gtg gaa ggt gct ggc ggg ctc atc ttg ttg ctc atc 580
 Ser Ala Ala Lys Val Glu Gly Ala Gly Leu Ile Leu Leu Ile
 175 180 185

atc gca gcg gtt ctt ctg ggt ggc gcg atg gtc ttc cag aag cgc gtc 628
 Ile Ala Ala Val Leu Leu Gly Gly Ala Met Val Phe Gln Lys Arg Val
 190 195 200 205

gtg aat ggg cac tgg gat cca gct ccc aac cgt gag cgc gtg gag aag 676
 Val Asn Gly His Trp Asp Pro Ala Pro Asn Arg Glu Arg Val Glu Lys
 210 215 220

gcg gaa gct gat gcc act cca acg gct ggg gct cgg acc tac cct aag 724
 Ala Glu Ala Asp Ala Thr Pro Thr Ala Gly Ala Arg Thr Tyr Pro Lys
 225 230 235

att gct cct ccg gcg ggc gct cct acc cca ccg gct cga agc 766
 Ile Ala Pro Pro Ala Gly Ala Pro Thr Pro Pro Ala Arg Ser
 240 245 250

taagatctcc aaaaccctga gat

789

<210> 26
 <211> 251
 <212> PRT
 <213> Corynebacterium glutamicum

<400> 26
 Met Ala Pro Pro Thr Val Gly Asn Tyr Ile Met Gln Ser Phe Thr Gln
 1 5 10 15
 Gly Leu Gln Phe Gly Val Ala Val Ala Val Ile Leu Phe Gly Val Arg
 20 25 30
 Thr Ile Leu Gly Glu Leu Val Pro Ala Phe Gln Gly Ile Ala Ala Lys
 35 40 45
 Val Val Pro Gly Ala Ile Pro Ala Leu Asp Ala Pro Ile Val Phe Pro
 50 55 60
 Tyr Ala Gln Asn Ala Val Leu Ile Gly Phe Leu Ser Ser Phe Val Gly
 65 70 75 80
 Gly Leu Val Gly Leu Thr Val Leu Ala Ser Trp Leu Asn Pro Ala Phe
 85 90 95
 Gly Val Ala Leu Ile Leu Pro Gly Leu Val Pro His Phe Phe Thr Gly
 100 105 110
 Gly Ala Ala Gly Val Tyr Gly Asn Ala Thr Gly Arg Arg Gly Ala
 115 120 125
 Val Phe Gly Ala Phe Ala Asn Gly Leu Leu Ile Thr Phe Leu Pro Ala
 130 135 140
 Phe Leu Leu Gly Val Leu Gly Ser Phe Gly Ser Glu Asn Thr Thr Phe
 145 150 155 160
 Gly Asp Ala Asp Phe Gly Trp Phe Gly Ile Val Val Gly Ser Ala Ala
 165 170 175
 Lys Val Glu Gly Ala Gly Leu Ile Leu Leu Leu Ile Ile Ala Ala
 180 185 190
 Val Leu Leu Gly Gly Ala Met Val Phe Gln Lys Arg Val Val Asn Gly
 195 200 205
 His Trp Asp Pro Ala Pro Asn Arg Glu Arg Val Glu Lys Ala Glu Ala
 210 215 220
 Asp Ala Thr Pro Thr Ala Gly Ala Arg Thr Tyr Pro Lys Ile Ala Pro
 225 230 235 240
 Pro Ala Gly Ala Pro Thr Pro Pro Ala Arg Ser
 245 250

<210> 27
 <211> 553
 <212> DNA

<213> Corynebacterium glutamicum

<220>

<221> CDS

<222> (101)..(553)

<223> RXC03001

<400> 27

cccggttacac gtgatcaatg acttcacgag caccgatgaa atcgatgctg cgcttcgtga 60

acgctacgac atctaactac tttaaaagga cgaaaatatt atg gac tgg tta acc 115
Met Asp Trp Leu Thr
1 5att cct ctt ttc ctc gtt aat gaa atc ctt gcg gtt ccg gct ttc ctc 163
Ile Pro Leu Phe Leu Val Asn Glu Ile Leu Ala Val Pro Ala Phe Leu
10 15 20atc ggt atc atc acc gcc gtg gga ttg ggt gcc atg ggg cgt tcc gtc 211
Ile Gly Ile Ile Thr Ala Val Gly Leu Gly Ala Met Gly Arg Ser Val
25 30 35ggc cag gtt atc ggt gga gca atc aaa gca acg ttg ggc ttt ttg ctc 259
Gly Gln Val Ile Gly Gly Ala Ile Lys Ala Thr Leu Gly Phe Leu Leu
40 45 50att ggt gcg ggt gcc acg ttg gtc act gcc tcc ctg gag cca ctg ggt 307
Ile Gly Ala Gly Ala Thr Leu Val Thr Ala Ser Leu Glu Pro Leu Gly
55 60 65gco atg atc atg ggt gcc aca ggc atg cgt ggt gtt gtc cca acg aat 355
Ala Met Ile Met Gly Ala Thr Gly Met Arg Gly Val Val Pro Thr Asn
70 75 80 85gaa gcc atc gcc gga atc gca cag gct gaa tac ggc gco cag gtg gco 403
Glu Ala Ile Ala Gly Ile Ala Gln Ala Glu Tyr Gly Ala Gln Val Ala
90 95 100tgg ctg atg att ctg ggc ttc gcc atc tct ttg gtc ttg gct cgt ttc 451
Trp Leu Met Ile Leu Gly Phe Ala Ile Ser Leu Val Leu Ala Arg Phe
105 110 115acc aac ctg cgt tat gtc ttg ctc aac gga cac cac gtg ctg ttg atg 499
Thr Asn Leu Arg Tyr Val Leu Leu Asn Gly His His Val Leu Leu Met
120 125 130tgc acc atg ctc acc atg gtc ttg gcc acc gga aga gtt gat gco tgg 547
Cys Thr Met Leu Thr Met Val Leu Ala Thr Gly Arg Val Asp Ala Trp
135 140 145atc ttc 553
Ile Phe
150

<210> 28

<211> 151

<212> PRT

<213> Corynebacterium glutamicum

<400> 28

Met Asp Trp Leu Thr Ile Pro Leu Phe Leu Val Asn Glu Ile Leu Ala
 1 5 10 15

Val Pro Ala Phe Leu Ile Gly Ile Ile Thr Ala Val Gly Leu Gly Ala
 20 25 30

Met Gly Arg Ser Val Gly Gln Val Ile Gly Gly Ala Ile Lys Ala Thr
 35 40 45

Leu Gly Phe Leu Leu Ile Gly Ala Gly Ala Thr Leu Val Thr Ala Ser
 50 55 60

Leu Glu Pro Leu Gly Ala Met Ile Met Gly Ala Thr Gly Met Arg Gly
 65 70 75 80

Val Val Pro Thr Asn Glu Ala Ile Ala Gly Ile Ala Gln Ala Glu Tyr
 85 90 95

Gly Ala Gln Val Ala Trp Leu Met Ile Leu Gly Phe Ala Ile Ser Leu
 100 105 110

Val Leu Ala Arg Phe Thr Asn Leu Arg Tyr Val Leu Leu Asn Gly His
 115 120 125

His Val Leu Leu Met Cys Thr Met Leu Thr Met Val Leu Ala Thr Gly
 130 135 140

Arg Val Asp Ala Trp Ile Phe
 145 150

<210> 29
 <211> 2172
 <212> DNA
 <213> *Corynebacterium glutamicum*

<220>
 <221> CDS
 <222> (101)..(2149)
 <223> RXN01943

<400> 29
 ccgattcttt ttcggcccaa ttcgtaacgg cgatcctctt aagtggacaa gaaaagtctct 60
 tgcccgcgaa agacagaccc tacgtttaga aaggtttgcac atg gcg tcc aaa ctg 115
 Met Ala Ser Lys Leu
 1 5

acg acg aca tcg caa cat att ctg gaa aac ctt ggt gga cca gac aat 163
 Thr Thr Ser Gln His Ile Leu Glu Asn Leu Gly Gly Pro Asp Asn
 10 15 20

att act tcg act cac tgt gcg act cgc ctt cgc ttc caa gtg aag 211
 Ile Thr Ser Met Thr His Cys Ala Thr Arg Leu Arg Phe Gln Val Lys
 25 30 35

gat caa tcc att gtt gat caa caa gaa att gac tcc gac cca tca gtt 259
 Asp Gln Ser Ile Val Asp Gln Gln Glu Ile Asp Ser Asp Pro Ser Val
 40 45 50

ctt ggc gta gta ccc caa gga tcc acc ggt atg cag gtg gtg atg ggt 307

Leu	Gly	Val	Val	Pro	Gln	Gly	Ser	Thr	Gly	Met	Gln	Val	Val	Met	Gly	
55																355
gga tct gtt gca aac tat tac caa gaa atc ctc aaa ctt gat gga atg																
Gly	Ser	Val	Ala	Asn	Tyr	Tyr	Gln	Glu	Ile	Leu	Lys	Leu	Asp	Gly	Met	
70																85
aag cac ttc gcc gac ggt gaa gct aca gag agt tca tcc aag aag gaa																
Lys	His	Phe	Ala	Asp	Gly	Glu	Ala	Thr	Glu	Ser	Ser	Lys	Lys	Glu		
															100	
tac ggc gga gtc cgt ggc aag tac tcg tgg att gac tac gcc ttc gag																
Tyr	Gly	Val	Arg	Gly	Lys	Tyr	Ser	Trp	Ile	Asp	Tyr	Ala	Phe	Glu		
															115	
ttc ttg tct gat act ttc cga cca atc ctg tgg gcc ctg ctt ggt gcc																
Phe	Leu	Ser	Asp	Thr	Phe	Arg	Pro	Ile	Leu	Trp	Ala	Leu	Leu	Gly	Ala	
120															499	
tca ctg att att acc ttg ttg gtt ctt gcg gat act ttc ggt ttg caa																
Ser	Leu	Ile	Ile	Thr	Leu	Leu	Val	Leu	Ala	Asp	Thr	Phe	Gly	Leu	Gln	
135															547	
gac ttc cgc gct cca atg gat gag cag cct gat act tat gta ttc ctg																
Asp	Phe	Arg	Ala	Pro	Met	Asp	Glu	Gln	Pro	Asp	Thr	Tyr	Val	Phe	Leu	
150															595	
cac tcc atg tgg cgc tcg gtc ttc tac ttc ctg cca att atg gtt ggt																
His	Ser	Met	Trp	Arg	Ser	Val	Phe	Tyr	Phe	Leu	Pro	Ile	Met	Val	Gly	
															643	
170																
gcc acc gca gct cga aag ctc ggc gca aac gag tgg att ggt gca gct																
Ala	Thr	Ala	Ala	Arg	Lys	Leu	Gly	Ala	Asn	Glu	Trp	Ile	Gly	Ala	Ala	
185															691	
att cca gcc gca ctt ctt act cca gaa ttc ttg gca ctg ggt tct gcc																
Ile	Pro	Ala	Ala	Leu	Leu	Thr	Pro	Glu	Phe	Leu	Ala	Leu	Gly	Ser	Ala	
200															739	
ggc gat acc gtc aca gtc ttt ggc ctg cca atg gtt ctg aat gac tac																
Gly	Asp	Thr	Val	Thr	Val	Phe	Gly	Leu	Pro	Met	Val	Leu	Asn	Asp	Tyr	
215															787	
tcc gga cag gta ttc cca ccg ctg att gca gca att ggt ctg tac tgg																
Ser	Gly	Gln	Val	Phe	Pro	Pro	Leu	Ile	Ala	Ala	Ile	Gly	Leu	Tyr	Trp	
230															835	
gtg gaa aag gga ctg aag aag atc atc cct gaa gca gtc caa atg gtg																
Val	Glu	Lys	Gly	Leu	Lys	Ile	Ile	Pro	Glu	Ala	Val	Gln	Met	Val		
250															883	
ttc gtc cca ttc ttc tcc ctg att atg atc cca gcg acc gca ttc																
Phe	Val	Pro	Phe	Phe	Ser	Leu	Leu	Ile	Met	Ile	Pro	Ala	Thr	Ala	Phe	
265															931	
ctg ctt gga cct ttc ggc atc ggt gtt ggt aac gga att tcc aac ctg																
Leu	Leu	Gly	Pro	Phe	Gly	Ile	Gly	Val	Gly	Asn	Gly	Ile	Ser	Asn	Leu	
280															979	
ctt gaa gcg att aac aac ttc agc cca ttt att ctt tcc atc gtt atc																
Leu	Glu	Ala	Ile	Asn	Asn	Phe	Ser	Pro	Phe	Ile	Leu	Ser	Ile	Val	Ile	
															1027	

295	300	305	
cca ttg ctc tac cca ttc ttg gtt cca ctt gga ttg cac tgg cca cta			1075
Pro Leu Leu Tyr Pro Phe Leu Val Pro Leu Gly Leu His Trp Pro Leu			
310	315	320	325
aac gcc atc atg atc cag aac atc aac acc ctg ggt tac gac ttc att			1123
Asn Ala Ile Met Ile Gln Asn Ile Asn Thr Leu Gly Tyr Asp Phe Ile			
330	335	340	
cag gga cca atg ggt gcc tgg aac ttc gcc tgc ttc ggc ctg gtc acc			1171
Gln Gly Pro Met Gly Ala Trp Asn Phe Ala Cys Phe Gly Leu Val Thr			
345	350	355	
ggc gtg ttc ttg ctc tcc att aag gaa cga aac aag gcc atg cgt cag			1219
Gly Val Phe Leu Leu Ser Ile Lys Glu Arg Asn Lys Ala Met Arg Gln			
360	365	370	
gtt tcc ctg ggt ggc atg ttg gct ggt ttg ctc ggc ggc att tcc gag			1267
Val Ser Leu Gly Gly Met Leu Ala Gly Leu Leu Gly Gly Ile Ser Glu			
375	380	385	
cct tcc ctc tac ggt gtt ctg ctc cga ttc aag aag acc tac ttc cgc			1315
Pro Ser Leu Tyr Gly Val Leu Leu Arg Phe Lys Lys Thr Tyr Phe Arg			
390	395	400	405
ctc ctg ccg ggt ttt ttg gca ggc ggt atc gtg atg ggc atc ttc gac			1363
Leu Leu Pro Gly Cys Leu Ala Gly Gly Ile Val Met Gly Ile Phe Asp			
410	415	420	
atc aag gcg tac gct ttc gtg ttc acc tcc ttg ctt acc atc cca gca			1411
Ile Lys Ala Tyr Ala Phe Val Phe Thr Ser Leu Leu Thr Ile Pro Ala			
425	430	435	
atg gac cca tgg ttg ggc tac acc att ggt atc gca gtt gca ttc ttc			1459
Met Asp Pro Trp Leu Gly Tyr Thr Ile Gly Ile Ala Val Ala Phe Phe			
440	445	450	
gtt tcc atg ttc ctt gtt ctc gca ctg gac tac cgt tcc aac gaa gag			1507
Val Ser Met Phe Leu Val Leu Ala Leu Asp Tyr Arg Ser Asn Glu Glu			
455	460	465	
cgc gat gag gca cgt gca aag gtt gct gac aag cag gca gaa gaa			1555
Arg Asp Glu Ala Arg Ala Lys Val Ala Ala Asp Lys Gln Ala Glu Glu			
470	475	480	485
gat ctg aag gca gaa gct aat gca act cct gca gct cca gta gct gct			1603
Asp Leu Lys Ala Glu Ala Asn Ala Thr Pro Ala Ala Pro Val Ala Ala			
490	495	500	
gca ggt gcg gga gcc ggt gca ggt gca gga gcc gct gct ggc gct gca			1651
Ala Gly Ala Gly Ala Gly Ala Gly Ala Ala Ala Gly Ala Ala			
505	510	515	
acc gcc gtg gca gct aag ccg aag ctg gcc gct ggg gaa gta gtg gac			1699
Thr Ala Val Ala Ala Lys Pro Lys Leu Ala Ala Gly Glu Val Val Asp			
520	525	530	
att gtt tcc cca ctc gaa ggc aag gca att cca ctt tct gaa gta cct			1747
Ile Val Ser Pro Leu Glu Gly Lys Ala Ile Pro Leu Ser Glu Val Pro			
535	540	545	

gac cca atc ttt gca gca ggc aag ctt gga cca ggc att gca atc caa	1795
Asp Pro Ile Phe Ala Ala Gly Lys Leu Gly Pro Gly Ile Ala Ile Gln	
550 555 560 565	
cca act gga aac acc gtt gtt gct cca gca gac gct act gtc atc ctt	1843
Pro Thr Gly Asn Thr Val Val Ala Pro Ala Asp Ala Thr Val Ile Leu	
570 575 580	
gtc cag aaa tct gga cac gca gtg gca ttg cgc tta gat agc gga gtt	1891
Val Gln Lys Ser Gly His Ala Val Ala Leu Arg Leu Asp Ser Gly Val	
585 590 595	
gaa atc ctt gtc cac gtt gga ttg gac acc gtg caa ttg ggc ggc gaa	1939
Glu Ile Leu Val His Val Gly Leu Asp Thr Val Gln Leu Gly Gly Glu	
600 605 610	
ggc ttc acc gtt cac gtt gag cgc agg cag caa gtc aag gcg ggg gat	1987
Gly Phe Thr Val His Val Glu Arg Arg Gln Gln Val Lys Ala Gly Asp	
615 620 625	
cca ctg atc act ttt gac gct gac ttc att cga tcc aag gat cta cct	2035
Pro Leu Ile Thr Phe Asp Ala Asp Phe Ile Arg Ser Lys Asp Leu Pro	
630 635 640 645	
ttg atc acc cca gtt gtg gtg tct aac gcc gcg aaa ttc ggt gaa att	2083
Leu Ile Thr Pro Val Val Val Ser Asn Ala Ala Lys Phe Gly Glu Ile	
650 655 660 665	
gaa ggt att cct gca gat cag gca aat tct tcc acg act gtg atc aag	2131
Glu Gly Ile Pro Ala Asp Gln Ala Asn Ser Ser Thr Thr Val Ile Lys	
665 670 675	
gtc aac ggc aag aac gag taacctggga tccatgttgc gca	2172
Val Asn Gly Lys Asn Glu	
680	

<210> 30
 <211> 683
 <212> PRT
 <213> *Corynebacterium glutamicum*

<400> 30	
Met Ala Ser Lys Leu Thr Thr Ser Gln His Ile Leu Glu Asn Leu	
1 5 10 15	
Gly Gly Pro Asp Asn Ile Thr Ser Met Thr His Cys Ala Thr Arg Leu	
20 25 30	
Arg Phe Gln Val Lys Asp Gln Ser Ile Val Asp Gln Gln Glu Ile Asp	
35 40 45	
Ser Asp Pro Ser Val Leu Gly Val Val Pro Gln Gly Ser Thr Gly Met	
50 55 60	
Gln Val Val Met Gly Gly Ser Val Ala Asn Tyr Tyr Gln Glu Ile Leu	
65 70 75 80	
Lys Leu Asp Gly Met Lys His Phe Ala Asp Gly Glu Ala Thr Glu Ser	
85 90 95	

Ser Ser Lys Lys Glu Tyr Gly Gly Val Arg Gly Lys Tyr Ser Trp Ile
 100 105 110
 Asp Tyr Ala Phe Glu Phe Leu Ser Asp Thr Phe Arg Pro Ile Leu Trp
 115 120 125
 Ala Leu Leu Gly Ala Ser Leu Ile Ile Thr Leu Leu Val Leu Ala Asp
 130 135 140
 Thr Phe Gly Leu Gln Asp Phe Arg Ala Pro Met Asp Glu Gln Pro Asp
 145 150 155 160
 Thr Tyr Val Phe Leu His Ser Met Trp Arg Ser Val Phe Tyr Phe Leu
 165 170 175
 Pro Ile Met Val Gly Ala Thr Ala Ala Arg Lys Leu Gly Ala Asn Glu
 180 185 190
 Trp Ile Gly Ala Ala Ile Pro Ala Ala Leu Leu Thr Pro Glu Phe Leu
 195 200 205
 Ala Leu Gly Ser Ala Gly Asp Thr Val Thr Val Phe Gly Leu Pro Met
 210 215 220
 Val Leu Asn Asp Tyr Ser Gly Gln Val Phe Pro Pro Leu Ile Ala Ala
 225 230 235 240
 Ile Gly Leu Tyr Trp Val Glu Lys Gly Leu Lys Lys Ile Ile Pro Glu
 245 250 255
 Ala Val Gln Met Val Phe Val Pro Phe Phe Ser Leu Leu Ile Met Ile
 260 265 270
 Pro Ala Thr Ala Phe Leu Leu Gly Pro Phe Gly Ile Gly Val Gly Asn
 275 280 285
 Gly Ile Ser Asn Leu Leu Glu Ala Ile Asn Asn Phe Ser Pro Phe Ile
 290 295 300
 Leu Ser Ile Val Ile Pro Leu Leu Tyr Pro Phe Leu Val Pro Leu Gly
 305 310 315 320
 Leu His Trp Pro Leu Asn Ala Ile Met Ile Gln Asn Ile Asn Thr Leu
 325 330 335
 Gly Tyr Asp Phe Ile Gln Gly Pro Met Gly Ala Trp Asn Phe Ala Cys
 340 345 350
 Phe Gly Leu Val Thr Gly Val Phe Leu Leu Ser Ile Lys Glu Arg Asn
 355 360 365
 Lys Ala Met Arg Gln Val Ser Leu Gly Gly Met Leu Ala Gly Leu Leu
 370 375 380
 Gly Gly Ile Ser Glu Pro Ser Leu Tyr Gly Val Leu Leu Arg Phe Lys
 385 390 395 400
 Lys Thr Tyr Phe Arg Leu Leu Pro Gly Cys Leu Ala Gly Gly Ile Val
 405 410 415

Met Gly Ile Phe Asp Ile Lys Ala Tyr Ala Phe Val Phe Thr Ser Leu
 420 425 430
 Leu Thr Ile Pro Ala Met Asp Pro Trp Leu Gly Tyr Thr Ile Gly Ile
 435 440 445
 Ala Val Ala Phe Phe Val Ser Met Phe Leu Val Leu Ala Leu Asp Tyr
 450 455 460
 Arg Ser Asn Glu Glu Arg Asp Glu Ala Arg Ala Lys Val Ala Ala Asp
 465 470 475 480
 Lys Gln Ala Glu Glu Asp Leu Lys Ala Glu Ala Asn Ala Thr Pro Ala
 485 490 495
 Ala Pro Val Ala Ala Gly Ala Gly Ala Gly Ala Gly Ala
 500 505 510
 Ala Ala Gly Ala Ala Thr Ala Val Ala Ala Lys Pro Lys Leu Ala Ala
 515 520 525
 Gly Glu Val Val Asp Ile Val Ser Pro Leu Glu Gly Lys Ala Ile Pro
 530 535 540
 Leu Ser Glu Val Pro Asp Pro Ile Phe Ala Ala Gly Lys Leu Gly Pro
 545 550 555 560
 Gly Ile Ala Ile Gln Pro Thr Gly Asn Thr Val Val Ala Pro Ala Asp
 565 570 575
 Ala Thr Val Ile Leu Val Gln Lys Ser Gly His Ala Val Ala Leu Arg
 580 585 590
 Leu Asp Ser Gly Val Glu Ile Leu Val His Val Gly Leu Asp Thr Val
 595 600 605
 Gln Leu Gly Gly Glu Gly Phe Thr Val His Val Glu Arg Arg Gln Gln
 610 615 620
 Val Lys Ala Gly Asp Pro Leu Ile Thr Phe Asp Ala Asp Phe Ile Arg
 625 630 635 640
 Ser Lys Asp Leu Pro Leu Ile Thr Pro Val Val Val Ser Asn Ala Ala
 645 650 655
 Lys Phe Gly Glu Ile Glu Gly Ile Pro Ala Asp Gln Ala Asn Ser Ser
 660 665 670
 Thr Thr Val Ile Lys Val Asn Gly Lys Asn Glu
 675 680

<210> 31
 <211> 1339
 <212> DNA
 <213> *Corynebacterium glutamicum*

<220>
 <221> CDS
 <222> (101)..(1339)
 <223> FRXA02191

<400> 31
 ccgattctt ttcggccaa ttcgtaacgg cgatcctctt aagtggacaa gaaagtctct 60
 tgcccgccc agacagaccc tacgtttaga aaggttgac atg gcg tcc aaa ctg 115
 Met Ala Ser Lys Leu
 1 5
 acg acg aca tcg caa cat att ctg gaa aac ctt ggt gga cca gac aat 163
 Thr Thr Thr Ser Gln His Ile Leu Glu Asn Leu Gly Gly Pro Asp Asn
 10 15 20
 att act tcg atg act cac tgt gcg act cgc ctt cgc ttc caa gtg aag 211
 Ile Thr Ser Met Thr His Cys Ala Thr Arg Leu Arg Phe Gln Val Lys
 25 30 35
 gat caa tcc att gtt gat caa caa gaa att gac tcc gac cca tca gtt 259
 Asp Gln Ser Ile Val Asp Gln Gln Glu Ile Asp Ser Asp Pro Ser Val
 40 45 50
 ctt ggc gta gta ccc caa gga tcc acc ggt atg cag gtg gtg atg ggt 307
 Leu Gly Val Val Pro Gln Gly Ser Thr Gly Met Gln Val Val Met Gly
 55 60 65
 gga tct gtt gca aac tat tac caa gaa atc ctc aaa ctt gat gga atg 355
 Gly Ser Val Ala Asn Tyr Tyr Gln Glu Ile Leu Lys Leu Asp Gly Met
 70 75 80 85
 aag cac ttc gcc gac ggt gaa gct aca gag agt tca tcc aag aag gaa 403
 Lys His Phe Ala Asp Gly Glu Ala Thr Glu Ser Ser Lys Lys Glu
 90 95 100
 tac ggc gga gtc cgt ggc aag tac tcg tgg att gac tac gcc ttc gag 451
 Tyr Gly Val Arg Gly Lys Tyr Ser Trp Ile Asp Tyr Ala Phe Glu
 105 110 115
 ttc ttg tct gat act ttc cga cca atc ctg tgg gcc ctg ctt ggt gcc 499
 Phe Leu Ser Asp Thr Phe Arg Pro Ile Leu Trp Ala Leu Leu Gly Ala
 120 125 130
 tca ctg att att acc ttg ttg gtt ctt gcg gat act ttc ggt ttg caa 547
 Ser Leu Ile Ile Thr Leu Leu Val Leu Ala Asp Thr Phe Gly Leu Gln
 135 140 145
 gac ttc cgc gct cca atg gat gag cag cct gat act tat gta ttc ctg 595
 Asp Phe Arg Ala Pro Met Asp Glu Gln Pro Asp Thr Tyr Val Phe Leu
 150 155 160 165
 cac tcc atg tgg cgc tcg gtc ttc tac ttc ctg cca att atg gtt ggt 643
 His Ser Met Trp Arg Ser Val Phe Tyr Phe Leu Pro Ile Met Val Gly
 170 175 180
 gcc acc gca gct cga aag ctc ggc gca aac gag tgg att ggt gca gct 691
 Ala Thr Ala Ala Arg Lys Leu Gly Ala Asn Glu Trp Ile Gly Ala Ala
 185 190 195
 att cca gcc gca ctt ctt act cca gaa ttc ttg gca ctg ggt tct gcc 739
 Ile Pro Ala Ala Leu Leu Thr Pro Glu Phe Leu Ala Leu Gly Ser Ala
 200 205 210
 ggc gat acc gtc aca gtc ttt ggc ctg cca atg gtt ctg aat gac tac 787

Gly Asp Thr Val Thr Val Phe Gly Leu Pro Met Val Leu Asn Asp Tyr			
215	220	225	
tcc gga cag gta ttc cca ccg ctg att gca gca att ggt ctg tac tgg 835			
Ser Gly Gln Val Phe Pro Pro Leu Ile Ala Ala Ile Gly Leu Tyr Trp			
230	235	240	245
gtg gaa aag gga ctg aag aag atc atc cct gaa gca gtc caa atg gtg 883			
Val Glu Lys Gly Leu Lys Ile Pro Glu Ala Val Gln Met Val			
250	255	260	
ttc gtc cca ttc tcc ctg ctg att atg atc cca gcg acc gca ttc 931			
Phe Val Pro Phe Ser Leu Leu Ile Met Ile Pro Ala Thr Ala Phe			
265	270	275	
ctg ctt gga cct ttc ggc atc ggt gtt ggt aac gga att tcc aac ctg 979			
Leu Leu Gly Pro Phe Gly Ile Gly Val Gly Asn Gly Ile Ser Asn Leu			
280	285	290	
ctt gaa gcg att aac aac ttc agc cca ttt att ctt tcc atc gtt atc 1027			
Leu Glu Ala Ile Asn Asn Phe Ser Pro Phe Ile Leu Ser Ile Val Ile			
295	300	305	
cca ttg ctc tac cca ttc ttg gtt cca ctt gga ttg cac tgg cca cta 1075			
Pro Leu Leu Tyr Pro Phe Leu Val Pro Leu Gly Leu His Trp Pro Leu			
310	315	320	325
aac gcc atc atg atc cag aac atc aac acc ctg ggt tac gac ttc att 1123			
Asn Ala Ile Met Ile Gln Asn Ile Asn Thr Leu Gly Tyr Asp Phe Ile			
330	335	340	
cag gga cca atg ggt gcc ttg aac ttc gcc tgc ttc ggc ctg gtc acc 1171			
Gln Gly Pro Met Gly Ala Trp Asn Phe Ala Cys Phe Gly Leu Val Thr			
345	350	355	
ggc gtg ttc ttg ctc tcc att aag gaa cga aac aag gcc atg cgt cag 1219			
Gly Val Phe Leu Leu Ser Ile Lys Glu Arg Asn Lys Ala Met Arg Gln			
360	365	370	
gtt tcc ctg ggt ggc atg ttg gct ggt ttg ctc ggc ggc att tcc gag 1267			
Val Ser Leu Gly Gly Met Leu Ala Gly Leu Leu Gly Gly Ile Ser Glu			
375	380	385	
cct tcc ctc tac ggt gtt ctg ctc cga ttc aag aag acc tac ttc cgc 1315			
Pro Ser Leu Tyr Gly Val Leu Leu Arg Phe Lys Lys Thr Tyr Phe Arg			
390	395	400	405
ctc ctg ccg ggt tgt ttg gca gca 1339			
Leu Leu Pro Gly Cys Leu Ala Ala			
410			

<210> 32
 <211> 413
 <212> PRT
 <213> Corynebacterium glutamicum

<400> 32
 Met Ala Ser Lys Leu Thr Thr Ser Gln His Ile Leu Glu Asn Leu
 1 5 10 15

Gly Gly Pro Asp Asn Ile Thr Ser Met Thr His Cys Ala Thr Arg Leu
 20 25 30
 Arg Phe Gln Val Lys Asp Gln Ser Ile Val Asp Gln Gln Glu Ile Asp
 35 40 45
 Ser Asp Pro Ser Val Leu Gly Val Val Pro Gln Gly Ser Thr Gly Met
 50 55 60
 Gln Val Val Met Gly Gly Ser Val Ala Asn Tyr Tyr Gln Glu Ile Leu
 65 70 75 80
 Lys Leu Asp Gly Met Lys His Phe Ala Asp Gly Glu Ala Thr Glu Ser
 85 90 95
 Ser Ser Lys Lys Glu Tyr Gly Gly Val Arg Gly Lys Tyr Ser Trp Ile
 100 105 110
 Asp Tyr Ala Phe Glu Phe Leu Ser Asp Thr Phe Arg Pro Ile Leu Trp
 115 120 125
 Ala Leu Leu Gly Ala Ser Leu Ile Ile Thr Leu Leu Val Leu Ala Asp
 130 135 140
 Thr Phe Gly Leu Gln Asp Phe Arg Ala Pro Met Asp Glu Gln Pro Asp
 145 150 155 160
 Thr Tyr Val Phe Leu His Ser Met Trp Arg Ser Val Phe Tyr Phe Leu
 165 170 175
 Pro Ile Met Val Gly Ala Thr Ala Ala Arg Lys Leu Gly Ala Asn Glu
 180 185 190
 Trp Ile Gly Ala Ala Ile Pro Ala Ala Leu Leu Thr Pro Glu Phe Leu
 195 200 205
 Ala Leu Gly Ser Ala Gly Asp Thr Val Thr Val Phe Gly Leu Pro Met
 210 215 220
 Val Leu Asn Asp Tyr Ser Gly Gln Val Phe Pro Pro Leu Ile Ala Ala
 225 230 235 240
 Ile Gly Leu Tyr Trp Val Glu Lys Gly Leu Lys Lys Ile Ile Pro Glu
 245 250 255
 Ala Val Gln Met Val Phe Val Pro Phe Phe Ser Leu Leu Ile Met Ile
 260 265 270
 Pro Ala Thr Ala Phe Leu Leu Gly Pro Phe Gly Ile Gly Val Gly Asn
 275 280 285
 Gly Ile Ser Asn Leu Leu Glu Ala Ile Asn Asn Phe Ser Pro Phe Ile
 290 295 300
 Leu Ser Ile Val Ile Pro Leu Leu Tyr Pro Phe Leu Val Pro Leu Gly
 305 310 315 320
 Leu His Trp Pro Leu Asn Ala Ile Met Ile Gln Asn Ile Asn Thr Leu
 325 330 335
 Gly Tyr Asp Phe Ile Gln Gly Pro Met Gly Ala Trp Asn Phe Ala Cys

340	345	350
-----	-----	-----

Phe Gly Leu Val Thr Gly Val Phe Leu Leu Ser Ile Lys Glu Arg Asn	355	360	365
-----------------------------------------------------------------	-----	-----	-----

Lys Ala Met Arg Gln Val Ser Leu Gly Gly Met Leu Ala Gly Leu Leu	370	375	380
-----------------------------------------------------------------	-----	-----	-----

Gly Gly Ile Ser Glu Pro Ser Leu Tyr Gly Val Leu Leu Arg Phe Lys	385	390	395	400
-----------------------------------------------------------------	-----	-----	-----	-----

Lys Thr Tyr Phe Arg Leu Leu Pro Gly Cys Leu Ala Ala	405	410
-----------------------------------------------------	-----	-----

<210> 33

<211> 428

<212> DNA

<213> *Corynebacterium glutamicum*

<220>

<221> CDS

<222> (1)..(405)

<223> FRXA01943

<400> 33

cct gac cca atc ttt gca gca ggc aag ctt gga cca ggc att gca atc	48		
Pro Asp Pro Ile Phe Ala Ala Gly Lys Leu Gly Pro Gly Ile Ala Ile			
1	5	10	15

caa cca act gga aac acc gtt gtt gct cca gca gac gct act gtc atc	96	
Gln Pro Thr Gly Asn Thr Val Val Ala Pro Ala Asp Ala Thr Val Ile		
20	25	30

ctt gtc cag aaa tct gga cac gca gtg gca ttg cgc tta gat agc gga	144	
Leu Val Gln Lys Ser Gly His Ala Val Ala Leu Arg Leu Asp Ser Gly		
35	40	45

gtt gaa atc ctt gtc cac gtt gga ttg gac acc gtg caa ttg ggc ggc	192	
Val Glu Ile Leu Val His Val Gly Leu Asp Thr Val Gln Leu Gly Gly		
50	55	60

gaa ggc ttc acc gtt cac gtt gag cgc agg cag caa gtc aag gcg ggg	240		
Glu Gly Phe Thr Val His Val Glu Arg Arg Gln Gln Val Lys Ala Gly			
65	70	75	80

gat cca ctg atc act ttt gac gct gac ttc att cga tcc aag gat cta	288	
Asp Pro Leu Ile Thr Phe Asp Ala Asp Phe Ile Arg Ser Lys Asp Leu		
85	90	95


cct ttg atc acc cca gtt gtg gtg tct aac gcc gcg aaa ttc ggt gaa	336	
Pro Leu Ile Thr Pro Val Val Val Ser Asn Ala Ala Lys Phe Gly Glu		
100	105	110

att gaa ggt att cct gca gat cag gca aat tct tcc acg act gtg atc	384	
Ile Glu Gly Ile Pro Ala Asp Gln Ala Asn Ser Ser Thr Thr Val Ile		
115	120	125

aag gtc aac ggc aag aac gag taacctggga tccatgttgc gca	428
Lys Val Asn Gly Lys Asn Glu	
130	135

<210> 34
<211> 135
<212> PRT
<213> *Corynebacterium glutamicum*

<400> 34
Pro Asp Pro Ile Phe Ala Ala Gly Lys Leu Gly Pro Gly Ile Ala Ile
1 5 10 15
Gln Pro Thr Gly Asn Thr Val Val Ala Pro Ala Asp Ala Thr Val Ile
20 25 30
Leu Val Gln Lys Ser Gly His Ala Val Ala Leu Arg Leu Asp Ser Gly
35 40 45
Val Glu Ile Leu Val His Val Gly Leu Asp Thr Val Gln Leu Gly Gly
50 55 60
Glu Gly Phe Thr Val His Val Glu Arg Arg Gln Gln Val Lys Ala Gly
65 70 75 80
Asp Pro Leu Ile Thr Phe Asp Ala Asp Phe Ile Arg Ser Lys Asp Leu
85 90 95
Pro Leu Ile Thr Pro Val Val Val Ser Asn Ala Ala Lys Phe Gly Glu
100 105 110
Ile Glu Gly Ile Pro Ala Asp Gln Ala Asn Ser Ser Thr Thr Val Ile
115 120 125
Lys Val Asn Gly Lys Asn Glu
130 135



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 January 2001 (11.01.2001)

PCT

(10) International Publication Number
WO 01/02583 A3

(51) International Patent Classification⁷: C12N 15/54, (DE). HABERHAUER, Gregor; Moselstrasse 42, 15/31, 9/00, 9/12, 15/77, C12P 1/04 D-67117 Limburgerhof (DE).

(21) International Application Number: PCT/IB00/00973 (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 27 June 2000 (27.06.2000)

(25) Filing Language: English (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(26) Publication Language: English

(30) Priority Data:

60/142,691	1 July 1999 (01.07.1999)	US
60/150,310	23 August 1999 (23.08.1999)	US
199 42 095.5	3 September 1999 (03.09.1999)	DE
199 42 097.1	3 September 1999 (03.09.1999)	DE

(71) Applicant: BASF AKTIENGESELLSCHAFT
[DE/DE]; D-67056 Ludwigshafen (DE).

(72) Inventors: POMPEJUS, Markus; Wcnjenstrasse 21, D-67251 Freinsheim (DE). KRÖGER, Burkhard; Im Waldhof 1, D-67117 Limburgerhof (DE). SCHRÖDER, Hartwig; Goethestrasse 5, D-69226 Nussloch (DE). ZELDER, Oskar; Rossmarktstrasse 27, D-67346 Speyer

Published:

— with international search report

(88) Date of publication of the international search report:
26 July 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

A3

WO 01/02583

(54) Title: *ORYNEBACTERIUM GLUTAMICUM GENES ENCODING PHOSPHOENOLPYRUVATE: SUGAR PHOSPHO-TRANSFERASE SYSTEM PROTEINS*

(57) Abstract: Isolated nucleic acid molecules, designated PTS nucleic acid molecules, which encode novel PTS proteins from *Corynebacterium glutamicum* are described. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PTS nucleic acid molecules, and host cells into which the expression vectors have been introduced. The invention still further provides isolated PTS proteins, mutated PTS proteins, fusion proteins, antigenic peptides and methods for the improvement of production of a desired compound from *C. glutamicum* based on genetic engineering of PTS genes in this organism.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IB 00/00973

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7	C12N15/54	C12N15/31	C12N9/00	C12N9/12	C12N15/77
	C12P1/04				

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C12P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, STRAND

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 98 18931 A (DOUGHERTY BRIAN A ; HUMAN GENOME SCIENCES INC (US); ROSEN CRAIG A () 7 May 1998 (1998-05-07)</p> <p>abstract; claims 8-20 see SEQ ID NO: 30, nucleotides 8500-9200 (p. 323) page 5 -page 7</p> <p>---</p> <p>-/-</p>	<p>1-3, 5-13, 15-19, 21, 25-27, 30-35,37</p>

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

14 November 2000

Date of mailing of the international search report

19.02.01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Oderwald, H

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IB 00/00973

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WAGNER E. ET AL: "Cloning and characterization of the <i>scrA</i> gene encoding the sucrose-specific enzyme II of the phosphotransferase system from <i>Staphylococcus xylosus</i>." <i>MOLECULAR & GENERAL GENETICS</i>, vol. 241, no. 1-2, 1993, pages 33-41, XP002152722 ISSN: 0026-8925 the whole document</p> <p>---</p>	1-3, 5-13, 15-19, 21, 25-27, 30-37
A	<p>LEE J-K ET AL: "Nucleotide sequence of the gene encoding the <i>Corynebacterium glutamicum</i> mannose enzyme II and analyses of the deduced protein sequence." <i>FEMS MICROBIOLOGY LETTERS</i>, vol. 119, no. 1-2, 1994, pages 137-145, XP000960685 ISSN: 0378-1097 the whole document</p> <p>---</p>	
A	<p>DOMINGUEZ H ET AL: "Complete sucrose metabolism requires fructose phosphotransferase activity in <i>Corynebacterium glutamicum</i> to ensure phosphorylation of liberated fructose." <i>APPLIED AND ENVIRONMENTAL MICROBIOLOGY</i>, vol. 62, no. 10, 1996, pages 3878-3880, XP000960659 ISSN: 0099-2240 the whole document</p> <p>---</p>	
A	<p>EP 0 358 940 A (DEGUSSA) 21 March 1990 (1990-03-21) the whole document</p> <p>-----</p>	

INTERNATIONAL SEARCH REPORT

In national application No.
PCT/IB 00/00973

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 35 is directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Claims 1-38 , partially:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: {1-38 partially}

An isolated nucleic acid from *Corynebacterium glutamicum* encoding a phosphoenolpyruvate:sugar phosphotransferase system protein as set forth in SEQ ID NO: 1. A vector, a host, a polypeptide as set forth in SEQ ID NO: 2, a method for producing fine chemicals, a method for diagnosing using said nucleic acid.

2. Claims: {1-38 partially}

same as invention 1 but comprising SEQ ID NO: 5 and 6.

3. Claims: {1-38 partially}

same as invention 1 but comprising SEQ ID NO: 7 and 8.

4. Claims: {1-38 partially}

same as invention 1 but comprising SEQ ID NO: 15 and 16.

5. Claims: {1-38 partially}

same as invention 1 but comprising SEQ ID NO: 17 and 18.

6. Claims: {1-38 partially}

same as invention 1 but comprising SEQ ID NO: 21 and 22.

7. Claims: {1-38 partially}

same as invention 1 but comprising SEQ ID NO: 23 and 24.

8. Claims: {1-38 partially}

same as invention 1 but comprising SEQ ID NO: 25 and 26.

9. Claims: {1-38 partially}

same as invention 1 but comprising SEQ ID NO: 27 and 28.

10. Claims: {1-38 partially}

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

same as invention 1 but comprising SEQ ID NO: 29 and 30.

11. Claims: {18, 19, 22, 36-38 partially}

An isolated phosphoenolpyruvate:sugar phosphotransferase system protein from *Corynebacterium glutamicum* as set forth in SEQ ID NO: 4, a host cell comprising a nucleic acid molecule as set forth in SEQ ID NO: 3.

12. Claims: {18, 19, 22, 36-38 partially}

same as invention 11 but comprising SEQ ID NO: 9 and 10.

13. Claims: {18, 19, 22, 36-38 partially}

same as invention 11 but comprising SEQ ID NO: 11 and 12.

14. Claims: {18, 19, 22, 36-38 partially}

same as invention 11 but comprising SEQ ID NO: 13 and 14.

15. Claims: {18, 19, 22, 36-38 partially}

same as invention 11 but comprising SEQ ID NO: 19 and 20.

16. Claims: {18, 19, 22, 36-38 partially}

same as invention 11 but comprising SEQ ID NO: 31 and 32.

17. Claims: {18, 19, 22, 36-38 partially}

same as invention 11 but comprising SEQ ID NO: 33 and 34.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 00/00973

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9818931	A 07-05-1998	AU 5194598	A	22-05-1998
		AU 6909098	A	22-05-1998
		EP 0942983	A	22-09-1999
		EP 0941335	A	15-09-1999
		WO 9818930	A	07-05-1998
		US 6159469	A	12-12-2000
EP 0358940	A 21-03-1990	GB 2223754	A	18-04-1990
		DE 68924227	D	19-10-1995
		DE 68924227	T	01-02-1996
		JP 2291276	A	03-12-1990

